Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of the cystic fibrosis transmembrane conductance regulator

JP2023549547A5Pending Publication Date: 2024-11-26VERTEX PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023529022
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-18
Filing Date
2021-11-17
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Current treatments for cystic fibrosis, particularly those involving CFTR modulators, are not sufficiently effective for severe forms of the disease, necessitating combination therapies and a need for more potent modulators to address mutations that affect CFTR function and abundance.

Method used

Development of novel macrocyclic compounds containing a 1,3,4-oxadiazole ring that act as CFTR modulators, including potentiators and correctors, to enhance CFTR activity and correct defective protein processing, potentially as standalone or combination therapies with existing modulators.

Benefits of technology

These compounds improve CFTR function and stability, offering potential therapeutic benefits for cystic fibrosis and other CFTR-mediated disorders, reducing disease severity and progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022109573000001
    Figure 2022109573000001
  • Figure 2022109573000002
    Figure 2022109573000002
  • Figure 2022109573000003
    Figure 2022109573000003
Patent Text Reader

Abstract

The present disclosure provides modulators of the cystic fibrosis transmembrane conductance regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treating cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators. Another aspect of the disclosure provides solid forms of the compound of Formula I, its deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing, which may be used in the methods of treatment and pharmaceutical compositions described herein. TIFF2023549547001108.tif3896
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 115,552, filed November 18, 2020, the contents of which are incorporated herein by reference in their entirety.

[0002] The present invention relates to modulators of the cystic fibrosis transmembrane conductance regulator (CFTR), pharmaceutical compositions containing the modulators, methods of treating cystic fibrosis and CFTR-mediated disorders using such modulators and pharmaceutical compositions, and processes for making such modulators.

[0003] Cystic fibrosis (CF) is a recessive genetic disease that affects approximately 83,000 children and adults worldwide. Despite advances in CF treatment, there is no cure.

[0004] In patients with CF, mutations in endogenously expressed CFTR in respiratory epithelia result in reduced apical anion secretion, leading to an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to increased mucus accumulation in the lungs, accompanied by microbial infections that ultimately lead to death in CF patients. In addition to respiratory disease, CF patients typically suffer from gastrointestinal disorders and pancreatic insufficiency, which, if left untreated, can lead to death. Furthermore, the majority of men with cystic fibrosis are infertile, and fertility is low in women with cystic fibrosis.

[0005] Sequence analysis of the CFTR gene has revealed a variety of disease-causing mutations (Cutting, G.R. et al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell 61:863:870; and Kerem, B.S. et al. (1989) Science 245:1073-1080; Kerem, B.S. et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, over 2,000 mutations have been identified in the CFTR gene. The CFTR2 database currently contains information on only 322 of these identified mutations, with 281 mutations providing sufficient evidence to define them as disease-causing. The most common disease-causing mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, commonly referred to as the F508del mutation. This mutation occurs in many cases of cystic fibrosis and is associated with severe disease.

[0006] CFTR is a cAMP / ATP-mediated anion channel expressed in various cell types, including absorptive and secretory epithelial cells, where it regulates anion flux across membranes and the activity of other ion channels and proteins. In epithelial cells, normal CFTR function is essential for maintaining electrolyte transport throughout the body, including respiratory and digestive tissues. CFTR is composed of 1,480 amino acids that encode a protein composed of tandem repeats of transmembrane domains, each containing six transmembrane helices and a nucleotide-binding domain. The two transmembrane domains are connected by a large polarity regulatory (R) domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.

[0007] Chloride transport is mediated by the coordinated activity of ENaC (epithelial sodium channel) and CFTR present on the apical membrane, and Na + -K + -ATPase pump and Cl -Secondary active transport of chloride from the luminal side leads to the accumulation of intracellular chloride, which is then transported through the Cl - It can passively leave the cell through channels, resulting in vectorial transport. + / 2Cl - / K + Na symporter on the basolateral surface + -K + -ATPase pump and basolateral membrane K + The channel, as well as the positioning of CFTR on the luminal side, regulates chloride secretion. Because water is probably never actively transported by itself, the flow of water across epithelia depends on a small transepithelial osmotic gradient generated by the overall flow of sodium and chloride. In recent years, several CFTR modulators have been identified. These modulators are considered, for example, potentiators, correctors, potentiators / co-potentiators, amplifiers, read-through agents, and nucleic acid therapies. CFTR modulators that increase the channel gating activity of mutant and wild-type CFTR at the epithelial cell surface are known as potentiators. Correctors improve defective protein processing, resulting in transport to the epithelial surface. Ghelani and Schneider-Futschik (2020) ACS Pharmacol. Transl. Sci. 3:4-10. Three CFTR correctors have been approved by the U.S. Food and Drug Administration for the treatment of cystic fibrosis. However, monotherapy with some CFTR correctors has proven ineffective, and as a result, combination therapy with potentiators is required to enhance CFTR activity. Currently, only one CFTR potentiator is approved for the treatment of cystic fibrosis. Thus, while the treatment of cystic fibrosis has been transformed by these new small molecule CFTR modulators, new and better modulators are needed to prevent disease progression, reduce the severity of cystic fibrosis and other CFTR-mediated diseases, and treat more severe forms of these diseases. [Prior art documents] [Non-patent literature]

[0008] [Non-Patent Document 1] Cutting, GRet al. (1990) Nature 346:366-369 [Non-patent document 2] Dean, M. et al. (1990) Cell 61:863:870 [Non-patent document 3] Kerem, BS. et al. (1989) Science 245:1073-1080 [Non-patent document 4] Kerem, BS et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451 [Non-Patent Document 5] Ghelani and Schneider-Futschik(2020)ACS Pharmacol. Transl. Sci.3:4-10 Summary of the Invention [Means for solving the problem]

[0009] One aspect of the present invention provides novel compounds, including compounds of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing.

[0010] For example, a compound of formula I is [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, In the formula, X is -N(R X1 )- and [ka] is selected from Ring A is independently a 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 groups selected from C1-C6 alkyl and oxo; R X1 is H, C1-C6 alkyl (independently hydroxy, oxo, -OR X2 , and -N(R X2 ) optionally substituted with 1-3 groups selected from 2), and C3-C8 cycloalkyl; Each R X2 are independently selected from H and C1-C6 alkyl groups; Each Y is independently -C(R Y )2-, -O-, -CO-, -NR YN - and [ka] wherein each R YN are independently H, C1-C4 alkyl, and COR YN1 Each R YN1 is independently selected from C1-C4 alkyl and C3-C6 cycloalkyl; Each R Y are independently selected from hydrogen, hydroxy, halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C1-C6 alkoxy, and Q), C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -OR Y1 , -CO2R Y1 , -COR Y1 , -CON(R Y1 )2, and -N(R Y1 )2 or or two R on the same atom Y are taken together to form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or two R Ytogether to form a π bond, Each R Y1 are independently selected from hydrogen and C1-C6 alkyl, or two R Y1 together form a 3- to 6-membered heterocyclyl, Ring B is ■C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen, C1-C6 alkyl, and C1-C6 alkoxy); ■ C3-C8 cycloalkyl, ■ 5- to 10-membered heteroaryl, and ■ 3- to 6-membered heterocyclyl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), Each Q is independently C1-C6 alkyl, independently ○Halogen, ○Oxo, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen and —OCF3), and C1-C6 alkyl optionally substituted with 1 to 3 groups selected from C3-C8 cycloalkyl, C3-C8 cycloalkyl, independently: ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen, -NH2, and -NHCOMe); ○C1-C6 alkoxy, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl), and ○ C3-C8 cycloalkyl optionally substituted with 1 to 3 groups selected from ■C6~C 10 aryl, independently ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen and hydroxy), ○C1-C6 alkoxy, independently ■Halogen, ■ C1-C6 alkoxy optionally substituted with 1 to 4 groups selected from C3-C8 cycloalkyl (optionally substituted with CF3); C3-C8 cycloalkyl (optionally substituted with 1 to 3 groups independently selected from halogen, CF3, OCF3, and C1-C6 alkyl), and ○C6~C 10 C-C optionally substituted with 1 to 3 groups selected from aryl 10 aryl, ■ 5- to 10-membered heteroaryl, independently ○Halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen), C3-C8 cycloalkyl (optionally substituted with 1 to 3 CF3 groups), and ○ 3- to 10-membered heterocyclyl, ■ 3- to 10-membered heterocyclyl, independently C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from oxo and C3-C8 cycloalkyl), and oxo, 3- to 10-membered heterocyclyl optionally substituted with 1 to 3 groups selected from Each R 1 are independently selected from halogen, C1-C6 fluoroalkyl, C1-C6 alkyl (hydroxy, C6-C 10 aryl, and 5- to 6-membered heteroaryl), -OR 2 , -N(R 2 )2, -CO2R 2 , -CO-N(R 2 )2, -CN, C3-C8 cycloalkyl, C6-C10 aryl, 5- to 6-membered heteroaryl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), 3- to 6-membered heterocyclyl, -B(OR 2 )2, -SO2R 2 , -SR 2 , -SOR 2 , -PO(OR 2 )2, and -PO(R 2 )2 is selected, Each R 2 are independently selected from hydrogen, C1-C6 alkyl (optionally substituted with 1 to 6 groups independently selected from halogen), C1-C6 fluoroalkyl, and C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 fluoroalkyl and C1-C6 fluoroalkoxy); Z is [ka] wherein ring C is selected from C to C 10 selected from aryl and 5- to 10-membered heteroaryl; R Z1 is hydrogen, —CN, C1-C6 alkyl (optionally substituted with 1-3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, C6-C 10 aryl, and 5- to 6-membered heteroaryl; R Z2 is hydrogen, halogen, hydroxy, NH2, NH(CO)(C1-C6 alkyl), and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and R Z2 together form a group selected from oxo and =N-OH, Each R Z3 are independently selected from hydroxy, C1-C6 alkoxy, C1-C6 alkyl, and C6-C 10aryl, or two R Z3 together form a 3- to 6-membered heterocyclyl, n is selected from 4, 5, 6, 7, and 8; m is selected from 0, 1, 2, and 3.

[0011] In some embodiments of Formula I, X is —N(R X1 )-.

[0012] In some embodiments of Formula I, X is [ka] is.

[0013] In some embodiments of Formula I, X is -NH-, -N(CH3)-, -N(CH2CH3)-, [ka] is selected from.

[0014] In some embodiments of Formula I, Each R Y are independently selected from hydrogen, hydroxy, halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C1-C6 alkoxy, and Q), C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -COR Y1 , and -CON(R Y1 )2 or or two R on the same atom Y taken together form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or or two R, one on one atom and the second on an adjacent atom Y together to form a π bond.

[0015] In some embodiments of Formula I, each R Y1 are independently selected from hydrogen and C1-C6 alkyl, or two R Y1 together form a 3- to 6-membered heterocyclyl.

[0016] In some embodiments of Formula I, each Q is independently C6 to C 10 aryl.

[0017] In some embodiments of Formula I, each Q is phenyl.

[0018] In some embodiments of Formula I, Each R Y is, independently, Hydrogen, hydroxy, -CH3, -CD3, -CH2CH3, [ka] Selected from or or two R on the same atom Y taken together form a ring selected from cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyrryl, and tetrahydrofuryl; or two R, one on one atom and the second on an adjacent atom Y together to form a π bond.

[0019] In some embodiments of Formula I, ring B is a C6-C 10 It is selected from aryl (optionally substituted with 1 to 3 groups independently selected from halogen and C1-C6 alkoxy) and 5-10 membered heteroaryl.

[0020] In some embodiments of Formula I, Ring B is selected from phenyl (optionally substituted with 1 to 3 groups independently selected from halogen and C1-C6 alkoxy) and pyridyl.

[0021] In some embodiments of Formula I, ring B is [ka] is selected from.

[0022] In some embodiments of Formula I, n is selected from 4, 5, 6, and 7.

[0023] In some embodiments of Formula I, -(Y) n -teeth, [ka] [ka] [ka] is selected from.

[0024] In some embodiments of Formula I, each R 1 are independently selected from halogen, C1-C6 fluoroalkyl, C1-C6 alkyl (C6-C 10 aryl), -OR 2 , -N(R 2 )2, -CO2R 2 , -CO-N(R 2 )2, -CN, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 6-membered heteroaryl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), 3- to 6-membered heterocyclyl, -B(OR 2 )2, SO2R 2 , -SR 2 , -SOR 2 , and -PO(R 2 )2 is selected.

[0025] In some embodiments of Formula I, each R 2 are independently C6 to C 10aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 fluoroalkoxy);

[0026] In some embodiments of Formula I, each R 1 are independently -Br, -CF3, -NH2, -CH3, -CH(CH3)2, -CN, -OH, -OCH3, -NH(CH3), -NH(CH2CH3), -CONH2, -CO2CH3, -SO2CH3, -SO2Ph, PO(CH3)2, B(OH)2, phenyl, pyridyl, tetrahydropyranyl, tetrahydrofuranyl, cyclopropyl, cyclohexyl, imidazolyl, [ka] is selected from.

[0027] In some embodiments of Formula I, Z is [ka] Ring C is selected from C to C 10 aryl.

[0028] In some embodiments of Formula I, the group: [ka] teeth, [ka] is selected from.

[0029] In some embodiments of Formula I, the group: [ka] teeth, [ka] is.

[0030] In some embodiments of Formula I, R Z1 is hydrogen, C1-C6 alkyl (optionally substituted with 1-3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, C6-C 10 It is selected from aryl, and 5- to 6-membered heteroaryl.

[0031] In some embodiments of Formula I, R Z2 are hydrogen, halogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 cycloalkyl).

[0032] In some embodiments of Formula I, R Z1 is selected from hydrogen, C1-C6 alkyl (optionally substituted with 1-3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, and C6-C 10 aryl; R Z2 is selected from hydrogen, halogen, and hydroxy; or R Z1 and R Z2 together form a group selected from oxo and =N-OH.

[0033] In some embodiments of Formula I, R Z1 is selected from hydrogen, CH, CF, CHOH, phenyl, cyclopropyl, and tetrahydropyranyl; R Z2 is selected from hydrogen, halogen, and hydroxy; or R Z1 and R Z2 together form a group selected from oxo and =N-OH.

[0034] In some embodiments of Formula I, R Z2 is hydroxy.

[0035] In some embodiments of Formula I, Z is [ka] is selected from.

[0036] In some embodiments of Formula I, Z is [ka] In some embodiments of Formula I, Z is [ka] In some embodiments of Formula I, Z is [ka] In some embodiments of Formula I, Z is [ka] wherein (R) refers to the stereochemical designation of the central carbon atom according to the Cahn-Ingold-Prelog convention. In some embodiments of Formula I, Z is [ka] where (S) refers to the stereochemical designation of the central carbon atom according to the Cahn-Ingold-Prelog convention.

[0037] In some embodiments of Formula I, m is selected from 1 and 2.

[0038] In some embodiments, the compounds of the invention are encompassed by Formula I': [ka] and deuterated derivatives thereof, and pharmaceutically acceptable salts of these compounds and deuterated derivatives, wherein: X is -N(R X1 )- and [ka] is selected from Ring A is independently a 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 groups selected from C1-C6 alkyl and oxo; R X1 is H, C1-C6 alkyl (independently hydroxy, oxo, -OR X2 , and -N(R X2 ) optionally substituted with 1-3 groups selected from 2), and C3-C8 cycloalkyl; Each R X2 are independently selected from H and C1-C6 alkyl groups; Each Y is independently -C(R Y )2-, -O-, -CO-, -NR YN - and [ka] wherein each R YN is independently selected from H, C1-C4 alkyl, and CO2Me; Each R Y are independently selected from hydrogen, hydroxy, halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C1-C6 alkoxy, and Q), C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -OR Y1 , -CO2R Y1 , -COR Y1 , -CON(R Y1 )2, and -N(R Y1 )2 or or two R on the same atom Y are taken together to form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or two R Y together to form a π bond, Each R Y1 are independently selected from hydrogen and C1-C6 alkyl, or two R Y1 together form a 3- to 6-membered heterocyclyl, Ring B is ■C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen, C1-C6 alkyl, and C1-C6 alkoxy); ■ C3-C8 cycloalkyl, ■ 5- to 10-membered heteroaryl, and ■ 3- to 6-membered heterocyclyl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), Each Q is independently C1-C6 alkyl, independently ○Halogen, ○Oxo, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen and —OCF3), and C1-C6 alkyl optionally substituted with 1 to 3 groups selected from C3-C8 cycloalkyl, C3-C8 cycloalkyl, independently: ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen, -NH2, and -NHCOMe); ○C1-C6 alkoxy, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl), and ○ C3-C8 cycloalkyl optionally substituted with 1 to 3 groups selected from ■C6~C 10 aryl, independently ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen and hydroxy), ○C1-C6 alkoxy, independently ■Halogen, ■ C1-C6 alkoxy optionally substituted with 1 to 4 groups selected from C3-C8 cycloalkyl (optionally substituted with CF3); C3-C8 cycloalkyl (optionally substituted with 1 to 3 groups independently selected from halogen, CF3, OCF3, and C1-C6 alkyl), and ○C6~C 10 C-C optionally substituted with 1 to 3 groups selected from aryl 10 aryl, ■ 5- to 10-membered heteroaryl, independently ○Halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen), C3-C8 cycloalkyl (optionally substituted with 1 to 3 CF3 groups), and ○ 3- to 10-membered heterocyclyl, ■ 3- to 10-membered heterocyclyl, independently C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from oxo and C3-C8 cycloalkyl), and oxo, 3- to 10-membered heterocyclyl optionally substituted with 1 to 3 groups selected from Each R 1 are independently selected from halogen, C1-C6 fluoroalkyl, C1-C6 alkyl (C6-C 10 optionally substituted with a group selected from aryl and 5- to 6-membered heteroaryl, -OR 2 , -N(R 2 )2, -CO2R 2 , -CO-N(R 2 )2, -CN, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10Aryl, 5- to 6-membered heteroaryl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), 3- to 6-membered heterocyclyl, -SO2R 2 , -SR 2 , -SOR 2 , -PO(OR 2 )2, and -PO(R 2 )2 is selected, Each R 2 are independently selected from hydrogen, C1-C6 alkyl (optionally substituted with 1 to 6 groups independently selected from halogen), C1-C6 fluoroalkyl, and C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 fluoroalkyl and C1-C6 fluoroalkoxy); Z is [ka] is selected from R Z1 is hydrogen, —CN, C1-C6 alkyl (optionally substituted with 1-3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, C6-C 10 aryl, and 5- to 6-membered heteroaryl; R Z2 are hydrogen, halogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and R Z2 together form a group selected from oxo and =N-OH, Each R Z3 are independently selected from hydroxy, C1-C6 alkoxy, C1-C6 alkyl, and C6-C 10 aryl, or two R Z3 together form a 3- to 6-membered heterocyclyl, n is selected from 4, 5, 6, and 7; m is selected from 0, 1, 2, and 3.

[0039] In some embodiments, the compound of formula I is a compound of formula I″: [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein all variables are as defined for Formula I.

[0040] In some embodiments of Formula I″, [ka] The portion of the compound represented by [ka] wherein (R) refers to the stereochemical designation of the central carbon atom according to the Cahn-Ingold-Prelog convention. In some embodiments of Formula I″, [ka] The portion of the compound represented by [ka] where (S) refers to the stereochemical designation of the central carbon atom according to the Cahn-Ingold-Prelog convention.

[0041] The compounds of the present invention also include compounds of formula Ia, IIa, IIb, IIc, IId, IIe, IIf, IIg, and IIh: [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein all variables are as defined for Formula I'.

[0042] The compounds of the present invention also include compounds of formula Ia', IIa', IIb', IIc', IId', IIe', IIf', IIg', and IIh': [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein all variables are as defined for Formula I.

[0043] In some embodiments of Formulas Ia', IIa', IIb', IIc', IId', IIe', IIf', IIg', and IIh', [ka] The portion of the compound represented by [ka] wherein (R) refers to the stereochemical designation of the central carbon atom according to the Cahn-Ingold-Prelog convention. In some embodiments of Formula I″, [ka] The portion of the compound represented by [ka] where (S) refers to the stereochemical designation of the central carbon atom according to the Cahn-Ingold-Prelog convention.

[0044] Another aspect of the present invention provides a pharmaceutical composition comprising at least one compound selected from compounds of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, and at least one pharmaceutically acceptable carrier, which composition may further comprise at least one additional active pharmaceutical ingredient. Accordingly, another aspect of the present invention provides a method of treating the CFTR-mediated disease cystic fibrosis, comprising administering to a subject in need thereof at least one compound selected from compounds of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, and at least one pharmaceutically acceptable carrier, optionally as part of a pharmaceutical composition comprising at least one additional ingredient.

[0045] In certain embodiments, the pharmaceutical compositions of the present invention comprise at least one compound selected from compounds of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing. In some embodiments, a composition comprising at least one compound selected from compounds of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, can optionally further comprise at least one compound selected from compound II, compound IV, compound V, compound VI, compound VII, compound VIII, compound IX, compound X, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing.

[0046] Another aspect of the present invention is a method of treating the CFTR-mediated disease cystic fibrosis, comprising administering to a patient in need of treatment at least one compound selected from the novel compounds disclosed herein, pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing, and optionally, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxypropyl)- ... N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound II), N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound III), or N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydro Quinoline-3-carboxamide (Compound III-d), 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound IV), N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidine-1-yl]-2- ... -yl]pyridine-3-carboxamide (Compound V), N-(benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound VI), (14S)-8-[3-(2-{dispiro[2.0.2.1]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6-Thia-3,9,11,18,23-pentaazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione (Compound VII), (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hexan-5-yl}-9-oxa-2λ 6 and further administering one or more additional CFTR modulators selected from -thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadeca-1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione (Compound VIII), N-(benzenesulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound IX), and N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound X).

[0047] Another aspect of the invention is a method of treating the CFTR-mediated disease cystic fibrosis, comprising administering to a patient in need of treatment at least one compound selected from the compounds of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, and optionally: [ka] (ASP-11) as disclosed in Journal of Cystic Fibrosis (2018), 17(5), 595-606, and [ka] and further administering one or more additional CFTR modulating agents selected from those disclosed in WO2016 / 105485 (nesolicaftor or PTI-428). In one embodiment, the additional CFTR modulating agent is ASP-11. In one embodiment, the additional CFTR modulating agent comprises PTI-428.

[0048] Another aspect of the invention is a method of treating the CFTR-mediated disease cystic fibrosis, comprising administering to a patient in need thereof at least one compound selected from the compounds of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing; and, optionally, [ka] Disclosed in U.S. Patent Application Publication No. 2016-0120841 (galicaftor or ABBV-2222); [ka] Disclosed in WO2018 / 065921 (ABBV-3221), [ka] and further administering one or more additional CFTR modulators selected from (posenacaftor or PTI-801) disclosed in WO2017 / 062581, ABBV-2851 disclosed in WO2017 / 009804, GLPG2737, ABBV-3748, ABBV-3903, and ABBV-119 disclosed in U.S. Patent Application Publication No. 2017-0101405. [Brief explanation of the drawings]

[0049] [Figure 1] 1 provides the X-ray powder diffraction (XRPD) pattern of amorphous Compound 4 (native form). [Figure 2] 1 provides a thermogravimetric analysis (TGA) curve of amorphous Compound 4 (unmodified form). [Figure 3] 1 provides a DSC analysis of amorphous Compound 4 (native form). [Figure 4] 1 provides the XRPD pattern of amorphous Compound 19 (native form). [Figure 5] 1 provides the TGA curve of amorphous Compound 19 (native form). [Figure 6] 1 provides a DSC analysis of amorphous Compound 19 (native form). [Figure 7] 1 provides an XRPD pattern of Form A of crystalline Compound 41. [Figure 8] 1 provides the TGA curve of crystalline Compound 41 Form A. [Figure 9] 1 provides the XRPD pattern of crystalline Compound 52 Form A (native). [Figure 10] 1 provides the TGA curve of crystalline Compound 52 Form A (native). [Figure 11] 1 provides a DSC analysis of crystalline Compound 52 Form A (native). [Figure 12] 1 provides the XRPD pattern of amorphous Compound 60 (native form). [Figure 13] 1 provides the TGA curve of amorphous Compound 60 (native form). [Figure 14] 1 provides a DSC analysis of amorphous Compound 60 (native form). [Figure 15] 1 provides the XRPD pattern of amorphous Compound 70 (native form). [Figure 16] 1 provides an XRPD pattern of crystalline Compound 163 Form A (native). [Figure 17] 1 provides a DSC analysis of crystalline Compound 163 Form A (native). [Figure 18] 1 provides the XRPD pattern of amorphous Compound 173 (native form). [Figure 19]1 provides the TGA curve of amorphous Compound 173 (native form). [Figure 20] 1 provides a DSC analysis of amorphous Compound 173 (native form).

[0050] definition As used herein, "Compound II" refers to (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, which may be represented by the following structure: [ka] Compound II can be in the form of a pharmaceutically acceptable salt. Compound II and methods of making and using Compound II are disclosed in WO2010 / 053471, WO2011 / 119984, WO2011 / 133751, WO2011 / 133951, and WO2015 / 160787, each of which is incorporated herein by reference.

[0051] As used throughout this disclosure, "Compound III" refers to N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide, and is represented by the following structure: [ka] Compound III may also be in the form of a pharmaceutically acceptable salt. Compound III and methods of making and using Compound III are disclosed in WO2006 / 002421, WO2007 / 079139, WO2010 / 108162, and WO2010 / 019239, each of which is incorporated herein by reference.

[0052] In some embodiments, a deuterated derivative of compound III (compound III-d) is utilized in the compositions and methods disclosed herein. Compound III-d has the chemical name N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d)propan-2-yl-1,1,1,3,3,3-d)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide and is represented by the following structure: [ka] Compound III-d can be in the form of a pharmaceutically acceptable salt. Compound III-d and methods for making and using Compound III-d are disclosed in WO2012 / 158885, WO2014 / 078842, and U.S. Patent No. 8,865,902, which are incorporated herein by reference.

[0053] As used herein, "Compound IV" refers to 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, represented by the following chemical structure: [ka] Compound IV can be in the form of a pharmaceutically acceptable salt. Compound IV and methods of making and using Compound IV are disclosed in WO2007 / 056341, WO2009 / 073757, and WO2009 / 076142, which are incorporated herein by reference.

[0054] As used herein, "Compound V" refers to N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, and is represented by the following chemical structure: [ka] Compound V can be in the form of a pharmaceutically acceptable salt. Compound V and methods of making and using Compound V are disclosed in WO2018 / 107100 and WO2019 / 113476, which are incorporated herein by reference.

[0055] As used herein, "Compound VI" refers to N-(benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, and is represented by the following chemical structure: [ka] Compound VI can be in the form of a pharmaceutically acceptable salt. Compound VI and methods of making and using Compound VI are disclosed in WO2018 / 064632, which is incorporated herein by reference.

[0056] As used herein, "Compound VII" refers to (14S)-8-[3-(2-{dispiro[2.0.2.1]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentaazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione, represented by the following chemical structure: [ka] Compound VII can be in the form of a pharmaceutically acceptable salt.Compound VII and the methods for making and using Compound VII are disclosed in WO22019 / 161078, WO2020 / 102346 and PCT Application No. PCT / US2020 / 046116, which are incorporated herein by reference.

[0057] As used herein, "Compound VIII" refers to (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hexan-5-yl}-9-oxa-2λ 6 -thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadeca-1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione, represented by the following chemical structure: [ka] Compound VIII can be in the form of a pharmaceutically acceptable salt. Compound VIII and methods for making and using Compound VIII are disclosed in WO2020 / 206080, which is incorporated herein by reference.

[0058] As used herein, "compound IX" refers to N-(benzenesulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, and is represented by the following chemical structure: [ka] Compound IX can be in the form of a pharmaceutically acceptable salt. Compound IX and methods of making and using Compound IX are disclosed in WO2016 / 057572, which is incorporated herein by reference.

[0059] As used herein, "Compound X" refers to N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, and is represented by the following chemical structure: [ka] Compound X may be in the form of a pharmaceutically acceptable salt. Compound X and methods of making and using Compound X are disclosed in WO2016 / 057572, which is incorporated herein by reference.

[0060] As used herein, the term "alkyl" refers to a saturated branched or unbranched aliphatic hydrocarbon having carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms, etc.). An alkyl group can be substituted or unsubstituted.

[0061] As used herein, the term "π bond" refers to a covalent bond formed by p orbitals of adjacent atoms. A π bond exists when there is a multiple bond, i.e., a double or triple bond, between two atoms. For example, a carbon-carbon double bond consists of one π bond, and a carbon-carbon triple bond consists of two π bonds.

[0062] As used herein, the term "haloalkyl group" refers to an alkyl or alkyl group substituted with one or more halogen atoms.

[0063] As used herein, the term "fluoroalkyl" refers to an alkyl group substituted with one or more fluorine atoms. In some embodiments, the fluoroalkyl group is substituted with 1 to 6 fluorine atoms. In some embodiments, the fluoroalkyl group is perfluorinated.

[0064] The term "alkoxy" as used herein refers to an alkyl or cycloalkyl covalently linked to an oxygen atom. An alkoxy group can be substituted or unsubstituted.

[0065] As used herein, the term "haloalkoxyl group" refers to an alkoxy group substituted with one or more halogen atoms.

[0066] As used herein, the term "fluoroalkoxy" refers to an alkoxy group substituted with one or more fluorine atoms. In some embodiments, the fluoroalkoxy group is substituted with 1 to 6 fluorine atoms. In some embodiments, the fluoroalkoxy group is perfluorinated.

[0067] As used herein, "cycloalkyl" refers to a cyclic, bicyclic, tricyclic, or polycyclic non-aromatic hydrocarbon group having 3 to 12 carbons (e.g., 3 to 10 carbons). "Cycloalkyl" groups encompass monocyclic, bicyclic, tricyclic, bridged, fused, and spirocyclic rings, including monospiro and dispiro rings. Non-limiting examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, norbornyl, and dispiro[2.0.2.1]heptane. Cycloalkyl groups can be substituted or unsubstituted.

[0068] The term "heteroaryl ring," as used herein, refers to an aromatic ring that contains at least one ring atom that is a heteroatom, such as O, N, or S.

[0069] As used herein, the terms "heterocyclyl ring" and "heterocyclyl" refer to a non-aromatic hydrocarbon containing 3 to 12 atoms (e.g., 3 to 10 atoms) in the ring, with at least one ring atom being a heteroatom such as O, N, S, or Si. "Heterocyclyl" rings encompass monocyclic, bicyclic, tricyclic, polycyclic, bridged, fused, and spiro rings, including monospiro and dispiro rings.

[0070] "Substituted" indicates that at least one hydrogen of the "substituted" group is replaced by a substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each of the substitutable positions of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be the same or different at each position.

[0071] Examples of nitrogen protecting groups include, for example, t-butyl carbamate (Boc), benzyl (Bn), para-methoxybenzyl (PMB), tetrahydropyranyl (THP), 9-fluorenylmethyl carbamate (Fmoc), benzyl carbamate (Cbz), methyl carbamate, ethyl carbamate, 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), allyl carbamate (Aloc or Alloc), formamide, acetamide, benzamide, allylamine, trifluoroacetamide, triphenylmethylamine, benzylideneamine, and p-toluenesulfonamide. A comprehensive list of nitrogen protecting groups can be found in Wuts, PGM, "Greene's Protective Groups in Organic Synthesis: Fifth Edition," 2014, John Wiley and Sons.

[0072] As used herein, "deuterated derivative" means the same chemical structure in which one or more hydrogen atoms have been replaced by deuterium atoms.

[0073] As used herein, "CFTR" means cystic fibrosis transmembrane conductance regulator.

[0074] As used herein, the term "CFTR modulator" refers to a compound that increases the activity of CFTR. Increased activity resulting from a CFTR modulator includes, but is not limited to, compounds that correct, enhance, stabilize, and / or amplify CFTR.

[0075] As used herein, the term "CFTR corrector" refers to a compound that enhances the processing and trafficking of CFTR, increasing the amount of CFTR at the cell surface.

[0076] As used herein, the term "CFTR potentiator" refers to a compound that increases the channel activity of the CFTR protein located on the cell surface, resulting in enhanced ion transport. The novel compounds disclosed herein are CFTR potentiators.

[0077] As used herein, the terms "CFTR potentiator," "CFTR potentiator," and "CFTR co-potentiator" are used interchangeably and refer to compounds that potentiate CFTR potentiation.

[0078] As used herein, the term "active pharmaceutical ingredient" ("API") or "therapeutic agent" refers to a biologically active compound.

[0079] The terms "patient" and "subject" are used interchangeably and refer to animals, including humans.

[0080] The terms "effective dose" and "effective amount" are used interchangeably herein and refer to the amount of a compound that, when administered, produces a desired effect (e.g., improvement in CF or symptoms of CF, or a reduction in the severity of CF or symptoms of CF). The exact amount of an effective dose will depend on the purpose of the treatment, and will be ascertainable by one of ordinary skill in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

[0081] As used herein, the terms "treatment," "treating," and the like generally refer to an improvement in one or more symptoms of CF or a reduction in the severity of CF or one or more symptoms of CF in a subject. As used herein, "treatment" includes, but is not limited to, an increase in growth, an increase in weight gain, a reduction in mucus in the lungs, an improvement in pancreatic and / or liver function, a reduction in lung infections, and / or a reduction in cough or shortness of breath in a subject. Improvement or a reduction in the severity of any of these symptoms can be readily assessed according to standard methods and techniques known in the art.

[0082] As used herein, the term "in combination with," when referring to two or more compounds, agents, or additional active pharmaceutical ingredients, means that the two or more compounds, agents, or active pharmaceutical ingredients are administered to a patient before, simultaneously with, or after each other.

[0083] The terms "about" and "approximately," when used in connection with a dose, amount, or weight percent of a component of a composition or dosage form, include a specific dose, amount, or weight percent value, or a range of doses, amounts, or weight percents, recognized by one of ordinary skill in the art, that provides the same pharmacological effect as that provided by the specific dose, amount, or weight percent. The terms "about" and "approximately" can refer to an acceptable range of error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In some embodiments, the terms "about" and "approximately" mean within 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, or 0.5% of a given value or range. As used herein, the symbol "~" appearing immediately before a numerical value has the same meaning as the terms "about" and "approximately."

[0084] As used herein, the term "solvent" refers to any liquid in which the product is at least partially soluble (solubility of product >1 g / L).

[0085] As used herein, the term "room temperature" or "ambient temperature" means 15°C to 30°C.

[0086] It is to be understood that certain compounds of the present invention may exist as separate stereoisomers or enantiomers and / or as mixtures of such stereoisomers or enantiomers. As used in the chemical structures disclosed herein, a "wedge" to a stereoatom [ka] or "hash" [ka] The bond denotes a chiral center of known absolute stereochemistry (i.e., one stereoisomer). As used in the chemical structures disclosed herein, a "wavy" bond to a stereoatom [ka] indicates a chiral center of unknown absolute stereochemistry (i.e., one stereoisomer). As used in the chemical structures disclosed herein, a "wavy" bond to a double bond carbon [ka] indicates a mixture of E / Z isomers. When used in the chemical structures disclosed herein, [ka] A (straight) bond indicates that a mixture (e.g., a racemate or concentrate) is present. As used herein, two bonds to a double bond carbon [ka] A ("straight") bond indicates that the double bond has the depicted E / Z stereochemistry. As used in the chemical structures disclosed herein, [ka] (i.e., a "wavy" line perpendicular to the "straight" bond to group "A") indicates that group "A" is a substituent, the point of attachment of which is the terminus of the bond that terminates at the "wavy" line.

[0087] Certain compounds disclosed herein may exist as tautomers, and both tautomeric forms are intended, even if only a single tautomeric structure is depicted. For example, a description of compound A is understood to include its tautomeric form, compound B, and vice versa, as well as mixtures thereof. [ka]

[0088] As used herein, "minimal function (MF) mutation" refers to a CFTR gene mutation associated with minimal CFTR function (a CFTR protein with little or no function), including, for example, mutations associated with a severe defect in the ability of the CFTR channel to open and close, known as a channel gating defect or "gating mutation," mutations associated with a severe defect in the cellular processing of CFTR and its delivery to the cell surface, mutations associated with no or minimal CFTR synthesis, and mutations associated with a severe defect in channel conductance.

[0089] As used herein, the term "pharmaceutically acceptable salt" refers to a salt form of a compound of the present disclosure, wherein the salt is non-toxic. Pharmaceutically acceptable salts of the compounds of the present disclosure include those derived from suitable inorganic and organic acids and bases. The "free base" form of a compound does not include, for example, ionically bonded salts.

[0090] The phrase "and pharmaceutically acceptable salts and deuterated derivatives thereof," with respect to one or more compounds or formulas of the invention, is used interchangeably with "and pharmaceutically acceptable salts and deuterated derivatives of any of the foregoing." These phrases are intended to encompass pharmaceutically acceptable salts of any one of the referenced compounds, deuterated derivatives of any one of the referenced compounds, and pharmaceutically acceptable salts of those deuterated derivatives.

[0091] Those skilled in the art will recognize that when an amount of "a compound or a pharmaceutically acceptable salt thereof" is disclosed, the amount of the pharmaceutically acceptable salt form of that compound is the amount equivalent to the concentration of the free base of that compound. Note that the disclosed amounts of compounds or their pharmaceutically acceptable salts herein are based on their free base forms.

[0092] Suitable pharmaceutically acceptable salts are, for example, those disclosed in S. M. Berge, et al. J. Pharmaceutical Sciences, 1977, 66, 1-19. For example, Table 1 of that article provides the following pharmaceutically acceptable salts: [Table 1]

[0093] Non-limiting examples of pharmaceutically acceptable acid addition salts include salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, or perchloric acid, salts formed with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, and salts formed using other methods used in the art, such as ion exchange. Non-limiting examples of pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy- Pharmaceutically acceptable salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts, and valerate salts. + (C 1-4(Alkyl) 4 salts are also included. The present disclosure also contemplates the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Suitable, non-limiting examples of alkali metal and alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium. Further non-limiting examples of pharmaceutically acceptable salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates. Other suitable, non-limiting examples of pharmaceutically acceptable salts include besylate and glucosamine salts.

[0094] As used herein, the term "amorphous" refers to a solid material that does not have long-range order in the position of its molecules. An amorphous solid is generally a supercooled liquid in which molecules are randomly arranged, with no clearly defined arrangement, e.g., no molecular packing, and no long-range order. An amorphous solid is generally isotropic, i.e., exhibits similar properties in all directions, and does not have a distinct melting point. For example, an amorphous substance is a solid substance that does not have sharp, characteristic crystalline peaks in its X-ray powder diffraction (XRPD) pattern (i.e., is not crystalline as determined by XRPD). Instead, one or several broad peaks (e.g., halos) are observed in its XRPD pattern. Broad peaks are characteristic of amorphous solids. For a comparison of XRPD of amorphous and crystalline substances, see US 2004 / 0006237. In some embodiments, a solid material may comprise an amorphous compound; for example, the solid material may be characterized by a lack of sharp, characteristic crystalline peaks in its XRPD spectrum (i.e., the solid material is not crystalline but is amorphous as determined by XRPD). Instead, one or several broad peaks (e.g., halos) may be observed in the XRPD pattern of the solid material. For a comparison of XRPD of amorphous and crystalline materials, see US 2004 / 0006237. A solid material comprising an amorphous compound may be characterized, for example, by a glass transition temperature that is lower than the melting point of the pure crystalline solid. Other techniques, such as, for example, solid-state NMR, may also be used to characterize crystalline or amorphous forms.

[0095] As used herein, the terms "crystal form," "crystalline form," and "form" refer interchangeably to a crystalline structure (or polymorph) having a particular molecular packing arrangement within a crystal lattice. A crystalline form can be identified by, for example, X-ray powder diffraction (XRPD), single crystal X-ray diffraction, and 13 C solid-state nuclear magnetic resonance ( 13C SSNMR). Accordingly, as used herein, the term "crystalline form [X] of Compound (I)" refers to a crystalline form of Compound (I) that can be identified and distinguished from one another by one or more characterization techniques, including, for example, XRPD, single crystal X-ray diffraction, and 13 It refers to a unique crystalline form that can be identified and distinguished from other forms by one or more characterization techniques, including C SSNMR. In some embodiments, the novel crystalline form is characterized by an X-ray powder diffractogram having one or more signals at one or more specific two-theta values ​​(°2θ).

[0096] As used herein, the term "free form" refers to the non-ionized form of a compound in the solid state. Examples of free forms include the free base and the free acid.

[0097] As used herein, the term "solvate" refers to a crystalline form that contains one or more molecules of a compound of the present disclosure and that contains one or more molecules of a stoichiometric or non-stoichiometric amount of a solvent incorporated into the crystal lattice. When the solvent is water, the solvate is referred to as a "hydrate."

[0098] In some embodiments, the solid material may comprise a mixture of crystalline and amorphous solids. A solid substance comprising an amorphous compound may comprise, for example, up to 30% crystalline solids. In some embodiments, a solid substance prepared to comprise an amorphous compound may also comprise, for example, up to 25%, 20%, 15%, 10%, 5%, or 2% crystalline solids. In embodiments where the solid substance comprises a mixture of crystalline and amorphous solids, characterization data such as XRPD may include indicators of both crystalline and amorphous solids. In some embodiments, the crystalline forms of the present disclosure may comprise up to 30% amorphous compound. In some embodiments, crystalline preparations of the compound of Formula I may comprise up to 25%, 20%, 15%, 10%, 5%, or 2% amorphous solids.

[0099] As used herein, the term "substantially amorphous" refers to a solid material that has little or no long-range order in the position of its molecules. For example, a substantially amorphous substance has less than 15% crystallinity (e.g., less than 10% crystallinity, or less than 5% crystallinity, or less than 2% crystallinity). Note that the term "substantially amorphous" also includes the descriptor "amorphous," which refers to a material that has no (0%) crystallinity.

[0100] As used herein, the term "substantially crystalline" refers to a solid material that has few or no amorphous molecules. For example, a substantially crystalline substance has less than 15% amorphous molecules (e.g., less than 10% amorphous molecules, less than 5% amorphous molecules, or less than 2% amorphous molecules). It should also be noted that the term "substantially crystalline" includes the descriptor "crystalline," which refers to a material that is 100% crystalline in form.

[0101] As used herein, a crystalline form is "substantially pure" if it accounts for 90% or more by weight of the sum of all solid forms in a sample, as determined by methods known in the art, such as quantitative XRPD. In some embodiments, a solid form is "substantially pure" if it accounts for 95% or more by weight of the sum of all solid forms in a sample. In some embodiments, a solid form is "substantially pure" if it accounts for 99% or more by weight of the sum of all solid forms in a sample. It should also be noted that the term "substantially pure" includes the descriptor "pure."

[0102] As used herein, the term "XRPD" refers to the analytical characterization method of X-ray powder diffraction. The XRPD patterns disclosed herein can be recorded at ambient conditions in transmission or reflection geometry using a diffractometer.

[0103] As used herein, the term "ambient conditions" refers to room temperature, open air conditions, and uncontrolled humidity conditions. The terms "room temperature" and "ambient temperature" refer to temperatures between 15°C and 30°C.

[0104] As used herein, the terms "X-ray powder diffractogram," "X-ray powder diffraction pattern," "XRPD pattern," and "XRPD spectrum" refer interchangeably to an experimentally obtained pattern that plots signal position (on the abscissa) against signal intensity (on the ordinate). For amorphous materials, the X-ray powder diffractogram may include one or more broad signals; for crystalline materials, the X-ray powder diffractogram may include one or more signals, each identified by its angular value, measured in degrees 2θ (°2θ), shown on the abscissa of the X-ray powder diffractogram, which may be expressed as "signal at ... degrees 2-theta," "signal at a 2-theta value of [a] of ...," and / or "signal at at least ... 2-theta values ​​selected from ...."

[0105] As used herein, a "signal" or "peak" refers to a point in an XRPD pattern where the intensity, as measured in counts, is at a local maximum. One of ordinary skill in the art will recognize that one or more signals (or peaks) in an XRPD pattern may overlap and, for example, may not be apparent to the naked eye. Indeed, one of ordinary skill in the art will recognize that several art-recognized methods are capable and suitable for determining whether a signal is present in a pattern, such as Rietveld refinement.

[0106] As used herein, "signal at ... degrees two theta" refers to the position of the X-ray reflection (°2θ) as measured and observed in an X-ray powder diffraction experiment.

[0107] The repeatability of the measured angle values ​​is within ±0.2° 2θ, i.e., the angle value can be at the recited angle value +0.2 degrees 2-theta, angle value -0.2 degrees 2-theta, or any value between those two endpoints (angle value +0.2 degrees 2-theta and angle value -0.2 degrees 2-theta).

[0108] The terms "signal intensity" and "peak intensity" refer interchangeably to relative signal intensities within a given X-ray powder diffractogram. Factors that can affect relative signal intensity or peak intensity include sample thickness and preferred orientation (e.g., crystalline particles are not randomly distributed).

[0109] As used herein, an X-ray powder diffractogram is "substantially similar to that of a [particular] figure" if at least 90%, such as at least 95%, at least 98%, or at least 99%, of the signals in the two diffractograms overlap. In determining "substantial similarity," one of skill in the art will understand that even for the same crystalline form, there may be variations in intensity and / or signal positions in XRPD diffractograms. Thus, one of skill in the art will understand that signal maxima (in degrees 2-theta) in an XRPD diffractogram generally mean that the values ​​are specified as ±0.2 degrees 2-theta of the reported value, which is an art-recognized variance.

[0110] As used herein, a solid-state nuclear magnetic resonance spectrum (SSNMR) is "substantially similar to that in a [particular] figure" if at least 90%, e.g., at least 95%, at least 98%, or at least 99% of the signals in the two spectra overlap. In determining "substantial similarity," one skilled in the art will understand that variations in intensity and / or signal positions may exist in SSNMR spectra even for the same crystalline form. Thus, one skilled in the art will understand that chemical shifts in SSNMR spectra (referred to herein in parts per million (ppm)) generally mean values ​​specified as ±0.2 ppm of the reported value, which is an art-recognized variance.

[0111] As used herein, the term "X-ray powder diffractogram having signals at 2-theta values..." refers to an XRPD pattern containing the X-ray reflection positions (° 2-theta) measured and observed in an X-ray powder diffraction experiment.

[0112] As used herein, the term "DSC" refers to the analytical method of differential scanning calorimetry.

[0113] As used herein, the term "onset of degradation" refers to the intersection of the baseline and the interreflection tangent before the transition.

[0114] As used herein, the term "glass transition temperature" or "Tg" refers to the temperature above which a hard, brittle "glassy" amorphous solid becomes viscous or rubbery.

[0115] As used herein, "melting temperature," "melting point," or "Tm" refers to the temperature at which a substance transitions from a solid to a liquid phase.

[0116] As used herein, the term "TGA" refers to the analytical method of Thermo Gravimetric (or thermogravimetric) analysis. DETAILED DESCRIPTION OF THE INVENTION

[0117] In addition to compounds of Formula I, pharmaceutically acceptable salts thereof, and deuterated derivatives of those compounds and salts, the present invention provides compounds of Formula I', I'', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, and pharmaceutically acceptable salts of any of the foregoing.

[0118] For example, in some embodiments, the compound of Formula I is a compound of any one of Formulas Ia, IIa, IIb, IIc, IId, IIe, IIf, IIg, and IIh: [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein all variables are as defined for Formula I'.

[0119] In some embodiments, the compound of formula I is a compound of formula I″: [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein all variables are as defined for Formula I.

[0120] In some embodiments, the compound of Formula I is a compound of any one of Formulas Ia′, IIa′, IIb′, IIc′, IId′, IIe′, IIf′, IIg′, and IIh′: [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein all variables are as defined for Formula I.

[0121] Also disclosed herein are compounds having a formula selected from any one of the formulas represented in Table 10, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of these compounds and deuterated derivatives.

[0122] solid form Another aspect of the present disclosure provides solid forms of compounds of Formula I (e.g., compounds of Formula I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing), which may be used in the methods of treatment and pharmaceutical compositions described herein.

[0123] Amorphous Compound 4 (native form) In some embodiments, the present invention provides a native solid form of Compound 4. In some embodiments, the present invention provides a native amorphous form of Compound 4. In some embodiments, the present invention provides amorphous Compound 4 (native form). Figure 1 provides an X-ray powder diffractogram of amorphous Compound 4 (native form) at room temperature.

[0124] In some embodiments, amorphous Compound 4 (native form) is substantially pure. In some embodiments, amorphous Compound 4 (native form) is substantially amorphous. In some embodiments, amorphous Compound 4 (native form) is characterized by an X-ray powder diffractogram generated by X-ray powder diffraction analysis using an incident beam of Cu Kα radiation.

[0125] In some embodiments, amorphous Compound 4 (native form) is characterized by an X-ray powder diffractogram substantially similar to FIG.

[0126] Crystalline Compound 5 Form A (native) In some embodiments, the present invention provides a native solid form of Compound 5. In some embodiments, the present invention provides a native crystalline form of Compound 5. In some embodiments, the present invention provides Form A (native) of crystalline Compound 5.

[0127] In some embodiments, crystalline Compound 5 Form A (native) is substantially pure. In some embodiments, crystalline Compound 5 Form A (native) is substantially crystalline.

[0128] In some embodiments, Form A (native) of crystalline Compound 5 has a tetragonal crystal system, I41 space group, and Cu K α It is characterized by the following unit cell dimensions measured at 100 K on a Bruker diffractometer using radiation (λ=1.54178 Å): [Table 2]

[0129] Amorphous Compound 19 (native form) In some embodiments, the present invention provides a native solid form of Compound 19. In some embodiments, the present invention provides a native amorphous form of Compound 19. In some embodiments, the present invention provides amorphous Compound 19 (native form). Figure 4 provides an X-ray powder diffractogram of amorphous Compound 19 (native form) at room temperature.

[0130] In some embodiments, amorphous Compound 19 (native form) is substantially pure. In some embodiments, amorphous Compound 19 (native form) is substantially amorphous. In some embodiments, amorphous Compound 19 (native form) is characterized by an X-ray powder diffractogram generated by X-ray powder diffraction analysis using an incident beam of Cu Kα radiation.

[0131] In some embodiments, amorphous Compound 19 (native form) is characterized by an X-ray powder diffractogram substantially similar to FIG.

[0132] Crystalline Compound 41 Form A (native) In some embodiments, the present invention provides a native solid form of Compound 41. In some embodiments, the present invention provides a crystalline form of Compound 41. In some embodiments, the present invention provides Form A of crystalline Compound 41. Figure 7 provides an X-ray powder diffractogram of Form A of crystalline Compound 41.

[0133] In some embodiments, Form A of crystalline Compound 41 is substantially pure. In some embodiments, Form A of crystalline Compound 41 is substantially crystalline. In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram generated by X-ray powder diffraction analysis using an incident beam of Cu Kα radiation.

[0134] In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram having signals at one or more of 14.2±0.2 degrees 2-theta, 19.5±0.2 degrees 2-theta, and 21.2±0.2 degrees 2-theta. In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram having signals at two or more of 14.2±0.2 degrees 2-theta, 19.5±0.2 degrees 2-theta, and 21.2±0.2 degrees 2-theta. In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram having signals at 14.2±0.2 degrees 2-theta, 19.5±0.2 degrees 2-theta, and 21.2±0.2 degrees 2-theta.

[0135] In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram having signals at three or more of 14.2±0.2 degrees 2-theta, 19.5±0.2 degrees 2-theta, 21.2±0.2 degrees 2-theta, 18.0±0.2 degrees 2-theta, 16.6±0.2 degrees 2-theta, and 20.7±0.2 degrees 2-theta. In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram having signals at four or more of 14.2±0.2 degrees 2-theta, 19.5±0.2 degrees 2-theta, 21.2±0.2 degrees 2-theta, 18.0±0.2 degrees 2-theta, 16.6±0.2 degrees 2-theta, and 20.7±0.2 degrees 2-theta. In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram having signals at five or more of 14.2±0.2 degrees 2-theta, 19.5±0.2 degrees 2-theta, 21.2±0.2 degrees 2-theta, 18.0±0.2 degrees 2-theta, 16.6±0.2 degrees 2-theta, and 20.7±0.2 degrees 2-theta. In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram having signals at 14.2±0.2 degrees 2-theta, 19.5±0.2 degrees 2-theta, 21.2±0.2 degrees 2-theta, 18.0±0.2 degrees 2-theta, 16.6±0.2 degrees 2-theta, and 20.7±0.2 degrees 2-theta.

[0136] In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram having signals at one, two, three, four, five, six, seven, eight, or more of 14.2±0.2 degrees 2-theta, 16.6±0.2 degrees 2-theta, 18.0±0.2 degrees 2-theta, 19.5±0.2 degrees 2-theta, 20.3±0.2 degrees 2-theta, 20.7±0.2 degrees 2-theta, 21.2±0.2 degrees 2-theta, 22.2±0.2 degrees 2-theta, and 25.1±0.2 degrees 2-theta.

[0137] In some embodiments, Form A of crystalline Compound 41 is characterized by an X-ray powder diffractogram substantially similar to FIG.

[0138] Crystalline Compound 52 Form A (native) In some embodiments, the present invention provides a native solid form of Compound 52. In some embodiments, the present invention provides a native crystalline form of Compound 52. In some embodiments, the present invention provides Form A (native) of crystalline Compound 52. Figure 9 provides an X-ray powder diffractogram of Form A (native) of crystalline Compound 52.

[0139] In some embodiments, Form A (native) of crystalline Compound 52 is substantially pure. In some embodiments, Form A (native) of crystalline Compound 52 is substantially crystalline. In some embodiments, Form A (native) of crystalline Compound 52 is characterized by an X-ray powder diffractogram generated by X-ray powder diffraction analysis using an incident beam of Cu Kα radiation.

[0140] In some embodiments, Form A (native) of crystalline Compound 52 is characterized by an X-ray powder diffractogram having signals at one or more of 6.8±0.2 degrees 2-theta, 17.3±0.2 degrees 2-theta, and 18.6±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 52 is characterized by an X-ray powder diffractogram having signals at two or more of 6.8±0.2 degrees 2-theta, 17.3±0.2 degrees 2-theta, and 18.6±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 52 is characterized by an X-ray powder diffractogram having signals at 6.8±0.2 degrees 2-theta, 17.3±0.2 degrees 2-theta, and 18.6±0.2 degrees 2-theta.

[0141] In some embodiments, Form A (native) of crystalline Compound 52 is characterized by an X-ray powder diffractogram having signals at three or more of 6.8±0.2 degrees 2-theta, 12.7±0.2 degrees 2-theta, 17.3±0.2 degrees 2-theta, 18.6±0.2 degrees 2-theta, 20.6±0.2 degrees 2-theta, and 21.4±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 52 is characterized by an X-ray powder diffractogram having signals at four or more of 6.8±0.2 degrees 2-theta, 12.7±0.2 degrees 2-theta, 17.3±0.2 degrees 2-theta, 18.6±0.2 degrees 2-theta, 20.6±0.2 degrees 2-theta, and 21.4±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 52 is characterized by an X-ray powder diffractogram having signals at five or more of 6.8±0.2 degrees 2-theta, 12.7±0.2 degrees 2-theta, 17.3±0.2 degrees 2-theta, 18.6±0.2 degrees 2-theta, 20.6±0.2 degrees 2-theta, and 21.4±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 52 is characterized by an X-ray powder diffractogram having signals at 12.7±0.2 degrees 2-theta, 17.3±0.2 degrees 2-theta, 18.6±0.2 degrees 2-theta, 20.6±0.2 degrees 2-theta, and 21.4±0.2 degrees 2-theta.

[0142] In some embodiments, crystalline Compound 52 Form A (native) is characterized by an X-ray powder diffractogram having signals at one, two, three, four, five, six, seven, eight, nine, ten, eleven, or more of 6.8±0.2 degrees two-theta, 12.7±0.2 degrees two-theta, 15.1±0.2 degrees two-theta, 15.5±0.2 degrees two-theta, 17.3±0.2 degrees two-theta, 18.6±0.2 degrees two-theta, 19.2±0.2 degrees two-theta, 19.7±0.2 degrees two-theta, 20.4±0.2 degrees two-theta, 20.6±0.2 degrees two-theta, 21.4±0.2 degrees two-theta, and 27.2±0.2 degrees two-theta.

[0143] In some embodiments, Form A (native) of crystalline Compound 52 is characterized by an X-ray powder diffractogram substantially similar to FIG.

[0144] Amorphous Compound 60 (native form) In some embodiments, the present invention provides a native solid form of Compound 60. In some embodiments, the present invention provides a native amorphous form of Compound 60. In some embodiments, the present invention provides amorphous Compound 60 (native form). Figure 12 provides an X-ray powder diffractogram of amorphous Compound 60 (native form) at room temperature.

[0145] In some embodiments, amorphous compound 60 (native form) is substantially pure. In some embodiments, amorphous compound 60 (native form) is substantially amorphous. In some embodiments, amorphous compound 60 (native form) is characterized by an X-ray powder diffractogram generated by X-ray powder diffraction analysis using an incident beam of Cu Kα radiation.

[0146] In some embodiments, amorphous compound 60 (native form) is characterized by an X-ray powder diffractogram substantially similar to FIG.

[0147] Amorphous Compound 70 (native form) In some embodiments, the present invention provides a native solid form of Compound 70. In some embodiments, the present invention provides a native amorphous form of Compound 70. In some embodiments, the present invention provides amorphous Compound 70 (native form). Figure 15 provides an X-ray powder diffractogram of amorphous Compound 70 (native form) at room temperature.

[0148] In some embodiments, amorphous compound 70 (native form) is substantially pure. In some embodiments, amorphous compound 70 (native form) is substantially amorphous. In some embodiments, amorphous compound 70 (native form) is characterized by an X-ray powder diffractogram generated by X-ray powder diffraction analysis using an incident beam of Cu Kα radiation.

[0149] In some embodiments, amorphous compound 70 (native form) is characterized by an X-ray powder diffractogram substantially similar to FIG.

[0150] Crystalline Compound 163 Form A (native) In some embodiments, the present invention provides a native solid form of Compound 163. In some embodiments, the present invention provides a native crystalline form of Compound 163. In some embodiments, the present invention provides Form A (native) of crystalline Compound 163. Figure 16 provides an X-ray powder diffractogram of Form A (native) of crystalline Compound 163.

[0151] In some embodiments, Form A (native) of crystalline Compound 163 is substantially pure. In some embodiments, Form A (native) of crystalline Compound 163 is substantially crystalline. In some embodiments, Form A (native) of crystalline Compound 163 is characterized by an X-ray powder diffractogram generated by X-ray powder diffraction analysis using an incident beam of Cu Kα radiation.

[0152] In some embodiments, crystalline Compound 163 Form A (native) is characterized by an X-ray powder diffractogram having a signal at 7.4±0.2 degrees two-theta.

[0153] In some embodiments, Form A (native) of crystalline Compound 163 is characterized by an X-ray powder diffractogram having signals at one or more of 7.4±0.2 degrees 2-theta, 8.4±0.2 degrees 2-theta, and 15.0±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 163 is characterized by an X-ray powder diffractogram having signals at two or more of 7.4±0.2 degrees 2-theta, 8.4±0.2 degrees 2-theta, and 15.0±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 163 is characterized by an X-ray powder diffractogram having signals at 7.4±0.2 degrees 2-theta, 8.4±0.2 degrees 2-theta, and 15.0±0.2 degrees 2-theta.

[0154] In some embodiments, Form A (native) of crystalline Compound 163 is characterized by an X-ray powder diffractogram having signals at three or more of: 7.4±0.2 degrees 2-theta, 8.4±0.2 degrees 2-theta, 14.1±0.2 degrees 2-theta, 15.0±0.2 degrees 2-theta, 19.1±0.2 degrees 2-theta, and 25.8±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 163 is characterized by an X-ray powder diffractogram having signals at four or more of: 7.4±0.2 degrees 2-theta, 8.4±0.2 degrees 2-theta, 14.1±0.2 degrees 2-theta, 15.0±0.2 degrees 2-theta, 19.1±0.2 degrees 2-theta, and 25.8±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 163 is characterized by an X-ray powder diffractogram having signals at five or more of 7.4±0.2 degrees 2-theta, 8.4±0.2 degrees 2-theta, 14.1±0.2 degrees 2-theta, 15.0±0.2 degrees 2-theta, 19.1±0.2 degrees 2-theta, and 25.8±0.2 degrees 2-theta. In some embodiments, Form A (native) of crystalline Compound 163 is characterized by an X-ray powder diffractogram having signals at 7.4±0.2 degrees 2-theta, 8.4±0.2 degrees 2-theta, 14.1±0.2 degrees 2-theta, 15.0±0.2 degrees 2-theta, 19.1±0.2 degrees 2-theta, and 25.8±0.2 degrees 2-theta.

[0155] In some embodiments, crystalline Compound 163 Form A (native) is characterized by an X-ray powder diffractogram having signals at one, two, three, four, five, six, seven, eight, nine, ten, or more of 7.4±0.2 degrees two-theta, 8.4±0.2 degrees two-theta, 14.1±0.2 degrees two-theta, 14.6±0.2 degrees two-theta, 15.0±0.2 degrees two-theta, 16.9±0.2 degrees two-theta, 19.1±0.2 degrees two-theta, 20.0±0.2 degrees two-theta, 22.5±0.2 degrees two-theta, 25.6±0.2 degrees two-theta, and 25.8±0.2 degrees two-theta.

[0156] In some embodiments, Form A (native) of crystalline Compound 163 is characterized by an X-ray powder diffractogram substantially similar to FIG.

[0157] Amorphous Compound 173 (native form) and crystalline Compound 173 Form A (native) In some embodiments, the present invention provides a native solid form of Compound 173. In some embodiments, the present invention provides a native amorphous form of Compound 173. In some embodiments, the present invention provides amorphous Compound 173 (native form). Figure 18 provides an X-ray powder diffractogram of amorphous Compound 173 (native form) at room temperature.

[0158] In some embodiments, amorphous compound 173 (native form) is substantially pure. In some embodiments, amorphous compound 173 (native form) is substantially amorphous. In some embodiments, amorphous compound 173 (native form) is characterized by an X-ray powder diffractogram generated by X-ray powder diffraction analysis using an incident beam of Cu Kα radiation.

[0159] In some embodiments, amorphous Compound 173 (native form) is characterized by an X-ray powder diffractogram substantially similar to FIG.

[0160] In some embodiments, the present invention provides native crystalline forms of Compound 173. In some embodiments, the present invention provides crystalline Compound 173, Form A (native).

[0161] In some embodiments, Form A (native) of crystalline Compound 173 is substantially pure. In some embodiments, Form A (native) of crystalline Compound 173 is substantially crystalline.

[0162] In some embodiments, Form A (native) of crystalline Compound 173 has a triclinic crystal system, P1 space group, and Cu K α It is characterized by the following unit cell dimensions measured at 150 K on a Bruker diffractometer using radiation (λ=1.54178 Å): [Table 3]

[0163] Crystalline Compound 175 Form A (native) In some embodiments, the present invention provides native solid forms of Compound 175. In some embodiments, the present invention provides native crystalline forms of Compound 175. In some embodiments, the present invention provides Form A (native) of crystalline Compound 175.

[0164] In some embodiments, Form A (native) of crystalline Compound 175 is substantially pure. In some embodiments, Form A (native) of crystalline Compound 175 is substantially crystalline.

[0165] In some embodiments, Form A (native) of crystalline Compound 175 has an orthorhombic crystalline system, a P212121 space group, and a Cu K α It is characterized by the following unit cell dimensions measured at 100 K on a Bruker diffractometer using radiation (λ=1.54178 Å): [Table 4]

[0166] Dichloromethane solvate Form A of crystalline Compound 188 In some embodiments, the present invention provides a solvated crystalline form of Compound 188. In some embodiments, the solvated crystalline form is a dichloromethane solvate. In some embodiments, the present invention provides dichloromethane solvate Form A of crystalline Compound 188.

[0167] In some embodiments, dichloromethane solvate Form A of crystalline Compound 188 is substantially pure. In some embodiments, dichloromethane solvate Form A of crystalline Compound 188 is substantially crystalline.

[0168] In some embodiments, the dichloromethane solvate Form A of crystalline Compound 188 has a monoclinic crystal system, P21 space group, and Cu K αIt is characterized by the following unit cell dimensions measured at 100 K on a Bruker diffractometer using radiation (λ=1.54178 Å): [Table 5]

[0169] Treatment method Any of the novel compounds and solid forms disclosed herein, such as compounds of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, can act as CFTR modulators, i.e., regulate CFTR activity in the body. Individuals suffering from mutations in the gene encoding CFTR may benefit from receiving a CFTR modulator. CFTR mutations can affect CFTR abundance, i.e., the number of CFTR channels on the cell surface, or can affect CFTR function, i.e., the functional ability of each channel to open and transport ions. Mutations that affect CFTR levels include those that cause synthesis defects (Class I defects), processing and trafficking defects (Class II defects), reduced synthesis of CFTR (Class V defects), and reduced surface stability of CFTR (Class VI defects). Mutations that affect CFTR function include those that cause gating defects (Class III defects) and conductance defects (Class IV defects). Some CFTR mutations exhibit characteristics of more than one class. Certain mutations in the CFTR gene result in cystic fibrosis.

[0170] Accordingly, in some embodiments, the present invention provides methods of treating, reducing the severity of, or palliatively treating cystic fibrosis in a patient, comprising administering to the patient an effective amount of any of the novel compounds and solid forms disclosed herein, e.g., a compound of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, alone or in combination with another active ingredient, such as another CFTR modulator. In some embodiments, the patient has an F508del / minimal function (MF) genotype, an F508del / F508del genotype (homozygous for the F508del mutation), an F508del / gating genotype, or an F508del / residual function (RF) genotype. In some embodiments, the patient is heterozygous and has one F508del mutation. In some embodiments, the patient is homozygous for the N1303K mutation.

[0171] In some embodiments, between 1 mg and 1000 mg of a compound disclosed herein, a deuterated derivative thereof, or a pharmaceutically acceptable salt of such a compound or salt is administered daily.

[0172] In some embodiments, the patient is heterozygous and carries the F508del mutation in one allele and a mutation selected from Table 2 in the other allele. [Table 6-1] [Table 6-2]

[0173] In some embodiments, the present disclosure is also directed to methods of treatment using isotopically labeled compounds of the foregoing compounds or pharmaceutically acceptable salts thereof, wherein the formulas and variables of such compounds and salts are each independently as described above or in any other embodiment above, except that one or more atoms therein are replaced (isotopically labeled) by an atom having an atomic mass or mass number different from the atomic mass or mass number of the atom normally occurring in nature. Examples of isotopes that are commercially available and suitable for the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, e.g., 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F, and 36 Examples include Cl.

[0174] Isotopically labeled compounds and salts can be used in several beneficial ways. They may be suitable for various types of assays, such as drug and / or substrate tissue distribution assays. For example, tritium ( 3 H) labeling and / or carbon-14 ( 14 C) labeled compounds are particularly useful in various types of assays, such as substrate tissue distribution assays, due to their relatively simple preparation and excellent detectability. 2 H) The labeled compound is therapeutically useful and non- 2 3H-labeled compounds have potential therapeutic advantages over H-labeled compounds. 2H) Labeled compounds and salts can have higher metabolic stability than non-isotopically labeled compounds due to the kinetic isotope effect described below. Higher metabolic stability directly translates into desired increased in vivo half-life or lower dosage. Isotopically labeled compounds and salts can generally be prepared by following the procedures disclosed in the synthetic schemes and related descriptions, examples, and preparations herein, substituting readily available isotopically labeled reactants for non-isotopically labeled reactants.

[0175] In some embodiments, isotopically labeled compounds and salts contain deuterium ( 2 H) labeled compounds and salts. In some specific embodiments, the isotopically labeled compounds and salts are deuterium ( 2 H) labeled compounds and salts in which one or more hydrogen atoms have been replaced by deuterium. In the chemical structures, deuterium is 2 It is represented by "H" or "D".

[0176] In discovering and developing therapeutic agents, those skilled in the art attempt to optimize pharmacokinetic parameters while retaining desirable in vitro properties, and it may be reasonable to assume that many compounds with poor pharmacokinetic profiles are susceptible to oxidative metabolism.

[0177] deuterium( 2 H) labeled compounds and salts can modulate the oxidative metabolism of compounds through the primary kinetic isotope effect. The primary kinetic isotope effect is a change in the rate of a chemical reaction resulting from the exchange of an isotope nucleus, which in turn is caused by a change in the ground state energy required for covalent bond formation after this isotope exchange. The exchange of a heavier isotope usually results in a lowering of the ground state energy of the chemical bond, and therefore a decrease in the rate-limiting bond breaking. If the bond breaking occurs within or near a saddle point region along the configuration of a multi-product reaction, the product distribution ratio can change significantly. For illustrative purposes, when deuterium is attached to a carbon atom in a non-exchangeable position, k M / k DA rate difference of 2 to 7 is typical. For further discussion, see S.L. Harbeson and R.D. Tung, Deuterium In Drug Discovery and Development, Ann. Rep. Med. Chem. 2011, 46, 403-417, which is incorporated herein by reference.

[0178] The concentration of an isotope (e.g., deuterium) incorporated into the isotopically labeled compounds and salts of the present disclosure can be defined by the isotopic enrichment factor. As used herein, the term "isotopic enrichment factor" means the ratio between the isotopic abundance and the natural abundance of a specified isotope. In some embodiments, when a substituent of a compound of the present disclosure is represented by deuterium, such compounds have an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

[0179] Combination therapy One aspect disclosed herein provides methods of treating cystic fibrosis and other CFTR-mediated diseases using any of the novel compounds and solid forms disclosed herein, such as compounds of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, in combination with at least one additional active pharmaceutical ingredient.

[0180] Accordingly, in some embodiments, the present invention provides methods of treating, reducing the severity of, or symptomatically treating cystic fibrosis in a patient, comprising administering to the patient an effective amount of any of the novel compounds and solid forms disclosed herein, e.g., a compound of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, alone or in combination with at least one additional active pharmaceutical ingredient, such as another CFTR modulator.

[0181] In some embodiments, the at least one additional active pharmaceutical ingredient is selected from a mucolytic agent, a bronchodilator, an antibiotic, an anti-infective, and an anti-inflammatory.

[0182] In some embodiments, the additional therapeutic agent is an antibiotic. Exemplary antibiotics useful herein include tobramycin, including tobramycin inhalation powder (TIP), azithromycin, aztreonam, including an aerosolized form of aztreonam, amikacin, including a liposomal formulation of amikacin, ciprofloxacin, including a formulation of ciprofloxacin suitable for administration by inhalation, levofloxacin, including an aerosolized formulation of levofloxacin, and a combination of two antibiotics, such as fosfomycin and tobramycin.

[0183] In some embodiments, the additional agent is a mucolytic agent. Exemplary mucolytic agents useful herein include Pulmozyme®.

[0184] In some embodiments, the additional agent is a bronchodilator. Exemplary bronchodilators include albuterol, metaproterenol sulfate, pirbuterol acetate, salmeterol, or tetrabuline sulfate.

[0185] In some embodiments, the additional agent is an anti-inflammatory agent, i.e., an agent that can reduce inflammation in the lungs. Examples of such agents useful herein include ibuprofen, docosahexaenoic acid (DHA), sildenafil, inhaled glutathione, pioglitazone, hydroxychloroquine, or simavastatin.

[0186] In some embodiments, the additional agent is a nutritional agent. Exemplary nutritional agents include pancrelipase (pancreatic enzyme replacement), including Pancrease®, Pancreacarb®, Ultrase®, or Creon®, Liprotomase® (formerly Trizytek®), Aquadeks®, or glutathione inhalation. In one embodiment, the additional nutritional agent is pancrelipase.

[0187] In some embodiments, the at least one additional active pharmaceutical ingredient is selected from a CFTR modulator. In some embodiments, the CFTR modulator is a CFTR corrector. In some embodiments, the CFTR modulator is a CFTR potentiator / co-potentiator (e.g., ASP-11). In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR amplifier. In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR readthrough agent. In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR nucleic acid therapy.

[0188] In some embodiments, at least one additional active pharmaceutical ingredient is an ENaC inhibitor. In some embodiments, at least one additional active pharmaceutical ingredient is a TMEM16A modulator. In some embodiments, at least one additional active pharmaceutical ingredient is a GPR39 agonist.

[0189] In some embodiments, the at least one additional active pharmaceutical ingredient is selected from (a) Compound II and its deuterated derivatives and pharmaceutically acceptable salts, (b) Compound IV and its deuterated derivatives and pharmaceutically acceptable salts, (c) Compound V and its deuterated derivatives and pharmaceutically acceptable salts, (d) Compound VI and its deuterated derivatives and pharmaceutically acceptable salts, (e) Compound VII and its deuterated derivatives and pharmaceutically acceptable salts, and (f) Compound VIII and its deuterated derivatives and pharmaceutically acceptable salts. Thus, in some embodiments, the combination therapy provided herein comprises a compound selected from the compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives, and at least one compound selected from Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, the combination therapy provided herein comprises: (a) at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives; (b) at least one compound selected from Compound II, Compound IV, and pharmaceutically acceptable salts and deuterated derivatives thereof; and (c) at least one compound selected from Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof.In some embodiments, the combination therapy provided herein comprises: (a) at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives; (b) at least one compound selected from Compound II, and pharmaceutically acceptable salts and deuterated derivatives thereof; and (c) at least one compound selected from Compound VII, and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0190] In some embodiments, the combination therapy provided herein comprises a compound selected from the group consisting of: (a) compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh'; Compounds 1-213; Compounds 214-222; deuterated derivatives of these compounds; and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives. (b) at least one compound selected from Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) a compound selected from the group consisting of compounds described in WO2016 / 105485, U.S. Patent Application Publication No. 2016-0120841, U.S. Patent Application Publication No. 2017-0101405, WO2017 / 009804, WO2018 / 065921, WO2017 / 062581, Phuan, P.-W. et al. al.J.Cyst. Fibros.2018,17(5),595-606, Pedemonte,N.et al.Sci.Adv.2020,6(8),eaay9669, Phuan,P.-W.et al.Sci.Rep.2019,9(1),17640, Bose,S.et al.J.Cyst. Fibros.2020,19 Suppl 1,S25-S32, Crawford,DKJPharmacol. Exp.Ther.2020,374(2),264-272, Brasell,EJ et al.PLoS One 2019,14(12),e0223954, Smith,NJ,Solovay,CF,Pharm. 2017, 6(4), 179-188, Kunzelmann, K. et al., Front. Pharmacol. 2019, 10, 3, or Son, J.-H. et al., Eur. J. of Med. Chem. 2020, 112888.

[0191] In some embodiments, the combination therapy provided herein comprises (a) a compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives; (b) at least one compound selected from Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one compound selected from PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG27 37, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837, GLPG2451 / ABBV-2451 (Icenticaftor )), GLPG3067 / ABBV-3067 (Navocaftor), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5 Rx, BI 1265162, AZ5634, ARO-ENaC1001, ETD002, and at least one compound selected from DS-1039.

[0192] In some embodiments, the combination therapy provided herein comprises (a) a compound selected from the group consisting of compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives; and (b) a compound selected from the group consisting of compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives; and 84, WO2011 / 133751, WO2011 / 133951, WO2015 / 160787, WO2007 / 056341, WO2009 / 073757, WO 2009 / 076142, WO2018 / 107100, WO2019 / 113476, WO2018 / 064632, WO2019 / 152940, WO2016 / 057572, WO2021 / 030554, WO2020 / 206080, WO2016 / 105485, U.S. Patent Application Publication No. 2016-0120841, U.S. Patent Application Publication No. 2017-0101405, WO2017 / 009804, WO2018 / 065921, WO2017 / 062581, Phuan, P.-W. et al.J.Cyst. Fibros.2018,17(5),595-606, Pedemonte,N.et al.Sci.Adv.2020,6(8),eaay9669, Phuan,P.-W.et al.Sci.Rep.2019,9(1),17640, Bose,S.et al.J.Cyst. Fibros.2020,19 Suppl 1,S25-S32, Crawford,DKJPharmacol. Exp.Ther.2020,374(2),264-272, Brasell,EJ et al.PLoS One 2019,14(12),e0223954, Smith,NJ,Solovay,CF,Pharm. Pat. Anal. 2017, 6(4), 179-188, Kunzelmann, K. et al., Front. Pharmacol. 2019, 10, 3, or Son, J.-H. et al.and at least two compounds selected from the compounds disclosed in Eur. J. of Med. Chem. 2020, 112888.

[0193] In some embodiments, the combination therapy provided herein comprises (a) a compound selected from the group consisting of compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives; and (b) a compound selected from the group consisting of Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-32 21, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837, GLPG2451 / ABBV-2451 (Icenticaftor), GLP and at least two compounds selected from G3067 / ABBV-3067 (navocaftor), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5 Rx, BI 1265162, AZ5634, ARO-ENaC1001, ETD002, and DS-1039, and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0194] In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives, is administered in combination with at least one compound selected from Compound II, and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', compounds 1-213, compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives, is administered in combination with at least one compound selected from compound IV, and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives, is administered in combination with at least one compound selected from Compound V, and deuterated derivatives and pharmaceutically acceptable salts thereof.In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives, is administered in combination with at least one compound selected from Compound VI, and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives, is administered in combination with at least one compound selected from Compound VII, and deuterated derivatives and pharmaceutically acceptable salts thereof. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, deuterated derivatives of these compounds, and pharmaceutically acceptable salts of any of the foregoing compounds and deuterated derivatives, is administered in combination with at least one compound selected from Compound VIII, and deuterated derivatives and pharmaceutically acceptable salts thereof.

[0195] Each of the compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof, independently, can be administered once daily, twice daily, or three times daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof is administered once daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, is administered twice daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof is administered once daily.In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof is administered twice daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound IV and a pharmaceutically acceptable salt thereof is administered once daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound IV and a pharmaceutically acceptable salt thereof is administered twice daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound V and a pharmaceutically acceptable salt thereof is administered once daily.In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound V and a pharmaceutically acceptable salt thereof is administered twice daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound VI and a pharmaceutically acceptable salt thereof is administered once daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound VI and a pharmaceutically acceptable salt thereof is administered twice daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound VII and a pharmaceutically acceptable salt thereof is administered once daily.In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound VII and a pharmaceutically acceptable salt thereof is administered twice daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound VIII and a pharmaceutically acceptable salt thereof is administered once daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound VIII and a pharmaceutically acceptable salt thereof is administered twice daily.

[0196] In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, at least one compound selected from Compound II, Compound IV, and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and pharmaceutically acceptable salts thereof is administered once daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, at least one compound selected from Compound II, Compound IV, and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and pharmaceutically acceptable salts thereof is administered twice daily. In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof, and at least one compound selected from Compound VII and a pharmaceutically acceptable salt thereof is administered once daily.In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof, and at least one compound selected from Compound VII and a pharmaceutically acceptable salt thereof is administered twice daily.

[0197] The compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof can be administered in a single pharmaceutical composition or in separate pharmaceutical compositions. Such pharmaceutical compositions can be administered once daily or multiple times daily, for example, twice daily. As used herein, the phrase that a given amount of API (e.g., Compound II, Compound VII, or a pharmaceutically acceptable salt thereof) is administered daily or once or twice per day means that the given amount is administered per dose, and that this dose can occur once or twice daily.

[0198] In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, is administered in a first pharmaceutical composition, and at least one compound selected from Compound VII and pharmaceutically acceptable salts thereof is administered in a second pharmaceutical composition.

[0199] In some embodiments, at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof is administered in a first pharmaceutical composition, at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof is administered in a second pharmaceutical composition, and at least one compound selected from Compound VII and a pharmaceutically acceptable salt thereof is administered in a third pharmaceutical composition.

[0200] Any suitable pharmaceutical composition known in the art can be used for the compounds and solid forms of Formula I, I', I", Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof. Some exemplary pharmaceutical compositions of Compound II and pharmaceutically acceptable salts thereof can be found in WO2011 / 119984 and WO2014 / 014841, which are incorporated herein by reference. Some exemplary pharmaceutical compositions of Compound III and pharmaceutically acceptable salts thereof can be found in WO2007 / 134279, WO2010 / 019239, WO2011 / 019413, WO2012 / 027731, and WO2013 / 130669, and some exemplary pharmaceutical compositions of Compound III-d and pharmaceutically acceptable salts thereof can be found in US8,865,902, US9,181,192, US9,512,079, WO2017 / 053455, and WO2018 / 080591, all of which are incorporated herein by reference. Some exemplary pharmaceutical compositions of Compound IV and its pharmaceutically acceptable salts can be found in WO2010 / 037066, WO2011 / 127421, and WO2014 / 071122, which are incorporated herein by reference. Some exemplary pharmaceutical compositions of Compound V and its pharmaceutically acceptable salts can be found in WO2019 / 152940, which are incorporated herein by reference. Some exemplary pharmaceutical compositions of Compound VI and its pharmaceutically acceptable salts can be found in WO2019 / 079760, which are incorporated herein by reference.

[0201] Pharmaceutical Composition Another aspect of the present invention provides pharmaceutical compositions comprising at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, and IIh', compounds 1-213, compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier.

[0202] In some embodiments, pharmaceutical compositions are provided comprising at least one compound selected from the compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', in combination with at least one additional active pharmaceutical ingredient. In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR modulator. In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR corrector. In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR potentiator. In some embodiments, the at least one additional active pharmaceutical ingredient is a compound that potentiates CFTR potentiation, i.e., a CFTR potentiator / co-potentiator. In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR amplifier. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR read-through agent. In some embodiments, at least one additional active pharmaceutical ingredient is a CFTR nucleic acid therapy. In some embodiments, at least one additional active pharmaceutical ingredient is an ENaC inhibitor. In some embodiments, at least one additional active pharmaceutical ingredient is a TMEM16A modulator. In some embodiments, at least one additional active pharmaceutical ingredient is a GPR39 agonist. In some embodiments, the pharmaceutical composition comprises at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', compounds 1-213, compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least two additional active pharmaceutical ingredients, each a CFTR corrector.In some embodiments, the pharmaceutical composition comprises at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', compounds 1-213, compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof, and at least two additional active pharmaceutical ingredients, one of which is a CFTR corrector and the other of which is a CFTR potentiator.

[0203] In some embodiments, the present invention provides pharmaceutical compositions comprising: (a) at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof; (b) at least one compound selected from Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0204] In some embodiments, the present invention provides pharmaceutical compositions comprising: (a) at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives thereof and pharmaceutically acceptable salts thereof; (b) at least one compound selected from Compound II and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0205] In some embodiments, the present invention provides pharmaceutical compositions comprising: (a) at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives thereof and pharmaceutically acceptable salts thereof; (b) at least one compound selected from Compound VII and pharmaceutically acceptable salts thereof; and (c) at least one pharmaceutically acceptable carrier.

[0206] In some embodiments, the present disclosure provides pharmaceutical compositions comprising: (a) at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof; (b) at least one compound selected from Compound II, Compound IV, and pharmaceutically acceptable salts thereof; (c) at least one compound selected from Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and pharmaceutically acceptable salts thereof; and (d) at least one pharmaceutically acceptable carrier.

[0207] In some embodiments, the present disclosure provides pharmaceutical compositions comprising: (a) at least one compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives thereof and pharmaceutically acceptable salts thereof; (b) at least one compound selected from Compound II and pharmaceutically acceptable salts thereof; (c) at least one compound selected from Compound VII and pharmaceutically acceptable salts thereof; and (d) at least one pharmaceutically acceptable carrier.

[0208] In some embodiments, the pharmaceutical compositions provided herein comprise (a) a compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives thereof and pharmaceutically acceptable salts thereof; and (b) Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and pharmaceutically acceptable salts and deuterated derivatives thereof; and (c) at least one compound selected from the group consisting of compounds described in WO2016 / 105485, U.S. Patent Application Publication No. 2016-0120841, U.S. Patent Application Publication No. 2017-0101405, WO2017 / 009804, WO2018 / 065921, WO2017 / 062581, Phuan, P.-W. et al. al.J.Cyst. Fibros.2018,17(5),595-606, Pedemonte,N.et al.Sci.Adv.2020,6(8),eaay9669, Phuan,P.-W.et al.Sci.Rep.2019,9(1),17640, Bose,S.et al.J.Cyst. Fibros.2020,19 Suppl 1,S25-S32, Crawford,DKJPharmacol. Exp.Ther.2020,374(2),264-272, Brasell,EJ et al.PLoS One 2019,14(12),e0223954, Smith,NJ,Solovay,CF,Pharm. Pat. Anal. 2017, 6(4), 179-188; Kunzelmann, K. et al., Front. Pharmacol. 2019, 10, 3; or Son, J.-H. et al., Eur. J. of Med. Chem. 2020, 112888; and (d) at least one pharmaceutically acceptable carrier.

[0209] In some embodiments, the pharmaceutical compositions provided herein comprise: (a) a compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof; (b) at least one compound selected from Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (c) at least one compound selected from PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG273, 7. ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837, GLPG2451 / ABBV-2451 (Icenticaftor) , GLPG3067 / ABBV-3067 (navocaftor), ABBV-191, ELX-02, MRT5005, Lunar-CF, RCT223, amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5 Rx, BI 1265162, AZ5634, ARO-ENaC1001, ETD002, and DS-1039; and (d) at least one pharmaceutically acceptable carrier.

[0210] In some embodiments, the pharmaceutical compositions provided herein comprise (a) a compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (b) a compound selected from compounds described in WO2019 / 195739, WO2019 / 200246, WO2021 / 030555, WO2021 / 030556, WO2010 / 053471, WO2011 / 119984, WO2011 / 1337 51, WO2011 / 133951, WO2015 / 160787, WO2007 / 056341, WO2009 / 073757, WO2009 / 07614 2, WO2018 / 107100, WO2019 / 113476, WO2018 / 064632, WO2019 / 152940, WO2016 / 057572, WO2021 / 030554, WO2020 / 206080, WO2016 / 105485, U.S. Patent Application Publication No. 2016-0120841, U.S. Patent Application Publication No. 2017-0101405, WO2017 / 009804, WO2018 / 065921, WO2017 / 062581, Phuan, P.-W. et. al.J.Cyst. Fibros.2018,17(5),595-606, Pedemonte,N.et al.Sci.Adv.2020,6(8),eaay9669, Phuan,P.-W.et al.Sci.Rep.2019,9(1),17640, Bose,S.et al.J.Cyst. Fibros.2020,19 Suppl 1,S25-S32, Crawford,DKJPharmacol. Exp.Ther.2020,374(2),264-272, Brasell,EJ et al.PLoS One 2019,14(12),e0223954, Smith,NJ,Solovay,CF,Pharm. Pat. Anal. 2017, 6 (4), 179-188, Kunzelmann, K. et al., Front. Pharmacol. 2019, 10, 3, or Son, J.-H. et al., Eur. J. of Med. Chem.and (c) at least one pharmaceutically acceptable carrier.

[0211] In some embodiments, the pharmaceutical compositions provided herein comprise (a) a compound selected from compounds and solid forms of Formula I, I', I'', Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', Compounds 1-213, Compounds 214-222, and deuterated derivatives and pharmaceutically acceptable salts thereof; and (b) Compound II, Compound IV, Compound V, Compound VI, Compound VII, Compound VIII, Compound IX, Compound X, PTI-428, ASP-11, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748 ... BBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, PTI-801, FDL-176, PTI-808, GLPG1837, GLPG2451 / ABBV-2451 (Icenticaftor), GLPG3067 / A and (c) at least one pharmaceutically acceptable carrier.

[0212] Any pharmaceutical composition disclosed herein may comprise at least one pharmaceutically acceptable carrier. In some embodiments, the at least one pharmaceutically acceptable carrier is selected from a pharmaceutically acceptable vehicle and a pharmaceutically acceptable adjuvant. In some embodiments, the at least one pharmaceutically acceptable is selected from a pharmaceutically acceptable filler, disintegrant, surfactant, binder, and lubricant.

[0213] The pharmaceutical compositions described herein are useful for the treatment of cystic fibrosis and other CFTR-mediated diseases.

[0214] As described above, the pharmaceutical compositions disclosed herein may optionally further comprise at least one pharmaceutically acceptable carrier. The at least one pharmaceutically acceptable carrier may be selected from adjuvants and vehicles. As used herein, at least one pharmaceutically acceptable carrier includes any solvent, diluent, other liquid vehicle, dispersion aid, suspension aid, surfactant, isotonicity agent, thickener, emulsifier, preservative, solid binder, and lubricant suitable for the desired specific dosage form. Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D.B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J.C. Boylan, 1988-1999, Marcel Dekker, New York, disclose various carriers used in formulating pharmaceutical compositions and known techniques for their preparation. Except insofar as any conventional carrier is incompatible with the compounds of the present disclosure, for example, by imparting any undesirable biological effect or otherwise interacting in a deleterious manner with any other component of the pharmaceutical composition, its use is contemplated within the scope of the present disclosure.Non-limiting examples of suitable pharmaceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances (e.g., phosphates, glycine, sorbic acid, and potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts, and electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts), colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars (e.g., lactose, glucose, and sucrose), starches (e.g., corn starch and potato starch), cellulose and its derivatives (e.g., carboxymethylcellulose), and the like. Examples of suitable additives include, but are not limited to, cellulose acetate, cellulose acetate, maltose, ethylcellulose, and cellulose acetate), powdered tragacanth, malt, gelatin, talc, excipients (e.g., cocoa butter and suppository waxes), oils (e.g., peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil), glycols (e.g., propylene glycol and polyethylene glycol), esters (e.g., ethyl oleate and ethyl laurate), agar, buffers (e.g., magnesium hydroxide and aluminum hydroxide), alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, phosphate buffer solution, non-toxic compatible lubricants (e.g., sodium lauryl sulfate and magnesium stearate), colorants, release agents, coating agents, sweetening agents, flavoring agents, fragrances, preservatives, and antioxidants.

[0215] Non-limiting exemplary embodiments 1. A compound selected from compounds of formula I: [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein X is -N(R X1 )- and [ka] is selected from Ring A is a 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl and oxo; R X1 H, C1-C6 alkyl (independently hydroxy, oxo, -OR X2 , and -N(R X2 ) optionally substituted with 1-3 groups selected from 2), and C3-C8 cycloalkyl; Each R X2 are independently selected from H and C1-C6 alkyl groups; Each Y is independently -C(R Y )2-, -O-, -CO-, -NR YN - and [ka] wherein each R YN are independently H, C1-C4 alkyl, and COR YN1 Each R YN1 is independently selected from C1-C4 alkyl and C3-C6 cycloalkyl; Each R Y are independently selected from hydrogen, hydroxy, halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C1-C6 alkoxy, and Q), C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -OR Y1 , -CO2R Y1 , -COR Y1 , -CON(R Y1 )2, and -N(R Y1 )2 or or two R on the same atom Y are taken together to form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or two R Ytogether to form a π bond, Each R Y1 are independently selected from hydrogen and C1-C6 alkyl, or two R Y1 together form a 3- to 6-membered heterocyclyl, Ring B is ■C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen, C1-C6 alkyl, and C1-C6 alkoxy); ■ C3-C8 cycloalkyl, ■ 5- to 10-membered heteroaryl, and ■ 3- to 6-membered heterocyclyl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), Each Q is independently C1-C6 alkyl, independently ○Halogen, ○Oxo, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen and —OCF3), and C1-C6 alkyl optionally substituted with 1 to 3 groups selected from C3-C8 cycloalkyl, C3-C8 cycloalkyl, independently: ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen, -NH2, and -NHCOMe); ○C1-C6 alkoxy, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl), and ○ C3-C8 cycloalkyl optionally substituted with 1 to 3 groups selected from ■C6~C 10 aryl, independently ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen and hydroxy), ○C1-C6 alkoxy, independently ■Halogen, ■ C1-C6 alkoxy optionally substituted with 1 to 4 groups selected from C3-C8 cycloalkyl (optionally substituted with CF3); C3-C8 cycloalkyl (optionally substituted with 1 to 3 groups independently selected from halogen, CF3, OCF3, and C1-C6 alkyl), and ○C6~C 10 C-C optionally substituted with 1 to 3 groups selected from aryl 10 aryl, ■ 5- to 10-membered heteroaryl, independently ○Halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen), C3-C8 cycloalkyl (optionally substituted with 1 to 3 CF3 groups), and ○ 3- to 10-membered heterocyclyl, ■ 3- to 10-membered heterocyclyl, independently C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from oxo and C3-C8 cycloalkyl), and oxo, 3- to 10-membered heterocyclyl optionally substituted with 1 to 3 groups selected from Each R 1 are independently selected from halogen, C1-C6 fluoroalkyl, C1-C6 alkyl (C6-C 10 optionally substituted with a group selected from aryl and 5- to 6-membered heteroaryl, -OR 2 , -N(R 2 )2, -CO2R 2 , -CO-N(R 2 )2, -CN, C3-C8 cycloalkyl, C6-C 10aryl, 5- to 6-membered heteroaryl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), 3- to 6-membered heterocyclyl, B(OR 2 )2, -SO2R 2 , -SR 2 , -SOR 2 , -PO(OR 2 )2, and -PO(R 2 )2 is selected, Each R 2 are independently selected from hydrogen, C1-C6 alkyl (optionally substituted with 1 to 6 groups independently selected from halogen), C1-C6 fluoroalkyl, and C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 fluoroalkyl and C1-C6 fluoroalkoxy); Z, [ka] wherein ring C is selected from C6 to C 10 selected from aryl and 5- to 10-membered heteroaryl; R Z1 is hydrogen, —CN, C1-C6 alkyl (optionally substituted with 1 to 3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, C6-C 10 aryl, and 5- to 6-membered heteroaryl; R Z2 is hydrogen, halogen, hydroxy, NH2, NH(CO)(C1-C6 alkyl), and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and R Z2 together form a group selected from oxo and =N-OH, Each R Z3 are independently selected from hydroxy, C1-C6 alkoxy, C1-C6 alkyl, and C6-C 10 aryl, or two R Z3together form a 3- to 6-membered heterocyclyl, n is selected from 4, 5, 6, 7, and 8; Compounds, and deuterated derivatives and pharmaceutically acceptable salts thereof, wherein m is selected from 0, 1, 2, and 3.

[0216] 2. X is -N(R X1 )- and [ka] is selected from Ring A is a 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl and oxo; R X1 H, C1-C6 alkyl (independently hydroxy, oxo, -OR X2 , and -N(R X2 ) optionally substituted with 1-3 groups selected from 2), and C3-C8 cycloalkyl; Each R X2 are independently selected from H and C1-C6 alkyl groups; Each Y is independently -C(R Y )2-, -O-, -CO-, -NR YN - and [ka] wherein each R YN is independently selected from H, C1-C4 alkyl, and CO2Me; Each R Y are independently selected from hydrogen, hydroxy, halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C1-C6 alkoxy, and Q), C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -OR Y1 , -CO2R Y1 , -CORY1 , -CON(R Y1 )2, and -N(R Y1 )2 or or two R on the same atom Y are taken together to form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or two R Y together to form a π bond, Each R Y1 are independently selected from hydrogen and C1-C6 alkyl, or two R Y1 together form a 3- to 6-membered heterocyclyl, Ring B is ■C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen, C1-C6 alkyl, and C1-C6 alkoxy); ■ C3-C8 cycloalkyl, ■ 5- to 10-membered heteroaryl, and ■ 3- to 6-membered heterocyclyl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), Each Q is independently C1-C6 alkyl, independently ○Halogen, ○Oxo, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen and —OCF3), and C1-C6 alkyl optionally substituted with 1 to 3 groups selected from C3-C8 cycloalkyl, C3-C8 cycloalkyl, independently: ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen, -NH2, and -NHCOMe); ○C1-C6 alkoxy, ○C6~C10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl), and ○ C3-C8 cycloalkyl optionally substituted with 1 to 3 groups selected from ■C6~C 10 aryl, independently ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen and hydroxy), ○C1-C6 alkoxy, independently ■Halogen, ■ C1-C6 alkoxy optionally substituted with 1 to 4 groups selected from C3-C8 cycloalkyl (optionally substituted with CF3); C3-C8 cycloalkyl (optionally substituted with 1 to 3 groups independently selected from halogen, CF3, OCF3, and C1-C6 alkyl), and ○C6~C 10 C-C optionally substituted with 1 to 3 groups selected from aryl 10 aryl, ■ 5- to 10-membered heteroaryl, independently ○Halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen), C3-C8 cycloalkyl (optionally substituted with 1 to 3 CF3 groups), and ○ 3- to 10-membered heterocyclyl, ■ 3- to 10-membered heterocyclyl, independently C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from oxo and C3-C8 cycloalkyl), and oxo, 3- to 10-membered heterocyclyl optionally substituted with 1 to 3 groups selected from Each R1 are independently selected from halogen, C1-C6 fluoroalkyl, C1-C6 alkyl (hydroxy, C6-C 10 aryl, and 5- to 6-membered heteroaryl), -OR 2 , -N(R 2 )2, -CO2R 2 , -CO-N(R 2 )2, -CN, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 6-membered heteroaryl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), 3- to 6-membered heterocyclyl; -SO2R 2 , -SR 2 , -SOR 2 , -PO(OR 2 )2, and -PO(R 2 )2 is selected, Each R 2 are independently selected from hydrogen, C1-C6 alkyl (optionally substituted with 1 to 6 groups independently selected from halogen), C1-C6 fluoroalkyl, and C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 fluoroalkyl and C1-C6 fluoroalkoxy); Z, [ka] is selected from R Z1 is hydrogen, —CN, C1-C6 alkyl (optionally substituted with 1 to 3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, C6-C 10 aryl, and 5- to 6-membered heteroaryl; R Z2 is hydrogen, halogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and RZ2 together form a group selected from oxo and =N-OH, Each R Z3 are independently selected from hydroxy, C1-C6 alkoxy, C1-C6 alkyl, and C6-C 10 aryl, or two R Z3 together form a 3- to 6-membered heterocyclyl, n is selected from 4, 5, 6, and 7; The compound, deuterated derivative, or salt of embodiment 1, wherein m is selected from 0, 1, 2, and 3.

[0217] 3. X is -NR X1 3. The compound, deuterated derivative, or salt of embodiment 1 or 2, wherein

[0218] 4. X is [ka] 4. The compound, deuterated derivative, or salt of any one of embodiments 1 to 3, selected from:

[0219] 5. X is [ka] 3. The compound, deuterated derivative, or salt of embodiment 1 or 2, wherein

[0220] 6. The compound, deuterated derivative, or salt of embodiment 1, 2, or 5, wherein Ring A is selected from pyrrolidine, piperazine, morpholine, and isothiazolidine.

[0221] 7. X is [ka] 7. The compound, deuterated derivative, or salt of claim 1, 2, 5, or 6, selected from:

[0222] 8. Each R Y But independently, Hydrogen, hydroxy, methyl, [ka] Selected from or or two R on the same atom Y taken together form a ring selected from cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyrryl, and tetrahydrofuryl; or two R, one on one atom and the second on an adjacent atom Y The compound, deuterated derivative, or salt of any one of embodiments 1-7, wherein:

[0223] 9. Each Q is independently a C6-C alkyl group substituted with at least 1-3 groups independently selected from halogen and C1-C6 alkyl. 10 9. The compound, deuterated derivative, or salt of any one of embodiments 1 to 8, wherein:

[0224] 10. The compound, deuterated derivative, or salt of any one of embodiments 1-9, wherein each Q is phenyl.

[0225] 11. Each ring B is independently C6 to C 10 The compound, deuterated derivative, or salt of any one of embodiments 1-10, selected from aryl (optionally substituted with at least 1-3 groups independently selected from halogen and C1-C6 alkoxy) and 5-10 membered heteroaryl.

[0226] 12. Ring B is independently [ka] 12. The compound, deuterated derivative, or salt of any one of embodiments 1 to 11, selected from:

[0227] 13. -(Y) n -but, [ka] 13. The compound, deuterated derivative, or salt of any one of embodiments 1 to 12, selected from:

[0228] 14. -(Y) n -but, [ka] [ka] 14. The compound, deuterated derivative, or salt of any one of embodiments 1 to 13, selected from:

[0229] 15. Each Y is -C(R Y 15. The compound, deuterated derivative, or salt of any one of embodiments 1-14, wherein:

[0230] 16. The compound, deuterated derivative, or salt of embodiment 15, wherein each Y is independently selected from —CH 2 — and —C(Me) 2 .

[0231] 17. Each R 1 are independently C1-C6 fluoroalkyl and —N(R 2 17. The compound, deuterated derivative, or salt of any one of embodiments 1-16, selected from:

[0232] 18. Each R 1 are independently Br, -CH3, -CF3, -CHF2, -OH, -OCH3, -CN, -NH2, [ka] 17. The compound, deuterated derivative, or salt of any one of embodiments 1 to 16, selected from:

[0233] 19. Each R 1 is independently selected from -CF3 and -NH2.

[0234] 20. Z is [ka] 20. The compound, deuterated derivative, or salt of any one of embodiments 1-19, selected from:

[0235] twenty one. R Z1 is selected from hydrogen, C1-C6 alkyl (optionally substituted with 1-3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, and C6-C 10 aryl; R Z2 is hydrogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and R Z2 The compound, deuterated derivative, or salt of any one of embodiments 1-20, wherein together form a group selected from oxo and =N-OH.

[0236] 22. Z is [ka] 22. The compound, deuterated derivative, or salt of any one of embodiments 1-21, wherein:

[0237] twenty three. [ka] but, [ka] 23. The compound, deuterated derivative, or salt of any one of embodiments 1-22, wherein:

[0238] 24. R Z1The compound, deuterated derivative, or salt of any one of embodiments 1-23, wherein is selected from C1-C6 fluoroalkyl.

[0239] 25. R Z1 The compound, deuterated derivative, or salt of any one of embodiments 1-24, wherein is —CF 3 .

[0240] 26. R Z2 The compound, deuterated derivative, or salt of any one of embodiments 1-25, wherein is hydroxy.

[0241] 27. Z is [ka] 22. The compound, deuterated derivative, or salt of any one of embodiments 1 to 21, selected from:

[0242] 28. [ka] but, [ka] 22. The compound, deuterated derivative, or salt of any one of embodiments 1 to 21, selected from:

[0243] 29. The compound, deuterated derivative, or salt of any one of embodiments 1-28, wherein n is selected from 4, 5, and 6.

[0244] 30. The compound, deuterated derivative, or salt of any one of embodiments 1-29, wherein n is 5.

[0245] 31. The compound, deuterated derivative, or salt of any one of embodiments 1-29, wherein n is 6.

[0246] 32. The compound, deuterated derivative, or salt of any one of embodiments 1-31, wherein m is selected from 1 and 2.

[0247] 33. The compound, deuterated derivative, or salt of any one of embodiments 1-32, wherein m is 2.

[0248] 34. A compound selected from compounds of formula Ia: [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, X is -NR X1 -and [ka] is selected from Ring A is a 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl and oxo; R X1 H, C1-C6 alkyl (independently hydroxy, oxo, -OR X2 , and -N(R X2 ) optionally substituted with 1-3 groups selected from 2), and C3-C8 cycloalkyl; Each R X2 are independently selected from H and C1-C6 alkyl groups; Each Y is independently -C(R Y )2-, -O-, -CO-, -NR YN - and [ka] wherein each R YN is independently selected from H, C1-C4 alkyl, and CO2Me; Each R Yare independently selected from hydrogen, hydroxy, halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C1-C6 alkoxy, and Q), C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -OR Y1 , -CO2R Y1 , -COR Y1 , -CON(R Y1 )2, and -N(R Y1 )2-Selected from or two R on the same atom Y are taken together to form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or two R Y together to form a π bond, Each R Y1 are independently selected from hydrogen and C1-C6 alkyl, or two R Y1 together form a 3- to 6-membered heterocyclyl, Ring B is ■C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen, C1-C6 alkyl, and C1-C6 alkoxy); ■ C3-C8 cycloalkyl, ■ 5- to 10-membered heteroaryl, and ■ 3- to 6-membered heterocyclyl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), Each Q is independently C1-C6 alkyl, independently ○Halogen, ○Oxo, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen and —OCF3), and C1-C6 alkyl optionally substituted with 1 to 3 groups selected from C3-C8 cycloalkyl, C3-C8 cycloalkyl, independently: ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen, -NH2, and -NHCOMe); ○C1-C6 alkoxy, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl), and ○ C3-C8 cycloalkyl optionally substituted with 1 to 3 groups selected from ■C6~C 10 aryl, independently ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen and hydroxy), ○C1-C6 alkoxy, independently ■Halogen, ■ C1-C6 alkoxy optionally substituted with 1 to 4 groups selected from C3-C8 cycloalkyl (optionally substituted with CF3); C3-C8 cycloalkyl (optionally substituted with 1 to 3 groups independently selected from halogen, CF3, OCF3, and C1-C6 alkyl), and ○C6~C 10 C-C optionally substituted with 1 to 3 groups selected from aryl 10 aryl, ■ 5- to 10-membered heteroaryl, independently ○Halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen), C3-C8 cycloalkyl (optionally substituted with 1 to 3 CF3 groups), and ○ 3- to 10-membered heterocyclyl, ■ 3- to 10-membered heterocyclyl, independently C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from oxo and C3-C8 cycloalkyl), and oxo, 3- to 10-membered heterocyclyl optionally substituted with 1 to 3 groups selected from Each R 1 are independently selected from halogen, C1-C6 fluoroalkyl, C1-C6 alkyl (C6-C 10 optionally substituted with a group selected from aryl and 5- to 6-membered heteroaryl, -OR 2 , -N(R 2 )2, -CO2R 2 , -CO-N(R 2 )2, -CN, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 6-membered heteroaryl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), 3- to 6-membered heterocyclyl, -SO2R 2 , -SR 2 , -SOR 2 , -PO(OR 2 )2, and -PO(R 2 )2 is selected, Each R 2 are independently selected from hydrogen, C1-C6 alkyl (optionally substituted with 1 to 6 groups independently selected from halogen), C1-C6 fluoroalkyl, and C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 fluoroalkyl and C1-C6 fluoroalkoxy); Z, [ka] is selected from R Z1is hydrogen, —CN, C1-C6 alkyl (optionally substituted with 1 to 3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, C6-C 10 aryl, and 5- to 6-membered heteroaryl; R Z2 is hydrogen, halogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and R Z2 together form a group selected from oxo and =N-OH, Each R Z3 are independently selected from hydroxy, C1-C6 alkoxy, C1-C6 alkyl, and C6-C 10 aryl, or two R Z3 together form a 3- to 6-membered heterocyclyl, A compound, deuterated derivative, or salt wherein n is selected from 4, 5, 6, and 7.

[0249] 35. X is -NR X1 35. The compound, deuterated derivative, or salt of embodiment 34, wherein:

[0250] 36. X is [ka] 36. The compound, deuterated derivative, or salt of embodiment 34 or 35, selected from:

[0251] 37. X is [ka] 35. The compound, deuterated derivative, or salt of embodiment 34, wherein:

[0252] 38. The compound, deuterated derivative, or salt of embodiment 34 or 37, wherein ring A is selected from pyrrolidine, piperazine, morpholine, and isothiazolidine.

[0253] 39. X is [ka] 39. The compound, deuterated derivative, or salt of claim 34, 37, or 38, selected from:

[0254] 40. Each R Y But independently, Hydrogen, hydroxy, methyl, [ka] or Two R on the same atom Y together form a ring selected from cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyrryl, and tetrahydrofuryl, or Two R, one on one atom and the second on an adjacent atom Y The compound, deuterated derivative, or salt of any one of embodiments 34-39, wherein together form a π bond.

[0255] 41. Each Q is independently a C6-C alkyl group substituted with at least 1-3 groups independently selected from halogen and C1-C6 alkyl. 10 41. The compound, deuterated derivative, or salt of any one of embodiments 34-40, wherein:

[0256] 42. The compound, deuterated derivative, or salt of any one of embodiments 34-41, wherein each Q is phenyl.

[0257] 43. Each ring B is independently C6-C 10The compound, deuterated derivative, or salt of any one of embodiments 34-42, selected from aryl (optionally substituted with at least 1-3 groups independently selected from halogen and C1-C6 alkoxy) and 5-10 membered heteroaryl.

[0258] 44. Ring B is independently [ka] 44. The compound, deuterated derivative, or salt of any one of embodiments 34-43, selected from:

[0259] 45. -(Y) n -but, [ka] 45. The compound, deuterated derivative, or salt of any one of embodiments 34-44, selected from:

[0260] 46. ​​-(Y) n -but, [ka] [ka] 46. ​​The compound, deuterated derivative, or salt of any one of embodiments 34-45, selected from:

[0261] 47. Each Y is -C(R Y 46. ​​The compound, deuterated derivative, or salt of any one of embodiments 34-45, wherein R is 1 or 2.

[0262] 48. The compound, deuterated derivative, or salt of embodiment 47, wherein each Y is independently selected from —CH2— and —C(Me)2.

[0263] 49. Each R 1 are independently C1-C6 fluoroalkyl and —N(R 249. The compound, deuterated derivative, or salt of any one of embodiments 34-48, selected from:

[0264] 50. Each R 1 are independently Br, -CH3, -CF3, -CHF2, -OH, -OCH3, -CN, -NH2, [ka] 49. The compound, deuterated derivative, or salt of any one of embodiments 34-48, selected from:

[0265] 51. Each R 1 is independently selected from -CF3 and -NH2.

[0266] 52. Z is [ka] 52. The compound, deuterated derivative, or salt of any one of embodiments 34-51, selected from:

[0267] 53. R Z1 is selected from hydrogen, C1-C6 alkyl (optionally substituted with 1-3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, and C6-C 10 aryl; R Z2 is hydrogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and R Z2 The compound, deuterated derivative, or salt of any one of embodiments 34-52, wherein:

[0268] 54. Z is [ka] 54. The compound, deuterated derivative, or salt of any one of embodiments 34-53, wherein:

[0269] 55. [ka] but, [ka] 55. The compound, deuterated derivative, or salt of any one of embodiments 34-54, wherein:

[0270] 56. R Z1 The compound, deuterated derivative, or salt of any one of embodiments 34-55, wherein is selected from C1-C6 fluoroalkyl.

[0271] 57. R Z1 The compound, deuterated derivative, or salt of any one of embodiments 34-56, wherein is —CF 3 .

[0272] 58. R Z2 The compound, deuterated derivative, or salt of any one of embodiments 34-57, wherein is hydroxy.

[0273] 59. Z is [ka] 54. The compound, deuterated derivative, or salt of any one of embodiments 34-53, selected from:

[0274] 60. [ka] but, [ka] 54. The compound, deuterated derivative, or salt of any one of embodiments 34-53, selected from:

[0275] 61. The compound, deuterated derivative, or salt of any one of embodiments 34-60, wherein n is selected from 4, 5, and 6.

[0276] 62. The compound, deuterated derivative, or salt of any one of embodiments 34-61, wherein n is 5.

[0277] 63. The compound, deuterated derivative, or salt of any one of embodiments 34-62, wherein n is 6.

[0278] 64. A compound selected from compounds of formula IIa, IIb, IIc, and IId: [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, X is -NR X1 -and [ka] is selected from Ring A is a 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl and oxo; R X1 H, C1-C6 alkyl (independently hydroxy, oxo, -OR X2 , and -N(R X2 ) optionally substituted with 1-3 groups selected from 2), and C3-C8 cycloalkyl; Each R X2 are independently selected from H and C1-C6 alkyl groups; Each Y is independently -C(R Y )2-, -O-, -CO-, -NR YN - and [ka] wherein each R YN is independently selected from H, C1-C4 alkyl, and CO2Me; Each R Y are independently selected from hydrogen, hydroxy, halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C1-C6 alkoxy, and Q), C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -OR Y1 , -CO2R Y1 , -COR Y1 , -CON(R Y1 )2, and -N(R Y1 )2-Selected from or two R on the same atom Y are taken together to form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or two R Y together to form a π bond, Each R Y1 are independently selected from hydrogen and C1-C6 alkyl, or two R Y1 together form a 3- to 6-membered heterocyclyl, Ring B is ■C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen, C1-C6 alkyl, and C1-C6 alkoxy); ■ C3-C8 cycloalkyl, ■ 5- to 10-membered heteroaryl, and ■ 3- to 6-membered heterocyclyl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), Each Q is independently C1-C6 alkyl, independently ○Halogen, ○Oxo, ○C6~C 10aryl (optionally substituted with 1 to 3 groups independently selected from halogen and —OCF3), and C1-C6 alkyl optionally substituted with 1 to 3 groups selected from C3-C8 cycloalkyl, C3-C8 cycloalkyl, independently: ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen, -NH2, and -NHCOMe); ○C1-C6 alkoxy, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl), and ○ C3-C8 cycloalkyl optionally substituted with 1 to 3 groups selected from ■C6~C 10 aryl, independently ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen and hydroxy), ○C1-C6 alkoxy, independently ■Halogen, ■ C1-C6 alkoxy optionally substituted with 1 to 4 groups selected from C3-C8 cycloalkyl (optionally substituted with CF3); C3-C8 cycloalkyl (optionally substituted with 1 to 3 groups independently selected from halogen, CF3, OCF3, and C1-C6 alkyl), and ○C6~C 10 C-C optionally substituted with 1 to 3 groups selected from aryl 10 aryl, ■ 5- to 10-membered heteroaryl, independently ○Halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen), C3-C8 cycloalkyl (optionally substituted with 1 to 3 CF3 groups), and ○ 3- to 10-membered heterocyclyl, ■ 3- to 10-membered heterocyclyl, independently C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from oxo and C3-C8 cycloalkyl), and oxo, 3- to 10-membered heterocyclyl optionally substituted with 1 to 3 groups selected from Each R 1 are independently selected from halogen, C1-C6 fluoroalkyl, C1-C6 alkyl (hydroxy, C6-C 10 aryl, and 5- to 6-membered heteroaryl), -OR 2 , -N(R 2 )2, -CO2R 2 , -CO-N(R 2 )2, -CN, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 6-membered heteroaryl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), 3- to 6-membered heterocyclyl; -SO2R 2 , -SR 2 , -SOR 2 , -PO(OR 2 )2, and -PO(R 2 )2 is selected, Each R 2 are independently selected from hydrogen, C1-C6 alkyl (optionally substituted with 1 to 6 groups independently selected from halogen), C1-C6 fluoroalkyl, and C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 fluoroalkyl and C1-C6 fluoroalkoxy); Z, [ka] is selected from R Z1 is hydrogen, —CN, C1-C6 alkyl (optionally substituted with 1 to 3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, C6-C 10 aryl, and 5- to 6-membered heteroaryl; R Z2 is hydrogen, halogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and R Z2 together form a group selected from oxo and =N-OH, Each R Z3 are independently selected from hydroxy, C1-C6 alkoxy, C1-C6 alkyl, and C6-C 10 aryl, or two R Z3 together form a 3- to 6-membered heterocyclyl, A compound wherein m is selected from 0, 1, 2, and 3.

[0279] 65. The compound according to embodiment 64, wherein m is selected from 1 and 2.

[0280] 66. The compound of embodiment 64 or 65, wherein m is 2.

[0281] 67. A compound selected from compounds of formula IIe, IIf, IIg, and IIh: [ka] and deuterated derivatives and pharmaceutically acceptable salts thereof, X is -NR X1 -and [ka] is selected from Ring A is a 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl and oxo; R X1 H, C1-C6 alkyl (independently hydroxy, oxo, -OR X2 , and -N(R X2 ) optionally substituted with 1-3 groups selected from 2), and C3-C8 cycloalkyl; Each R X2 are independently selected from H and C1-C6 alkyl groups; Each Y is independently -C(R Y )2-, -O-, -CO-, -NR YN - and [ka] wherein each R YN is independently selected from H, C1-C4 alkyl, and CO2Me; Each R Y are independently selected from hydrogen, hydroxy, halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C1-C6 alkoxy, and Q), C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -OR Y1 , -CO2R Y1 , -COR Y1 , -CON(R Y1 )2, and -N(R Y1 )2-Selected from or two R on the same atom Y are taken together to form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or two R Y together to form a π bond, Each R Y1 are independently selected from hydrogen and C1-C6 alkyl, or two R Y1together form a 3- to 6-membered heterocyclyl, Ring B is ■C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen, C1-C6 alkyl, and C1-C6 alkoxy); ■ C3-C8 cycloalkyl, ■ 5- to 10-membered heteroaryl, and ■ 3- to 6-membered heterocyclyl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), Each Q is independently C1-C6 alkyl, independently ○Halogen, ○Oxo, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen and —OCF3), and C1-C6 alkyl optionally substituted with 1 to 3 groups selected from C3-C8 cycloalkyl, C3-C8 cycloalkyl, independently: ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen, -NH2, and -NHCOMe); ○C1-C6 alkoxy, ○C6~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 alkyl), and ○ C3-C8 cycloalkyl optionally substituted with 1 to 3 groups selected from ■C6~C 10 aryl, independently ○Halogen, ○CN, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen and hydroxy), ○C1-C6 alkoxy, independently ■Halogen, ■ C1-C6 alkoxy optionally substituted with 1 to 4 groups selected from C3-C8 cycloalkyl (optionally substituted with CF3); C3-C8 cycloalkyl (optionally substituted with 1 to 3 groups independently selected from halogen, CF3, OCF3, and C1-C6 alkyl), and ○C6~C 10 C-C optionally substituted with 1 to 3 groups selected from aryl 10 aryl, ■ 5- to 10-membered heteroaryl, independently ○Halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen), C3-C8 cycloalkyl (optionally substituted with 1 to 3 CF3 groups), and ○ 3- to 10-membered heterocyclyl, ■ 3- to 10-membered heterocyclyl, independently C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from oxo and C3-C8 cycloalkyl), and oxo, 3- to 10-membered heterocyclyl optionally substituted with 1 to 3 groups selected from Each R 1 are independently selected from halogen, C1-C6 fluoroalkyl, C1-C6 alkyl (C6-C 10 optionally substituted with a group selected from aryl and 5- to 6-membered heteroaryl, -OR 2 , -N(R 2 )2, -CO2R 2 , -CO-N(R 2 )2, -CN, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, 5- to 6-membered heteroaryl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), 3- to 6-membered heterocyclyl, -SO2R 2, -SR 2 , -SOR 2 , -PO(OR 2 )2, and -PO(R 2 )2 is selected, Each R 2 are independently selected from hydrogen, C1-C6 alkyl (optionally substituted with 1 to 6 groups independently selected from halogen), C1-C6 fluoroalkyl, and C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C1-C6 fluoroalkyl and C1-C6 fluoroalkoxy); Z, [ka] is selected from R Z1 is hydrogen, —CN, C1-C6 alkyl (optionally substituted with 1 to 3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, C6-C 10 aryl, and 5- to 6-membered heteroaryl; R Z2 is hydrogen, halogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and R Z2 together form a group selected from oxo and =N-OH, Each R Z3 are independently selected from hydroxy, C1-C6 alkoxy, C1-C6 alkyl, and C6-C 10 aryl, or two R Z3 taken together to form a 3- to 6-membered heterocyclyl,

[0282] 68. X is -NR X1 68. The compound, deuterated derivative, or salt of any one of embodiments 64-67, wherein:

[0283] 69. X is [ka] 69. The compound, deuterated derivative, or salt of any one of embodiments 64-68, selected from:

[0284] 70. X is [ka] 68. The compound, salt, or deuterated derivative of any one of embodiments 64-67, wherein:

[0285] 71. The compound, deuterated derivative, or salt of any one of embodiments 64-67 or 70, wherein Ring A is selected from pyrrolidine, piperazine, morpholine, and isothiazolidine.

[0286] 72. X is [ka] 72. The compound, deuterated derivative, or salt of embodiment 64-67, 70, or 71, selected from:

[0287] 73. Each R Y But independently, Hydrogen, hydroxy, methyl, [ka] or Two R on the same atom Y together form a ring selected from cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyrryl, and tetrahydrofuryl, or Two R, one on one atom and the second on an adjacent atom Y The compound, deuterated derivative, or salt of any one of embodiments 64-72, wherein together form a π bond.

[0288] 74. Each Q is independently a C6-C alkyl group substituted with at least 1-3 groups independently selected from halogen and C1-C6 alkyl. 10 The compound, deuterated derivative, or salt of any one of embodiments 64-73, wherein:

[0289] 75. The compound, deuterated derivative, or salt of any one of embodiments 64-74, wherein each Q is phenyl.

[0290] 76. Each ring B is independently C6-C 10 The compound, deuterated derivative, or salt of any one of embodiments 64-75, selected from aryl (optionally substituted with at least 1-3 groups independently selected from halogen and C1-C6 alkoxy) and 5-10 membered heteroaryl.

[0291] 77. Ring B is independently [ka] 77. The compound, deuterated derivative, or salt of any one of embodiments 64-76, selected from:

[0292] 78. (-YYYYYYY-) [ka] The compound, deuterated derivative, or salt of any one of embodiments 64-77, wherein:

[0293] 79. (-YYYYYYY-) [ka] 79. The compound, deuterated derivative, or salt of embodiment 78, wherein:

[0294] 80. (-YYYYYY-) [ka] The compound, deuterated derivative, or salt of any one of embodiments 64-77, wherein:

[0295] 81. (-YYYYYY-) [ka] [ka] The compound, deuterated derivative, or salt of embodiment 80, wherein:

[0296] 82. (-YYYYY-) [ka] 78. The compound, deuterated derivative, or salt of any one of embodiments 64-77, selected from:

[0297] 83. (-YYYYY-) [ka] The compound, deuterated derivative, or salt of embodiment 82, wherein R is a group selected from:

[0298] 84. (-YYYY-) [ka] The compound, deuterated derivative, or salt of any one of embodiments 64-77, wherein:

[0299] 85. (-YYYY-) [ka] The compound, deuterated derivative, or salt of embodiment 84, wherein:

[0300] 86. Each Y is -C(R Y 78. The compound, deuterated derivative, or salt of any one of embodiments 64-77, wherein:

[0301] 87. The compound, deuterated derivative, or salt of embodiment 86, wherein each Y is independently selected from —CH 2 — and —C(Me) 2 .

[0302] 88. Each R 1 are independently C1-C6 fluoroalkyl and —N(R 2 88. The compound, deuterated derivative, or salt of any one of embodiments 64-87, selected from:

[0303] 89. Each R 1 are independently Br, -CH3, -CF3, -CHF2, -OH, -OCH3, -CN, -NH2, [ka] 88. The compound, deuterated derivative, or salt of any one of embodiments 64-87, selected from:

[0304] 90. Each R 1 The compound, deuterated derivative, or salt of any one of embodiments 64-89, wherein is independently selected from -CF3 and -NH2.

[0305] 91. Z is [ka] 91. The compound, deuterated derivative, or salt of any one of embodiments 64-90, selected from:

[0306] 92. R Z1 is selected from hydrogen, C1-C6 alkyl (optionally substituted with 1-3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, and C6-C 10 aryl; RZ2 is hydrogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 optionally substituted with 1 to 3 groups selected from cycloalkyl; or R Z1 and R Z2 The compound, deuterated derivative, or salt of any one of embodiments 64-91, wherein together form a group selected from oxo and =N-OH.

[0307] 93. Z is [ka] 93. The compound, deuterated derivative, or salt of any one of embodiments 64-92, wherein:

[0308] 94. [ka] but, [ka] 94. The compound, deuterated derivative, or salt of any one of embodiments 64-93, wherein:

[0309] 95. R Z1 The compound, deuterated derivative, or salt of any one of embodiments 64-94, wherein is selected from C1-C6 fluoroalkyl.

[0310] 96. R Z1 The compound, deuterated derivative, or salt of any one of embodiments 64-95, wherein is —CF 3 .

[0311] 97. R Z2 The compound, deuterated derivative, or salt of any one of embodiments 64-96, wherein is hydroxy.

[0312] 98. Z is [ka] 93. The compound, deuterated derivative, or salt of any one of embodiments 64-92, selected from:

[0313] 99. [ka] but, [ka] 93. The compound, deuterated derivative, or salt of any one of embodiments 64-92, selected from:

[0314] 100. X is -N(R X1 )-.

[0315] 101. X is [ka] 2. The compound of embodiment 1, a deuterated derivative, or a pharmaceutically acceptable salt thereof, wherein:

[0316] 102. X is -NH-, -N(CH3)-, -N(CH2CH3)-, [ka] 2. The compound of embodiment 1, a deuterated derivative, or a pharmaceutically acceptable salt thereof, selected from:

[0317] 103. Each R Y are independently selected from hydrogen, hydroxy, halogen, C1-C6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C1-C6 alkoxy, and Q), C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -COR Y1, and -CON(R Y1 )2 or or two R on the same atom Y taken together form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or or two R, one on one atom and the second on an adjacent atom Y The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-102, wherein:

[0318] 104. Each R Y1 are independently selected from hydrogen and C1-C6 alkyl, or two R Y1 The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-103, wherein:

[0319] 105. Each Q is independently C6~C 10 105. The compound of any one of embodiments 1 and 100-104, a deuterated derivative, or a pharmaceutically acceptable salt thereof, wherein:

[0320] 106. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-105, wherein each Q is phenyl.

[0321] 107. Each R Y But independently, Hydrogen, hydroxy, -CH3, -CD3, -CH2CH3, [ka] Selected from or or two R on the same atom Y taken together form a ring selected from cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyrryl, and tetrahydrofuryl; or two R, one on one atom and the second on an adjacent atom Y The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-106, wherein:

[0322] 108. Ring B is C6~C 10 The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-107, selected from aryl (optionally substituted with 1-3 groups independently selected from halogen and C1-C6 alkoxy) and 5-10 membered heteroaryl.

[0323] 109. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-108, wherein Ring B is selected from phenyl (optionally substituted with 1-3 groups independently selected from halogen and C1-C6 alkoxy) and pyridyl.

[0324] 110. Ring B is [ka] 110. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-109, selected from:

[0325] 111. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-110, wherein n is selected from 4, 5, 6, and 7.

[0326] 112. -(Y) n -but, [ka] [ka] [ka] 112. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-111, selected from:

[0327] 113. Each R 1 are independently selected from halogen, C1-C6 fluoroalkyl, C1-C6 alkyl (C6-C 10 aryl), -OR 2 , -N(R 2 )2, -CO2R 2 , -CO-N(R 2 )2, -CN, C1-C6 alkoxy, C3-C8 cycloalkyl, C6-C 10 aryl, 5- to 6-membered heteroaryl (optionally substituted with 1 to 3 groups independently selected from C1 to C6 alkyl), 3- to 6-membered heterocyclyl, -B(OR 2 )2, -SO2R 2 , -SR 2 , -SOR 2 , and -PO(R 2 113. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-112, selected from:

[0328] 114. Each R 2 But independently, C6~C 10 aryl (optionally substituted with 1-3 groups independently selected from C1-C6 fluoroalkoxy), a deuterated derivative, or a pharmaceutically acceptable salt of any one of embodiments 1 and 100-113.

[0329] 115. Each R 1 are independently -Br, -CF3, -NH2, -CH3, -CH(CH3)2, -CN, -OH, -OCH3, -NH(CH3), -NH(CH2CH3), -CONH2, -CO2CH3, -SO2CH3, -SO2Ph, PO(CH3)2, B(OH)2, phenyl, pyridyl, tetrahydropyranyl, tetrahydrofuranyl, cyclopropyl, cyclohexyl, imidazolyl, [ka] 115. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-114, selected from:

[0330] 116. Z, [ka] and ring C is selected from C to C 10 116. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-115, wherein:

[0331] 117. Base: [ka] but, [ka] 117. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-116, selected from:

[0332] 118. Base: [ka] but, [ka] 118. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-117, wherein:

[0333] 118A.R. Z1 is hydrogen, C1-C6 alkyl (optionally substituted with 1-3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, C6-C 10aryl, and 5-6 membered heteroaryl, a compound, deuterated derivative, or a pharmaceutically acceptable salt according to any one of embodiments 1 and 100-117.

[0334] 118B.R Z2 is hydrogen, halogen, hydroxy, and C1-C6 alkoxy (independently C3-C 10 118. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-117, wherein the compound is selected from the group consisting of cycloalkyl, cyclopropyl, ...

[0335] 119. R Z1 is selected from hydrogen, C1-C6 alkyl (optionally substituted with 1-3 hydroxy), C1-C6 fluoroalkyl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, and C6-C 10 aryl; R Z2 is selected from hydrogen, halogen, and hydroxy; or R Z1 and R Z2 The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-118, wherein:

[0336] 120. R Z1 is selected from hydrogen, CH, CF, CHOH, phenyl, cyclopropyl, and tetrahydropyranyl; R Z2 is selected from hydrogen, halogen, and hydroxy; or R Z1 and R Z2 The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-119, wherein:

[0337] 121. R Z2121. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-120, wherein is hydroxy.

[0338] 122. Z, [ka] 122. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-121, selected from:

[0339] 123. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-122, wherein m is selected from 1 and 2.

[0340] 124. X is -N(R X1 )- and [ka] is selected from Ring A is a 4- to 6-membered heterocyclyl; R X1 is selected from H and C1-C6 alkyl; Each Y is independently -C(R Y )2- and [ka] is selected from Each R Y are independently selected from halogen, C1-C6 alkyl, and C3-C8 cycloalkyl, C6-C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen); or two R on the same atom Y are taken together to form a ring selected from C3-C8 cycloalkyl and 3- to 7-membered heterocyclyl, or two R Y together to form a π bond, Ring B is C6~C10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen); Each R 1 is independently selected from C1-C6 fluoroalkyl and -NH2; Z, [ka] and R Z1 is C1-C6 fluoroalkyl, R Z2 is hydroxy, n is selected from 4, 5, and 6; The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-123, wherein m is 2.

[0341] 125. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-124, wherein ring A is pyrrolidine.

[0342] 126. X is -NH-, -N(CH3)-, [ka] 126. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-125, selected from:

[0343] 127. Each R Y But independently, Hydrogen, -CH3, -CD3, [ka] Selected from or or two R on the same atom Y taken together form a ring selected from cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyrryl, and tetrahydrofuryl; or two R, one on one atom and the second on an adjacent atom Y The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-126, wherein:

[0344] 128. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-127, wherein ring B is phenyl (optionally substituted with 1-3 groups independently selected from halogen).

[0345] 129. Ring B is [ka] 129. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-128, wherein:

[0346] 130. -(Y) n -but, [ka] 130. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-129, selected from:

[0347] 131. Each R 1 is independently selected from CF3 and -NH2, or a deuterated derivative or a pharmaceutically acceptable salt thereof.

[0348] 132. R Z1 The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-131, wherein is CF3.

[0349] 133. Z, [ka] 133. The compound, deuterated derivative, or pharmaceutically acceptable salt of any one of embodiments 1 and 100-132, selected from:

[0350] 134. A compound selected from the compounds of Table 10, pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing.

[0351] 135. The compound of embodiment 134, wherein the compound is selected from the following: [Table 7-1] [Table 7-2] [Table 7-3]

[0352] 136. A pharmaceutical composition comprising a compound, salt, or deuterated derivative according to any one of embodiments 1 to 135, and a pharmaceutically acceptable carrier.

[0353] 137. The pharmaceutical composition of embodiment 136, further comprising one or more additional therapeutic agents.

[0354] 138. The pharmaceutical composition of embodiment 137, wherein the one or more additional therapeutic agents comprise a compound having CFTR modulating activity, or a salt or deuterated derivative thereof.

[0355] 139. The pharmaceutical composition of embodiment 137 or 138, wherein the one or more additional therapeutic agents comprises a CFTR corrector.

[0356] 140. The pharmaceutical composition of any one of embodiments 137-139, wherein the one or more additional therapeutic agents comprises (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (compound II). [ka]

[0357] 141. The pharmaceutical composition of any one of embodiments 137-140, wherein the one or more additional therapeutic agents comprises 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound IV). [ka]

[0358] 142. The pharmaceutical composition of any one of embodiments 137-141, wherein the one or more additional therapeutic agents comprises N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound V). [ka]

[0359] 143. The pharmaceutical composition of any one of embodiments 137-142, wherein the one or more additional therapeutic agents comprises N-(benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (compound VI). [ka] Compound VI

[0360] 144. The one or more additional therapeutic agents are (14S)-8-[3-(2-{dispiro[2.0.2.1]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6 144. The pharmaceutical composition according to any one of embodiments 137 to 143, comprising -thia-3,9,11,18,23-pentaazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione (compound VII). [ka]

[0361] 145. The one or more additional therapeutic agents are (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hexan-5-yl}-9-oxa-2λ 6 145. The pharmaceutical composition according to any one of embodiments 137 to 144, comprising -thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadeca-1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione (compound VIII). [ka]

[0362] 146. The pharmaceutical composition of any one of embodiments 137-145, wherein the one or more additional therapeutic agents comprises at least one compound selected from PTI-428, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, and PTI-801.

[0363] 147. The pharmaceutical composition of any one of embodiments 137-146, wherein the one or more additional therapeutic agents comprises a CFTR potentiator.

[0364] 148. A pharmaceutical composition described in any one of embodiments 137-147, wherein the one or more additional therapeutic agents comprises ASP-11.

[0365] 149. A pharmaceutical composition according to any one of embodiments 137-148, wherein the one or more additional therapeutic agents comprises a CFTR potentiator.

[0366] 150. The compound of claim 1, wherein the one or more additional therapeutic agents is N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (compound III): [ka] and, N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (compound III-d): [ka] The pharmaceutical composition according to any one of embodiments 137 to 149, comprising compound III-d.

[0367] 151. The pharmaceutical composition of any one of embodiments 137-150, wherein the one or more additional therapeutic agents comprises at least one compound selected from FDL-176, PTI-808, GLPG1837, GLPG2451 / ABBV-2451 (isenticaftor), GLPG3067 / ABBV-3067 (navocaftor), and ABBV-191.

[0368] 152. The pharmaceutical composition of any one of embodiments 137-151, wherein the one or more additional therapeutic agents comprises a CFTR amplifier.

[0369] 153. The pharmaceutical composition of any one of embodiments 137-152, wherein the one or more additional therapeutic agents comprises PTI-428.

[0370] 154. The pharmaceutical composition of any one of embodiments 137-153, wherein the one or more additional therapeutic agents comprises a CFTR readthrough agent.

[0371] 155. A pharmaceutical composition according to any one of embodiments 137-154, wherein the one or more additional therapeutic agents comprises ELX-02.

[0372] 156. A pharmaceutical composition described in any one of embodiments 137 to 155, wherein the one or more additional therapeutic agents comprises a nucleic acid therapy.

[0373] 157. The pharmaceutical composition of any one of embodiments 137-156, wherein the one or more additional therapeutic agents comprises at least one agent selected from MRT5005, Lunar-CF, and RCT223.

[0374] 158. A pharmaceutical composition according to any one of embodiments 137-157, wherein the one or more additional therapeutic agents comprises an ENaC inhibitor.

[0375] 159. The pharmaceutical composition of any one of embodiments 137-158, wherein the one or more additional therapeutic agents comprise amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5 Rx, BI 1265162, AZ5634, and ARO-ENaC1001.

[0376] 160. The pharmaceutical composition of any one of embodiments 137-159, wherein the one or more additional therapeutic agents comprises a TMEM16A modulator.

[0377] 161. A pharmaceutical composition described in any one of embodiments 137-160, wherein the one or more additional therapeutic agents comprises ETD002.

[0378] 162. The pharmaceutical composition of any one of embodiments 137-161, wherein the one or more additional therapeutic agents comprises a GPR39 agonist.

[0379] 163. The pharmaceutical composition of any one of embodiments 137-162, wherein the one or more additional therapeutic agents comprises DS-1039.

[0380] 164. A method for treating cystic fibrosis, comprising administering to a patient in need of treatment an effective amount of a compound, salt, or deuterated derivative described in any one of embodiments 1-135, or a pharmaceutical composition described in any one of embodiments 136-163.

[0381] 165. The method of embodiment 164, further comprising administering one or more additional therapeutic agents.

[0382] 166. The method of embodiment 165, wherein the one or more additional therapeutic agents comprise a compound having CFTR modulating activity, or a salt or deuterated derivative thereof.

[0383] 167. The method of embodiment 165 or 166, wherein the one or more additional therapeutic agents comprises a CFTR corrector.

[0384] 168. The method of any one of embodiments 165-167, wherein the one or more additional therapeutic agents comprises (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (compound II). [ka]

[0385] 169. The method of any one of embodiments 165-168, wherein the one or more additional therapeutic agents comprises 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (compound IV). [ka]

[0386] 170. The method of any one of embodiments 165-169, wherein the one or more additional therapeutic agents comprises N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (compound V). [ka]

[0387] 171. The method of any one of embodiments 165-170, wherein the one or more additional therapeutic agents comprises N-(benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (compound VI). [ka]

[0388] 172. The one or more additional therapeutic agents are (14S)-8-[3-(2-{dispiro[2.0.2.1]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6172. The method of any one of embodiments 165-171, comprising -thia-3,9,11,18,23-pentaazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione (compound VII). [ka]

[0389] 173. The one or more additional therapeutic agents are (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hexan-5-yl}-9-oxa-2λ 6 173. The method of any one of embodiments 165-172, comprising -thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadeca-1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione (compound VIII). [ka]

[0390] 174. The method of any one of embodiments 165-173, wherein the one or more additional therapeutic agents comprises at least one compound selected from PTI-428, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, ABBV-2851, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, and PTI-801.

[0391] 175. The method of any one of embodiments 165-174, wherein the one or more additional therapeutic agents comprises a CFTR potentiator.

[0392] 176. The method of any one of embodiments 165-175, wherein the one or more additional therapeutic agents comprises ASP-11.

[0393] 177. The method of any one of embodiments 165-176, wherein the one or more additional therapeutic agents comprises a CFTR enhancer.

[0394] 178. The compound of claim 1, wherein the one or more additional therapeutic agents is N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (compound III): [ka] and, N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (compound III-d): [ka] The method of any one of embodiments 165 to 177, comprising:

[0395] 179. The pharmaceutical composition of any one of embodiments 165-178, wherein the one or more additional therapeutic agents comprises at least one compound selected from FDL-176, PTI-808, GLPG1837, GLPG2451 / ABBV-2451 (isenticaftor), GLPG3067 / ABBV-3067 (navocaftor), and ABBV-191.

[0396] 180. The method of any one of embodiments 165-179, wherein the one or more additional therapeutic agents comprises a CFTR amplifier.

[0397] 181. The method of any one of embodiments 165-180, wherein the one or more additional therapeutic agents comprises PTI-428.

[0398] 182. The method of any one of embodiments 165-181, wherein the one or more additional therapeutic agents comprises a CFTR readthrough agent.

[0399] 183. The method of any one of embodiments 165-182, wherein the one or more additional therapeutic agents comprises ELX-02.

[0400] 184. The method of any one of embodiments 165-183, wherein the one or more additional therapeutic agents comprise a nucleic acid therapy.

[0401] 185. The pharmaceutical composition of any one of embodiments 165-184, wherein the one or more additional therapeutic agents comprises at least one agent selected from MRT5005, Lunar-CF, and RCT223.

[0402] 186. The method of any one of embodiments 165-185, wherein the one or more additional therapeutic agents comprises an ENaC inhibitor.

[0403] 187. The pharmaceutical composition of any one of embodiments 165-186, wherein the one or more additional therapeutic agents comprise amiloride, ETD001, CF552, GS-9411, GS-5737, P-1037 (VX-371), P-1055 (VX-551), AZD5634, SPX-101, Ionis-ENaC-2.5 Rx, BI 1265162, AZ5634, and ARO-ENaC1001.

[0404] 188. The method of any one of embodiments 165-187, wherein the one or more additional therapeutic agents comprises a TMEM16A modulator.

[0405] 189. The method of any one of embodiments 165-188, wherein the one or more additional therapeutic agents comprises ETD002.

[0406] 190. The method of any one of embodiments 165-180, wherein the one or more additional therapeutic agents comprises a GPR39 agonist.

[0407] 191. The method of any one of embodiments 165-190, wherein the one or more additional therapeutic agents comprises DS-1039.

[0408] 192. A compound, salt, or deuterated derivative according to any one of embodiments 1-135, or a pharmaceutical composition according to any one of embodiments 136-163, for use in the treatment of cystic fibrosis.

[0409] 193. Use of a compound, salt, or deuterated derivative according to any one of embodiments 1 to 135, or a pharmaceutical composition according to any one of embodiments 136 to 163, in the manufacture of a medicament for the treatment of cystic fibrosis.

[0410] 194. Substantially amorphous Compound 4 (native form) (i.e., less than 15% of Compound 4 is in crystalline form; less than 10% of Compound 4 is in crystalline form; less than 5% of Compound 4 is in crystalline form).

[0411] 195. The substantially amorphous Compound 4 (native form) of embodiment 194, wherein Compound 4 is 100% amorphous.

[0412] 196. The substantially amorphous compound 4 (native form) of embodiment 194 or 195, characterized by an X-ray powder diffractogram substantially similar to FIG. 1.

[0413] 197. Substantially crystalline Compound 5 Form A (native) (i.e., less than 15% of Compound 5 is in amorphous form; less than 10% of Compound 5 is in amorphous form; less than 5% of Compound 5 is in amorphous form).

[0414] 198. The substantially crystalline Form A (native) of Compound 5, as described in embodiment 197, wherein Form A (native) of Compound 5 is 100% crystalline.

[0415] 199. Tetragonal crystal system, I41 space group, and Cu K α Form A (native) of substantially crystalline compound 5 according to embodiment 197 or 198, characterized by the following unit cell dimensions measured at 100 K on a Bruker diffractometer using radiation (λ=1.54178 Å): [Table 8]

[0416] 200. Substantially amorphous Compound 19 (native form) (i.e., less than 15% of Compound 19 is in crystalline form, less than 10% of Compound 19 is in crystalline form, less than 5% of Compound 19 is in crystalline form).

[0417] 201. The substantially amorphous Compound 19 (native form) of embodiment 200, wherein Compound 19 is 100% amorphous.

[0418] 202. Substantially amorphous Compound 19 (native form) according to embodiment 200 or 201, characterized by an X-ray powder diffractogram substantially similar to that in FIG. 4.

[0419] 203. Form A of Compound 41 that is substantially crystalline (i.e., less than 15% of Compound 41 is in amorphous form, less than 10% of Compound 41 is in amorphous form, less than 5% of Compound 41 is in amorphous form).

[0420] 204. The substantially crystalline Form A of Compound 41, as described in embodiment 203, wherein Form A of Compound 41 is 100% crystalline.

[0421] 205. Form A of the substantially crystalline Compound 41 of embodiment 203 or 204, characterized by an X-ray powder diffractogram having one, two, or three signals selected from 14.2±0.2 degrees two-theta, 19.5±0.2 degrees two-theta, and 21.2±0.2 degrees two-theta.

[0422] 206. Form A of the substantially crystalline Compound 41 of any one of embodiments 203-205, characterized by an X-ray powder diffractogram having one, two, three, four, five, or six signals selected from 14.2±0.2 degrees two-theta, 19.5±0.2 degrees two-theta, 21.2±0.2 degrees two-theta, 18.0±0.2 degrees two-theta, 16.6±0.2 degrees two-theta, and 20.7±0.2 degrees two-theta.

[0423] 207. Form A of the substantially crystalline Compound 41 of any one of embodiments 203-206, characterized by an X-ray powder diffractogram having one, two, three, four, five, six, seven, eight, or nine signals selected from 14.2±0.2 degrees two-theta, 16.6±0.2 degrees two-theta, 18.0±0.2 degrees two-theta, 19.5±0.2 degrees two-theta, 20.3±0.2 degrees two-theta, 20.7±0.2 degrees two-theta, 21.2±0.2 degrees two-theta, 22.2±0.2 degrees two-theta, and 25.1±0.2 degrees two-theta.

[0424] 208. Form A of substantially crystalline Compound 41, as described in any one of embodiments 203-207, characterized by an X-ray powder diffractogram substantially similar to FIG. 7.

[0425] 209. Substantially crystalline Form A (native) of Compound 52 (i.e., less than 15% of Compound 52 is in amorphous form, less than 10% of Compound 52 is in amorphous form, less than 5% of Compound 52 is in amorphous form).

[0426] 210. The substantially crystalline Form A (native) of Compound 52, as described in embodiment 209, wherein Form A (native) of Compound 52 is 100% crystalline.

[0427] 211. Form A (native) of substantially crystalline Compound 52, according to embodiment 209 or 210, characterized by an X-ray powder diffractogram having one, two, or three signals selected from 6.8±0.2 degrees two-theta, 17.3±0.2 degrees two-theta, and 18.6±0.2 degrees two-theta.

[0428] 212. Form A (native) of substantially crystalline Compound 52, according to any one of embodiments 209-211, characterized by an X-ray powder diffractogram having one, two, three, four, five, or six signals selected from 6.8±0.2 degrees two-theta, 12.7±0.2 degrees two-theta, 17.3±0.2 degrees two-theta, 18.6±0.2 degrees two-theta, 20.6±0.2 degrees two-theta, and 21.4±0.2 degrees two-theta.

[0429] 213. Form A (native) of substantially crystalline Compound 52 of any one of embodiments 209-212, characterized by an X-ray powder diffractogram having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 signals selected from 6.8±0.2 degrees 2-theta, 12.7±0.2 degrees 2-theta, 15.1±0.2 degrees 2-theta, 15.5±0.2 degrees 2-theta, 17.3±0.2 degrees 2-theta, 18.6±0.2 degrees 2-theta, 19.2±0.2 degrees 2-theta, 19.7±0.2 degrees 2-theta, 20.4±0.2 degrees 2-theta, 20.6±0.2 degrees 2-theta, 21.4±0.2 degrees 2-theta, and 27.2±0.2 degrees 2-theta.

[0430] 214. Form A (native) of substantially crystalline Compound 52, as described in any one of embodiments 209-213, characterized by an X-ray powder diffractogram substantially similar to Figure 9.

[0431] 215. Substantially amorphous Compound 60 (native form) (i.e., less than 15% of Compound 60 is in crystalline form, less than 10% of Compound 60 is in crystalline form, less than 5% of Compound 60 is in crystalline form).

[0432] 216. The substantially amorphous Compound 60 (native form) of embodiment 215, wherein Compound 60 is 100% amorphous.

[0433] 217. Substantially amorphous Compound 60 (native form) according to embodiment 215 or 216, characterized by an X-ray powder diffractogram substantially similar to that in FIG. 12.

[0434] 218. Substantially amorphous Compound 70 (native form) (i.e., less than 15% of Compound 70 is in crystalline form, less than 10% of Compound 70 is in crystalline form, less than 5% of Compound 70 is in crystalline form).

[0435] 219. The substantially amorphous Compound 70 (native form) of embodiment 218, wherein Compound 70 is 100% amorphous.

[0436] 220. Substantially amorphous Compound 70 (native form) of embodiment 218 or 219, characterized by an X-ray powder diffractogram substantially similar to FIG. 15.

[0437] 221. Substantially crystalline Compound 163 Form A (native) (i.e., less than 15% of Compound 163 is in amorphous form, less than 10% of Compound 163 is in amorphous form, less than 5% of Compound 163 is in amorphous form).

[0438] 222. The substantially crystalline Form A (native) of Compound 163, as described in embodiment 221, wherein Form A (native) of Compound 163 is 100% crystalline.

[0439] 223. Form A (native) of the substantially crystalline Compound 163 of embodiment 221 or 222, characterized by an X-ray powder diffractogram having a signal at 7.4±0.2 degrees two-theta.

[0440] 224. Form A (native) of substantially crystalline Compound 163, according to any one of embodiments 221 to 223, characterized by an X-ray powder diffractogram having one, two, or three signals selected from 7.4±0.2 degrees two-theta, 8.4±0.2 degrees two-theta, and 15.0±0.2 degrees two-theta.

[0441] 225. Form A (native) of substantially crystalline Compound 163 of any one of embodiments 221-224, characterized by an X-ray powder diffractogram having one, two, three, four, five, or six signals selected from 7.4±0.2 degrees two-theta, 8.4±0.2 degrees two-theta, 14.1±0.2 degrees two-theta, 15.0±0.2 degrees two-theta, 19.1±0.2 degrees two-theta, and 25.8±0.2 degrees two-theta.

[0442] 226. Form A (native) of substantially crystalline Compound 163 of any one of embodiments 221-225, characterized by an X-ray powder diffractogram having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 signals selected from 7.4±0.2 degrees 2-theta, 8.4±0.2 degrees 2-theta, 14.1±0.2 degrees 2-theta, 14.6±0.2 degrees 2-theta, 15.0±0.2 degrees 2-theta, 16.9±0.2 degrees 2-theta, 19.1±0.2 degrees 2-theta, 20.0±0.2 degrees 2-theta, 22.5±0.2 degrees 2-theta, 25.6±0.2 degrees 2-theta, and 25.8±0.2 degrees 2-theta.

[0443] 227. Form A (native) of substantially crystalline Compound 163, as described in any one of embodiments 221-226, characterized by an X-ray powder diffractogram substantially similar to FIG. 16.

[0444] 228. Substantially amorphous Compound 173 (native form) (i.e., less than 15% of Compound 173 is in crystalline form; less than 10% of Compound 173 is in crystalline form; less than 5% of Compound 173 is in crystalline form).

[0445] 229. The substantially amorphous Compound 173 (native form) of embodiment 228, wherein Compound 173 is 100% amorphous.

[0446] 230. The substantially amorphous compound 173 (native form) of embodiment 228 or 229, characterized by an X-ray powder diffractogram substantially similar to FIG. 18.

[0447] 231. Substantially crystalline Compound 173 (native form) (i.e., less than 15% of Compound 173 is in amorphous form, less than 10% of Compound 173 is in amorphous form, less than 5% of Compound 173 is in amorphous form).

[0448] 232. The substantially crystalline Form A (native) of Compound 173, as described in embodiment 231, wherein Form A (native) of Compound 173 is 100% crystalline.

[0449] 233. Triclinic system, P1 space group, and Cu K α 233. The substantially crystalline Form A (native) of Compound 173 according to any one of embodiments 231 and 232, characterized by the following unit cell dimensions measured at 150 K on a Bruker diffractometer using radiation (λ=1.54178 Å): [Table 9]

[0450] 234. Substantially crystalline Form A (native) of Compound 175 (i.e., less than 15% of Compound 175 is in amorphous form, less than 10% of Compound 175 is in amorphous form, less than 5% of Compound 175 is in amorphous form).

[0451] 235. The substantially crystalline Form A (native) of Compound 175, as described in embodiment 234, wherein Form A (native) of Compound 175 is 100% crystalline.

[0452] 236. Orthogonal system, P212121 space group, and Cu K α Form A (native) of the substantially crystalline Compound 175 according to any one of embodiments 234 and 235, characterized by the following unit cell dimensions measured at 100 K on a Bruker diffractometer using radiation (λ=1.54178 Å): [Table 10]

[0453] 237. A substantially crystalline dichloromethane solvate Form A of Compound 188 (i.e., less than 15% of the dichloromethane solvate of Compound 188 is in amorphous form, less than 10% of the dichloromethane solvate of Compound 188 is in amorphous form, less than 5% of the dichloromethane solvate of Compound 188 is in amorphous form).

[0454] 238. The substantially crystalline dichloromethane solvate Form A of Compound 188, as described in embodiment 237, wherein the dichloromethane solvate Form A of Compound 188 is 100% crystalline.

[0455] 239. Monoclinic system, P21 space group, and Cu K α The dichloromethane solvate Form A of the substantially crystalline Compound 188 according to embodiment 237 or 238, characterized by the following unit cell dimensions measured at 100 K on a Bruker diffractometer using radiation (λ=1.54178 Å): [Table 11] [Example]

[0456] General experimental procedure Abbreviation AcOH: acetic acid Boc anhydride ((Boc)2O): Di-tert-butyl dicarbonate Boc: butoxycarbonyl BOP: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate t-BuOH: tert-butanol CDCl3: chloroform-d CDI: 1,1′-carbonyldiimidazole CD3OD: methyl-d4 alcohol-d CH2Cl2: Dichloromethane CH3CN:Acetonitrile CO2: Carbon dioxide Cs2CO3: Cesium carbonate CuI: Copper(I) iodide DCE: 1,2-dichloroethane DCM: dichloromethane DIEA: (DIPEA; N,N-diisopropylethylamine) DMAP: 4-dimethylaminopyridine DMF: N,N-dimethylformamide DMP: Dess-Martin periodinane DMSO: dimethyl sulfoxide DMSO-d6: dimethyl sulfoxide-d6 EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide ESI-MS: Electrospray ionization mass spectrometry Et2O: Diethyl ether Et3N or TEA: Triethylamine EtOAc: ethyl acetate EtOH: ethanol Et2O: Diethyl ether ESI-MS: Electrospray ionization mass spectrometry Second-generation Grubbs catalyst: [1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichloro-[(2-isopropoxyphenyl)methylene]ruthenium H2: Hydrogen HATU: N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide HCl: Hydrochloric acid HOBT: Hydroxybenzotriazole HPLC: High-performance liquid chromatography H2: Hydrogen H2O2: Hydrogen peroxide KHSO4: Potassium sulfite KOH: Potassium hydroxide K2CO3: Potassium carbonate KMnO4: Potassium permanganate KHCO3: Potassium bicarbonate LC: liquid chromatography LiAlH4: Lithium aluminum hydride LiOH: Lithium hydroxide MeMgCl: methylmagnesium chloride MeTHF or 2-MeTHF or 2-Me-THF: 2-methyltetrahydrofuran MeOH: Methanol MTBE: Methyl tert-butyl ether MgSO4: Magnesium sulfate MS: Mass spectrometry n-Bu4NF·H2O: Tetra-n-butylammonium fluoride monohydrate Na: Sodium NaH: sodium hydride NaHCO3: Sodium bicarbonate NaOAc: sodium acetate NaOH: Sodium hydroxide Na2SO4: Sodium sulfate NBS: N-bromosuccinimide NH3: Ammonia NH4Cl: Ammonium chloride NH4HCO3: Ammonium bicarbonate NMP: N-methyl-2-pyrrolidone NMR: nuclear magnetic resonance N2: Nitrogen Pd / C: Palladium on carbon Pd2(dba)3: Tris(dibenzylideneacetone)dipalladium(0) Pd(dppf)Cl2: 1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride Pd(OAc)2: Palladium(II) acetate PhI(OAc)2: (diacetoxyiodo)benzene POCl3: Phosphoryl chloride PtO2: platinum oxide RT or rt: room temperature SFC: Supercritical Fluid Chromatography Silica Cat Pd: Palladium silica SiO2: Silica gel TBAF: tetra-n-butylammonium fluoride TBAI: Tetrabutylammonium iodide TBDPS-Cl or TBDPSCl: tert-butyldiphenylchlorosilane TEA: Triethylamine TEMPO: 2,2,6,6-tetramethylpiperidinyloxy TFA: Trifluoroacetic acid THF: tetrahydrofuran Ti(OEt)4: Titanium(IV) ethoxide TMEDA: Tetramethylethylenediamine TMSCF3: Trifluoromethyltrimethylsilane p-TsCl or tosyl chloride: p-toluenesulfonyl chloride or 4-toluenesulfonyl chloride T3P: 1-propanephosphonic anhydride UPLC: Ultra-high performance liquid chromatography Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene Zhan Catalyst-1B: Dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene][[5-[(dimethylamino)sulfonyl]-2-(1-methylethoxy-O)phenyl]methylene-C]ruthenium(II)

[0457] Common UPLC-MS / HPLC-MS / GC analysis methods: LC Method A: Waters Acquity UPLC-MS BEH C 18 Analytical reversed-phase UPLC-MS was performed using a column (50 x 2.1 mm, 1.7 μm particle size) (product number: 186002350) and a dual gradient run of 1% to 99% mobile phase B over 3.0 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0458] LC method B: Kinetex C 18 Analytical reverse-phase HPLC-MS was performed using a column (4.6 × 50 mm, 2.6 μm particle size): Temperature: 45°C, Flow rate: 2.0 mL / min, Run time: 3 min, Mobile phase: Initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient of 2.0 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 1.0 min.

[0459] LC method C: Kinetex Polar C 18 Analytical reverse-phase HPLC-MS using a column (3.0 × 50 mm, 2.6 μm particle size), temperature: 45°C, flow rate: 1.2 mL / min, run time: 6 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient for 4.0 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 2.0 min.

[0460] LC Method D: Waters Acquity UPLC-MS BEH C 18 Analytical reversed-phase UPLC-MS was performed using a column (50 x 2.1 mm, 1.7 μm particle size) (product number: 186002350) and a dual gradient run of 1% to 99% mobile phase B over 5.0 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0461] LC method E: Kinetex Polar C 18 Analytical reverse-phase HPLC-MS using a column (3.0 × 50 mm, 2.6 μm particle size), temperature: 45°C, flow rate: 1.2 mL / min, run time: 3 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient for 2.0 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 1.0 min.

[0462] LC method F:Kinetex C18 Analytical reverse-phase HPLC-MS using a column (4.6 × 50 mm, 2.6 μm particle size), temperature: 45°C, flow rate: 2.0 mL / min, run time: 6 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient for 4.0 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 2.0 min.

[0463] LC method G: Merckmillipore Chromolith SpeedROD C 18 Analytical reversed-phase HPLC-MS was performed using a column (50 × 4.6 mm) and a double gradient run of 5% to 100% mobile phase B over 6 min. Mobile phase A = water (+0.1% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.1% trifluoroacetic acid).

[0464] LC Method H: Waters Cortex C 18 Analytical reverse-phase HPLC-MS was performed using a 3.0 x 50 mm, 2.7 μm particle size column (product number 186007370), temperature: 55 °C, flow rate: 1.2 mL / min, mobile phase A: water (+0.1% trifluoroacetic acid). Mobile phase B: acetonitrile (+0.1% trifluoroacetic acid). Gradient: 5% to 100% B over 4 min, equilibration at 100% B for 0.5 min, equilibration to 5% B over 1.5 min.

[0465] LC Method I: Waters Acquity UPLC-MS BEH C 18 Analytical reversed-phase UPLC-MS was performed using a column (30 x 2.1 mm, 1.7 μm particle size) (product number: 186002349) and a dual gradient run of 1% to 99% mobile phase B over 1.2 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 1.5 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0466] LC Method J: Waters Acquity UPLC-MS BEH C 18Analytical reversed-phase UPLC-MS was performed using a column (50 x 2.1 mm, 1.7 μm particle size) (product number: 186002350) and a dual gradient run of 30% to 99% mobile phase B over 3.0 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0467] LC method K:Kinetex EVO C 18 Analytical reverse-phase HPLC-MS using a column (4.6 × 50 mm, 2.6 μm particle size), temperature: 45°C, flow rate: 2.0 mL / min, run time: 4 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient for 2.0 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 2.0 min.

[0468] LCMS method L: X-Terra MS C 18 Analytical reverse-phase HPLC-MS using a column (4.6 × 150 mm, 5 μm particle size), temperature: 40 °C, flow rate: 1.5 mL / min, run time: 10 min, mobile phase: initial 95% water (+10 mM ammonium bicarbonate) and 5% acetonitrile linear gradient - 95% acetonitrile for 6.5 min, then hold at 95% acetonitrile for 3.5 min.

[0469] LC Method M: Waters Acquity UPLC-MS BEH C 18 Analytical reversed-phase UPLC-MS was performed using a column (50 x 2.1 mm, 1.7 μm particle size) (product number: 186002350) and a dual gradient run of 50% to 99% mobile phase B over 3.0 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0470] LC Method N: Waters Acquity UPLC-MS BEH C 18Analytical reversed-phase UPLC-MS was performed using a column (50 x 2.1 mm, 1.7 μm particle size) (product number: 186002350) and a dual gradient run of 1% to 99% mobile phase B over 3.0 min. Mobile phase A = water (0.05% ammonium formate). Mobile phase B = acetonitrile. Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0471] LC method O:Kinetex Polar C 18 Analytical reverse-phase HPLC-MS using a column (3.0 × 50 mm, 2.6 μm particle size), temperature: 45°C, flow rate: 1.2 mL / min, run time: 4 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient for 3.0 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 1.0 min.

[0472] LC method P: Waters Acquity UPLC-MS BEH C 18 Analytical reversed-phase UPLC-MS was performed using a column (100 x 2.1 mm, 1.7 μm particle size) (product number: 186002352) and a dual gradient run of 1% to 99% mobile phase B over 13.5 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 0.8 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0473] LC Method Q: Onyx Monolithic C sold by Phenomenex 18 Analytical reversed-phase HPLC-MS using a column (50 x 4.6 mm) (product number: CH0-7644) and a double gradient run of 1% to 99% mobile phase B over 2.9 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 12 mL / min, injection volume = 50 μL, and column temperature = 25 °C.

[0474] LC method R: Waters Acquity UPLC-MS BEH C 18Analytical reversed-phase UPLC-MS was performed using a column (30 x 2.1 mm, 1.7 μm particle size) (product number: 186002349) and a dual gradient run of 30% to 99% mobile phase B over 1.0 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0475] LC method: Waters Acquity UPLC-MS BEH C 18 Analytical reversed-phase UPLC-MS was performed using a column (30 x 2.1 mm, 1.7 μm particle size) (product number: 186002349) and a dual gradient run of 1% to 99% mobile phase B over 1.0 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 1.5 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0476] LC method: Waters Acquity UPLC-MS BEH C 18 Analytical reversed-phase UPLC-MS was performed using a column (30 x 2.1 mm, 1.7 μm particle size) (product number: 186002349) and a double gradient run of 50% to 99% mobile phase B over 1.0 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0477] LC method: Waters Acquity UPLC-MS BEH C 18 Analytical reversed-phase UPLC-MS was performed using a column (30 x 2.1 mm, 1.7 μm particle size) (product number: 186002349) and a dual gradient run of 75% to 99% mobile phase B over 1.0 min. Mobile phase A = water (+0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60 °C.

[0478] LC method V:Kinetex EVO C 18Analytical reverse-phase HPLC-MS was performed using a column (2.1 × 50 mm, 2.6 μm particle size), temperature: 45 °C, flow rate: 1.0 mL / min, run time: 1.5 min, mobile phase: initial 98% mobile phase A (10 mM ammonium formate in water:acetonitrile, 95:5, pH 9) and 2% mobile phase B (acetonitrile) linear gradient in 1.15 min, hold at 98% acetonitrile for 0.2 min, then return to 98% water and 10 mM ammonium formate for 0.05 min and hold for 0.1 min.

[0479] LC method W: Kinetex Polar C 18 Analytical reverse-phase HPLC-MS using a column (3.0 × 50 mm, 2.6 μm particle size), temperature: 45°C, flow rate: 1.2 mL / min, run time: 4 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient for 3.0 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 1.0 min.

[0480] LC method X: Kinetex Polar C 18 Analytical reverse-phase HPLC-MS using a column (3.0 × 50 mm, 2.6 μm particle size), temperature: 45°C, flow rate: 1.2 mL / min, run time: 5 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient for 4.0 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 1.0 min.

[0481] LC Method Y: Luna C 18 Analytical reverse-phase HPLC-MS using a column (3.0 × 50 mm, 3 μm particle size), temperature: 45 °C, flow rate: 1.5 mL / min, run time: 3.5 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient of 1.3 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 2.2 min.

[0482] LC Method Z: Luna C 18Analytical reverse-phase HPLC-MS using a column (3.0 × 50 mm, 3 μm particle size), temperature: 45°C, flow rate: 1.5 mL / min, run time: 2.5 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient of 1.3 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 1.2 min.

[0483] LC method AA: SunFire C 18 Analytical reverse-phase HPLC-MS using a column (4.6 × 75 mm, 3.5 μm particle size), temperature: 45°C, flow rate: 1.5 mL / min, run time: 6 min, mobile phase: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient for 4.0 min to 95% acetonitrile (+0.1% formic acid), then hold at 95% acetonitrile (+0.1% formic acid) for 2.0 min.

[0484] LC Method BB:XBridge C 18 Analytical reverse-phase HPLC-MS using a column (4.6 × 75 mm, 5 μm particle size), flow rate: 1.5 mL / min, run time: 6 min, mobile phase: initial 95% water (+10 mM ammonium bicarbonate) and 5% acetonitrile-5% water (+10 mM ammonium bicarbonate) and 95% acetonitrile for 3 min, then hold at 95% acetonitrile and 5% water (+10 mM ammonium bicarbonate) for 3 min.

[0485] LC Method CC: Analytical GC using a Phenomenex ZB-1MS column (0.25 x 30 mm, 0.25 μm particle size), starting temperature 50°C, ramp 20°C / min to 300°C, hold for 5 min.

[0486] LC method DD: Merckmillipore Chromolith SpeedROD C 18 Analytical reversed-phase HPLC-MS was performed using a column (50 × 4.6 mm) and a double gradient run of 5% to 100% mobile phase B over 12 min. Mobile phase A = water (+0.1% trifluoroacetic acid). Mobile phase B = acetonitrile (+0.1% trifluoroacetic acid).

[0487] LC method EE: Kinetex EVO C 18 Analytical reverse-phase HPLC-MS was performed using a column (4.6 × 50 mm, 2.6 μm particle size), temperature: 45°C, flow rate: 2.0 ml / min, run time: 3 min. Mobile phase conditions: initial 95% water (+0.1% formic acid) and 5% acetonitrile (+0.1% formic acid) linear gradient to 95% acetonitrile (+0.1% formic acid) for 2.0 min, followed by a 1.0 min hold at 95% acetonitrile (+0.1% formic acid).

[0488] Common X-ray powder diffraction (XRPD) methods X-ray powder diffraction (XRPD) patterns were recorded at room temperature in continuous mode using a PANalytical Empyrean X-ray diffractometer (Almelo, The Netherlands). X-rays were generated using a Cu tube operated at 45 kV and 40 mA. A pixelated 1d detector was used with an anti-scatter slit P8. The divergence optics was a Bragg Brentano high resolution (BBHD) with a 10 mm mask, a 1 / 8 divergence slit, and a 1 / 2 anti-scatter slit. Continuous scan mode utilized a 0.0131 degree step size and a 13.77 second count time per step, integrating over a range of 4 to 40 degrees 2-theta. Powder samples were placed on the notched area in a zero-background holder and flattened with a glass slide.

[0489] Common thermogravimetric analysis (TGA) methods TGA was used to investigate the presence of residual solvents in the characterized batches and to identify the temperature at which sample decomposition occurs. Unless otherwise specified in the following examples, TGA data was collected on a Mettler Toledo TGA / DSC 3+ STARe system. The TGA data of compound 4 was collected on a TA instrument Discovery series equipped with a TRIOS system.

[0490] Common Differential Scanning Calorimetry (DSC) Methods Unless otherwise specified in the following examples, the melting point or glass transition temperature of a material was measured using a Mettler Toledo TGA / DSC 3+ STARe system. DSC data for compound 4 was collected on a TA instrument Discovery series equipped with a TRIOS system.

[0491] General synthetic scheme Another aspect of the present disclosure provides methods for making compounds of Formula I, I', I", I", Ia, Ia', IIa, IIa', IIb, IIb', IIc, IIc', IId, IId', IIe, IIe', IIf, IIf', IIg, IIg', IIh, IIh', compounds 1-213, compounds 214-222, deuterated derivatives thereof, and pharmaceutically acceptable salts of these compounds and deuterated derivatives, as well as intermediates for making any of the foregoing. In some embodiments of the schemes and examples below, the nitrogen and oxygen atoms may each optionally bear one or more protecting groups selected from the range of protecting groups disclosed herein in addition to, or in place of, the designated variable substituents. In some embodiments of the schemes and examples below, each compound may be replaced with a deuterated derivative.

[0492] [ka] Scheme 1 shows a process for preparing an intermediate compound of formula 1-7 from a compound of formula 1-1. Alk is selected from a C1-C6 linear or branched alkyl group. X 1 is selected from halogens such as Cl, I, or Br. 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). a is an integer selected from 2, 3, 4, and 5. Y is as defined in Formula I above.

[0493] Any suitable conditions for Grignard-type addition can be used to react a compound of Formula 1-1 with a compound of Formula 1-2 to form a compound of Formula 1-3. For example, Grignard addition of a compound of Formula 1-1 with a compound of Formula 1-2 can be carried out in EtO at −78° C., followed by the addition of 1N aqueous HCl to produce a compound of Formula 1-3. Conversion of a compound of Formula 1-3 to a compound of Formula 1-4 can be achieved by any suitable benzylation procedure to introduce an oxygen protecting group. Conversion of an ester of Formula 1-4 to a carboxylic acid of Formula 1-5 can be achieved by any suitable hydrolysis conditions. For example, conversion of a carboxylic acid of Formula 1-5 to a compound of Formula 1-6 can be achieved by reacting a compound of Formula 1-5 with HATU and EtN in DMF, followed by the addition of tert-butyl N-aminocarbamate. Any suitable hydrolysis conditions can be used to convert a carbamate of Formula 1-6 to a hydrazide of Formula 1-7. For example, compounds of formula 1-7 can be obtained by reacting compounds of formula 1-6 with HCl in CH2Cl2 at ambient temperature.

[0494] [ka] Scheme 2 refers to a process for preparing intermediate compounds of formula 2-3 from compounds of formula 2-1. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). a is an integer selected from 2, 3, 4, and 5. R 1 , m, and Y are as defined for formula I above.

[0495] Any suitable conditions for forming an amide bond can be used to generate a compound of formula 2-3 from a compound of formula 2-1 and a compound of formula 1-7. For example, a compound of formula S2-1 can be reacted with CDI in acetonitrile and DMF, followed by the addition of a compound of formula 1-7 to generate a compound of formula S2-2. Any suitable conditions for oxadiazole formation can be used to convert a compound of formula 2-2 to a compound of formula 2-3. For example, a compound of formula 2-2 can be reacted with DIPEA in acetonitrile, followed by the addition of p-toluenesulfonyl chloride to generate a compound of formula 2-3.

[0496] [ka] Scheme 3 refers to a process for preparing compounds of formula 3-8 from compounds of formula 3-1. Alk is selected from C1-C6 linear or branched alkyl groups. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). a is an integer selected from 1, 2, 3, and 4, and b is an integer selected from 0, 1, 2, 3, and 4, provided that a+b is 5 or less. Rings A, R 1 , m, and Y are as defined for formula I above.

[0497] The reaction of a compound of formula 3-1 with a compound of formula 3-2 to give a compound of formula 3-3 can be achieved by any suitable aromatic substitution conditions. The conversion of the ester of formula 3-3 to a carboxylic acid of formula 3-4 can be achieved by any suitable hydrolysis conditions. The compound of formula 3-5 can be prepared from a compound of formula 3-4 and a compound of formula 1-7 using any suitable amide bond formation conditions. The compound of formula 3-5 can be converted to a compound of formula 3-6 using any conditions suitable for oxadiazole formation. For example, the compound of formula 3-5 can be reacted with DIPEA in acetonitrile, followed by the addition of p-toluenesulfonyl chloride to give a compound of formula 3-6. The macrocyclization of a compound of formula 3-6 can be achieved by any suitable ring-closing metathesis conditions. For example, the compound of formula 3-6 can be reacted in the presence of a second generation Grubbs catalyst in DCE to give the E / Z isomer ( [ka] The macrocycle of formula 3-7 can be produced as a mixture of the unsaturated compounds of formula 3-7 (as indicated by the bond). Any suitable procedure for olefin reduction and benzyl deprotection can be used to achieve the conversion of the unsaturated compound of formula 3-7 to the macrocycle of formula 3-8.

[0498] [ka] Scheme 4 refers to a process for preparing compounds of formula 4-3 from compounds of formula 2-3. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). Each of a and b is independently an integer selected from 1, 2, 3, and 4, provided that a+b is 5 or less. Rings A, R 1 , m, and Y are as defined for formula I above.

[0499] The reaction of a compound of formula 2-3 with a compound of formula 3-2 to give a compound of formula 4-1 can be achieved by any suitable aromatic substitution conditions. The macrocyclization of a compound of formula 4-1 to give a compound of formula 4-2 can be achieved by any suitable ring-closing metathesis conditions. For example, a compound of formula 4-1 is reacted in the presence of Zhan's catalyst-1B in DCE to give the E / Z isomer ( [ka] The macrocycle of formula 4-2 can be produced as a mixture of the unsaturated compounds of formula 4-2 and 4-3 (as indicated by the bond). Any suitable procedure for olefin reduction and alcohol deprotection can be used to achieve the conversion of the unsaturated compound of formula 4-2 to the macrocycle of formula 4-3.

[0500] [ka] Scheme 5 refers to a process for preparing compounds of formula 5-5 from compounds of formula 2-3. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). 2 is selected from suitable nitrogen protecting groups such as Boc and Fmoc. Each of a and b is independently an integer selected from 1, 2, 3, and 4, provided that a+b is 5 or less. Ring A, R 1 , m, and Y are as defined for formula I above.

[0501] The reaction of a compound of formula 2-3 with a compound of formula 5-1 to produce a compound of formula 5-2 can be achieved by any cross-metathesis conditions. For example, a terminal olefin-containing compound of formula 2-3 can be reacted with a terminal olefin-containing compound of formula 5-1 in the presence of a Grubbs second generation catalyst in DCE to produce a cross-metathesis product of formula 5-2. Any suitable procedures for olefin reduction and amine deprotection can be used to achieve the conversion of the unsaturated compound of formula 5-2 to a compound of formula 5-3. Macrocyclization of a compound of formula 5-3 to produce a compound of formula 5-4 can be achieved by any suitable aromatic substitution conditions. Any suitable procedures for alcohol deprotection can be used to achieve the conversion of a compound of formula 5-4 to an alcohol of formula 5-5.

[0502] [ka] Scheme 6 refers to a process for preparing compounds of formula 6-7 from compounds of formula 3-1. Alk is selected from C1-C6 linear or branched alkyl groups. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). Each of a and b is independently an integer selected from 1, 2, 3, and 4, with the proviso that a+b is 5 or less. R 1 , m, Y, and R X1 is as defined for formula I above.

[0503] The reaction of a compound of formula 3-1 with a compound of formula 6-1 to give a compound of formula 6-2 can be achieved by any suitable aromatic substitution conditions. The conversion of the ester of formula 6-2 to a carboxylic acid of formula 6-3 can be achieved by any suitable hydrolysis conditions. The compound of formula 6-4 can be prepared from a compound of formula 6-3 and a compound of formula 1-7 using any suitable amide bond formation conditions. The compound of formula 6-4 can be converted to a compound of formula 6-5 using any conditions suitable for oxadiazole formation. For example, the compound of formula 6-4 can be reacted with DIEA in acetonitrile, followed by the addition of p-toluenesulfonyl chloride to give a compound of formula 6-5. The macrocyclization of a compound of formula 6-5 to give a compound of formula 6-6 can be achieved by any suitable ring-closing metathesis conditions. For example, the compound of formula 6-5 can be reacted in the presence of Zhan's catalyst-1B in DCE to give the E / Z isomer ( [ka] The macrocycle of formula 6-6 can be produced as a mixture of the unsaturated compounds of formula 6-6 and formula 6-7 (as indicated by the bond). Any suitable procedure for olefin reduction and alcohol deprotection can be used to achieve the conversion of the unsaturated compound of formula 6-6 to the macrocycle of formula 6-7.

[0504] [ka] Scheme 7 refers to a process for preparing a compound of Formula 7-7 from a compound of Formula 3-1. Alk is selected from a C1-C6 linear or branched alkyl group. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). Each of a and b is independently an integer selected from 0, 1, 2, and 3, provided that a+b is 4 or less. R 1 , m, Y, R X1 , and R Y is as defined for formula I above.

[0505] The reaction of a compound of formula 7-1 with a compound of formula 3-1 to give a compound of formula 7-2 can be achieved by any suitable aromatic substitution conditions. The conversion of the ester of formula 7-2 to a carboxylic acid of formula 7-3 can be achieved by any suitable hydrolysis conditions. The compound of formula 7-4 can be prepared from a compound of formula 7-3 and a compound of formula 1-7 using any suitable amide bond formation conditions. The compound of formula 7-4 can be converted to a compound of formula 7-5 using any conditions suitable for oxadiazole formation. For example, the compound of formula 7-4 can be reacted with DIEA in acetonitrile, followed by the addition of p-toluenesulfonyl chloride to give a compound of formula 7-5. The macrocyclization of a compound of formula 7-5 to give a compound of formula 7-6 can be achieved by any suitable ring-closing metathesis conditions. For example, the compound of formula 7-5 can be reacted in the presence of Zhan's catalyst-1B in DCE to give the E / Z isomer ( [ka] The macrocycle of formula 7-6 can be produced as a mixture of the unsaturated compounds of formula 7-6 (as indicated by the bond). Any suitable procedure for olefin reduction and alcohol deprotection can be used to achieve the conversion of the unsaturated compound of formula 7-6 to the macrocycle of formula 7-7.

[0506] [ka] Scheme 8 refers to a process for preparing compounds of formula 8-3 from compounds of formula 2-3. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). Each of a and b is independently an integer selected from 1, 2, 3, and 4, with the proviso that a+b is 5 or less. R 1 , m, Y, and R X1 is as defined for formula I above.

[0507] The reaction of the compound of formula 2-3 with the compound of formula 6-1 to give the compound of formula 8-1 can be achieved by any suitable aromatic substitution conditions. For example, the compound of formula 2-3 can be reacted with DIEA in acetonitrile and heated to give the compound of formula 8-1. The macrocyclization of the compound of formula 8-1 to give the compound of formula 8-2 can be achieved by any suitable ring-closing metathesis conditions. For example, the compound of formula 8-1 can be reacted in the presence of Zhan's catalyst-1B in DCE to give the E / Z isomer ( [ka] The macrocycle of formula 8-2 can be obtained as a mixture of the unsaturated compounds of formula 8-2 and 8-3 (as indicated by the bond). Any suitable procedure for olefin reduction and alcohol deprotection can be used to achieve the conversion of the unsaturated compound of formula 8-2 to the macrocycle of formula 8-3.

[0508] [ka] Scheme 9 refers to a process for preparing compounds of formula 9-5 from compounds of formula 9-1. X is selected from halogens such as Cl, I, or Br, and c is independently an integer selected from 1, 2, 3, and 4. Ring A, Ring B, R 1 , m, and Y are as defined for formula I above.

[0509] The reaction of a compound of formula 9-1 with a compound of formula 9-2 to give a compound of formula 9-3 can be achieved by any suitable oxadiazole-forming conditions. For example, a compound of formula 9-2 can be reacted with (N-isocyanoimino)triphenylphosphorane in DCM, followed by the dropwise addition of a compound of formula 9-1 to give a compound of formula 9-3. Macrocyclization of a compound of formula 9-3 to give a compound of formula 9-4 can be achieved by any suitable palladium-catalyzed olefin coupling conditions. For example, a compound of formula 9-3 in acetonitrile can be reacted with tris-o-tolylphosphane and Pd(OAc)2, followed by the addition of triethylamine to give the E / Z isomer ( [ka] The cyclic compounds of formula 9-4 can be obtained as a mixture of the unsaturated compounds of formula 9-4 (as indicated by the bond). Any suitable procedure for olefin reduction can be used to achieve the conversion of the unsaturated compounds of formula 9-4 to the macrocycles of formula 9-5.

[0510] [ka] Scheme 10 refers to a process for preparing compounds of formula 10-8 from compounds of formula 10-1. Alk is selected from C1-C6 linear or branched alkyl groups. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. Each of a and b is independently an integer selected from 1, 2, 3, and 4, provided that a+b is 5 or less. Rings A, R 1 and Y are as defined for formula I above.

[0511] The reaction of a compound of formula 10-1 with a compound of formula 3-2 to give a compound of formula 10-2 can be achieved by any suitable aromatic substitution conditions. For example, a compound of formula 10-1 can be reacted with a compound of formula 3-2 and DIEA in acetonitrile to give a compound of formula 10-2. Conversion of the ester of formula 10-2 to a carboxylic acid of formula 10-3 can be achieved by any suitable hydrolysis conditions. A compound of formula 10-4 can be prepared from a compound of formula 10-3 and a compound of formula 1-7 using any suitable amide bond formation conditions. A compound of formula 10-4 can be converted to a compound of formula 10-5 using any conditions suitable for oxadiazole formation. For example, a compound of formula 10-4 can be reacted with DIEA in acetonitrile, followed by the addition of p-toluenesulfonyl chloride to give a compound of formula 10-5. Macrocyclization of a compound of formula 10-5 to give a compound of formula 10-6 can be achieved by any suitable ring-closing metathesis conditions. For example, the compound of formula 10-5 is reacted in the presence of Zhan's catalyst-1B in DCE to give the E / Z isomer ( [ka] The macrocycle of formula 10-6 can be produced as a mixture of the following: (indicated by the bond). Conversion of the compound of formula 10-7 to the compound of formula 10-8 can be achieved by any suitable aromatic substitution conditions. Conversion of the unsaturated compound of formula 10-7 to the macrocycle of formula 10-8 can be achieved using any suitable procedure for olefin reduction and benzyl deprotection.

[0512] [ka] Scheme 11 refers to a process for preparing compounds of formula 11-4 from compounds of formula 2-3. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). Each of a and b is independently an integer selected from 1, 2, 3, and 4, with the proviso that a+b is 5 or less. R 1 , m, Y, R X1 , and R YN is as defined for formula I above.

[0513] The reaction of a compound of formula 2-3 with a compound of formula 11-1 to give a compound of formula 11-2 can be achieved by any suitable aromatic substitution conditions. For example, a compound of formula 2-3 and a compound of formula 11-1 can be reacted in DMSO in the presence of heat to give a compound of formula 11-2. The conversion of a terminal olefin-containing compound of formula 11-2 to a carboxylic acid of formula 11-3 can be achieved by any oxidative cleavage conditions. For example, a compound of formula 11-2 can be reacted in a mixture of dioxane and water in the presence of osmium oxide and sodium periodate to give a compound of formula 11-3. The macrocyclization of a compound of formula 11-3 to give a compound of formula 11-4 can be achieved by any suitable amide bond formation conditions. For example, a compound of formula 11-3 can be reacted with IDEA in DMF, followed by the addition of HATU to give a compound of formula 11-4.

[0514] [ka] Scheme 12 refers to a process for preparing compounds of formula 12-4 from compounds of formula 2-3. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl moieties and silyl moieties (e.g., TBDPS, TBS, and TMS). a is an integer selected from 3, 4, 5, and 6. Ring A, R 1 , m, and Y are as defined for formula I above.

[0515] Conversion of a terminal olefin-containing compound of formula 2-3 to a carboxylic acid of formula 12-1 can be achieved by any oxidation conditions. For example, a compound of formula 2-3 can be converted to an alcohol by hydroboration / oxidation, followed by oxidation of the alcohol to a carboxylic acid to produce a compound of formula 12-1. Reaction of a compound of formula 12-1 with a compound of formula 12-2 to produce a compound of formula 12-3 can be achieved by any suitable aromatic substitution conditions. For example, a compound of formula 12-1 can be reacted with a compound of formula 12-2 and diisopropylethylamine in a microwave to produce a compound of formula 12-3. Macrocyclization of a compound of formula 12-3 to produce a compound of formula 12-4 can be achieved by any suitable amide bond formation conditions. For example, a compound of formula 12-3 can be reacted with DIEA in DMF, followed by the addition of HATU to produce a compound of formula 12-4.

[0516] [ka] Scheme 13 refers to a process for preparing compounds of Formula 13-7 from compounds of Formula 3-1. Each Alk is independently selected from C1-C6 linear or branched alkyl groups. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). Each of a and b is independently an integer selected from 1, 2, 3, and 4, provided that a+b is 5 or less. R 1 , m, X, Y, R X1 , and R Y is as defined for formula I above.

[0517] The reaction of a compound of formula 3-1 with a compound of formula 13-1 to give a compound of formula 13-2 can be achieved by any suitable aromatic substitution conditions. For example, a compound of formula 3-1 and a compound of formula 13-1 can be stirred in acetonitrile, followed by the dropwise addition of diisopropylethylamine and heating to give a compound of formula 13-2. The conversion of an ester of formula 13-2 to a carboxylic acid of formula 13-3 or 13-4 can be achieved by any suitable hydrolysis conditions, followed by suitable amide bond formation conditions. For example, a compound of formula 13-2 can be reacted with hydrazine monohydrate in methanol to give a compound of formula 13-3 or 13-4. The conversion of a compound of formula 13-3 or 13-4 to a compound of formula 13-5 can be achieved by any suitable amide bond formation conditions. The conversion of a compound of formula 13-5 to a compound of formula 13-6 can be achieved using any conditions suitable for oxadiazole formation. For example, compounds of formula 13-5 can be reacted with N,N-diisopropylethylamine in acetonitrile, followed by the addition of 4-methylbenzenesulfonyl chloride to give oxadiazoles of formula 13-6. Conversion of compounds of formula 13-6 to alcohols of formula 13-7 can be achieved by any suitable alcohol deprotection procedure.

[0518] [ka] Scheme 14 refers to a process for preparing compounds of formula 14-7 from compounds of formula 14-1. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). 2 is selected from suitable nitrogen protecting groups such as Boc and Fmoc. Each of a and b is independently an integer selected from 1, 2, 3, and 4, with the proviso that a+b is 5 or less. R 1 , m, X, Y, and R X1 is as defined for formula I above.

[0519] The reaction of a compound of formula 14-1 with a compound of formula 14-2 to give a compound of formula 14-3 can be achieved by any suitable amide bond forming conditions. The conversion of a compound of formula 14-3 to a compound of formula 14-4 can be achieved by any suitable procedure for converting an alcohol to a leaving group. For example, a compound of formula 14-3 can be reacted with triphenylphosphine followed by 2,2,2-trichloroacetonitrile in anhydrous THF to give a compound of formula 14-4. The conversion of a compound of formula 14-4 to a compound of formula 14-5 can be achieved by any suitable amine deprotection conditions. The macrocyclization of a compound of formula 14-5 to give a compound of formula 14-6 can be achieved by any suitable aromatic substitution conditions. For example, a compound of formula 14-5 can be reacted with TFA in DCM to give a compound of formula 14-6. The conversion of a compound of formula 14-6 to an alcohol of formula 14-7 can be achieved by any suitable alcohol deprotection procedure.

[0520] [ka] Scheme 15 refers to a process for preparing compounds of formula 15-4 from compounds of formula 7-6. 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). Each of a and b is independently an integer selected from 0, 1, 2, and 3, provided that a+b is 4 or less. R 1 , m, Y, R X1 , and R Y is as defined for formula I above.

[0521] Conversion of compounds of formula 7-6 to alcohols of formula 15-1 can be achieved by any suitable olefin oxidation procedure. Conversion of compounds of formula 15-1 to compounds of formula 15-2 can be achieved by any suitable alcohol deprotection conditions. Conversion of alcohols of formula 15-2 to carbonyl-containing compounds of formula 15-3 can be achieved by any suitable oxidation procedure. Conversion of carbonyl-containing compounds of formula 15-3 to produce compounds of formula 15-4 can be achieved by any suitable reduction procedure.

[0522] [ka] Scheme 16 refers to a process for preparing compounds of formula 16-10 and 16-11 from compounds of formula 3-1. Alk is selected from C1-C6 linear or branched alkyl groups. LG is selected from halogens and oxygen-based leaving groups such as OTf and OTs. PG 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). Each of a and b is independently an integer selected from 1, 2, 3, and 4, with the proviso that a+b is 5 or less. R 1 , m, X, Y, and R Z1 is as defined for formula I above.

[0523] The reaction of a compound of formula 3-1 with a compound of formula 16-1 to give a compound of formula 16-2 can be achieved by any suitable aromatic substitution conditions. The conversion of the ester of formula 16-2 to a carboxylic acid of formula 16-3 can be achieved by any suitable hydrolysis conditions. The compound of formula 16-5 can be prepared from a compound of formula 16-3 and a compound of formula 16-4 using any suitable amide bond formation conditions. The compound of formula 16-5 can be converted to a compound of formula 16-6 using any conditions suitable for oxadiazole formation. For example, the compound of formula 16-5 can be reacted with DIEA in acetonitrile, followed by the addition of p-toluenesulfonyl chloride to give the oxadiazole of formula 16-6. The macrocyclization of a compound of formula 16-6 to give a compound of formula 16-7 can be achieved by any suitable ring-closing metathesis conditions. For example, the compound of formula 16-6 can be reacted in the presence of Zhan's catalyst-1B in DCE to give the E / Z isomer ( [ka] The macrocycle of formula 16-7 can be produced as a mixture of olefins (as indicated by the bond). Conversion of compounds of formula 16-7 to compounds of formula 16-8 can be achieved using any suitable procedure for olefin reduction and benzyl deprotection. Conversion of compounds of formula 16-8 to carbonyl-containing compounds of formula 16-9 can be achieved using any suitable oxidation conditions. Conversion of carbonyl-containing compounds of formula 16-9 to oximes of formula 16-10 can be achieved using any suitable oxime-forming procedure. Conversion of carbonyl-containing compounds of formula 16-9 to alcohols of formula 16-11 can be achieved using any suitable procedure for nucleophilic addition to a carbonyl.

[0524] [ka] Scheme 17 refers to a process for preparing compounds of formula 17-7 from compounds of formula 17-1. Each of a and b is independently an integer selected from 1, 2, 3, and 4, with the proviso that a+b is 5 or less. 1 , m, X, Y, and RZ1 is as defined for formula I above.

[0525] The reaction of a carboxylic acid of formula 17-1 with an aldehyde of formula 17-2 to give a compound of formula 17-3 can be achieved using any suitable conditions for oxadiazole formation. For example, a compound of formula 17-1 can be reacted with a compound of formula 17-2 and N-isocyanoimino)triphenylphosphorane in DCM to give a compound of formula 17-3. The conversion of an alcohol of formula 17-3 to a carbonyl-containing compound of formula 17-4 can be achieved by any suitable oxidation procedure. The conversion of a carbonyl-containing compound of formula 17-4 to an alcohol of formula 17-5 can be achieved using any suitable procedure for nucleophilic addition to a carbonyl. Macrocyclization of a compound of formula 17-5 to give a compound of formula 17-6 can be achieved by any suitable ring-closing metathesis conditions. For example, when the compound of formula 17-5 is reacted in the presence of [1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichloro-[(2-isopropoxy-5-nitro-phenyl)methylene]ruthenium in DCE, the E / Z isomer ( [ka] The macrocycle of formula 17-6 can be obtained as a mixture of the following: (denoted by the bond): Conversion of compounds of formula 17-6 to compounds of formula 17-7 can be achieved using any suitable procedure for olefin reduction.

[0526] [ka] Scheme 18 refers to a process for preparing compounds of formula 18-5 from compounds of formula 17-1. 1 is selected from suitable oxygen protecting groups such as benzyl and silyl moieties (e.g., TBDPS, TBS, and TMS). Each of a and b is independently an integer selected from 1, 2, 3, and 4, with the proviso that a+b is 5 or less. R 1, m, X, and Y are as defined for Formula I above.

[0527] The reaction of a compound of formula 17-1 with a compound of formula 18-1 to give a compound of formula 18-2 can be achieved by any suitable amide bond forming conditions. Any conditions suitable for oxadiazole formation can be used to convert a compound of formula 18-2 to a compound of formula 18-3. For example, a compound of formula 18-2 can be reacted with diisopropylethylamine and p-toluenesulfonyl chloride to give an oxadiazole of formula 18-3. Macrocyclization of a compound of formula 18-3 to give a compound of formula 18-4 can be achieved by any suitable ring-closing metathesis conditions. For example, a compound of formula 18-3 can be reacted in the presence of Zhan's catalyst-1B in DCE to give the E / Z isomer ( [ka] The conversion of compounds of formula 18-4 to compounds of formula 18-5 can be achieved using any suitable procedure for olefin reduction and alcohol deprotection.

[0528] [ka] Scheme 19 refers to a process for preparing compounds of formula 19-2 from compounds of formula 13-7. Each of a and b is independently an integer selected from 1, 2, 3, and 4, with the proviso that a+b is 5 or less. 1 , m, X, and Y are as defined for Formula I above.

[0529] Conversion of compounds of formula 13-7 to olefins of formula 19-1 can be achieved using any suitable dehydration procedure. Conversion of compounds of formula 19-1 to compounds of formula 19-2 can be achieved using any suitable olefin reduction procedure.

[0530] [ka] Scheme 20 refers to a process for preparing compounds of formula 20-2 from compounds of formula 20-1. Each of a and b is independently an integer selected from 1, 2, 3, and 4, with the proviso that a+b is 5 or less. 1 , m, X, Y, R Z1 , and R 2 is as defined for formula I above.

[0531] Conversion of amines of formula 20-2 to amines of formula 20-1 can be achieved using any suitable amination procedure. For example, amines of formula 20-1 can be reacted with an alkyl halide in the presence of sodium bis(trimethylsilyl)amino to give compounds of formula 20-2.

[0532] Preparation of intermediates Intermediate 1: Preparation of methyl 3-[bis(tert-butoxycarbonyl)amino]-6-bromo-5-(trifluoromethyl)pyridine-2-carboxylate [ka] Step 1: Methyl 3-(benzhydrylideneamino)-5-(trifluoromethyl)pyridine-2-carboxylate [ka] A mixture of methyl 3-chloro-5-(trifluoromethyl)pyridine-2-carboxylate (47.3 g, 197.43 mmol), diphenylmethanimine (47 g, 259.33 mmol), Xantphos (9.07 g, 15.675 mmol), and cesium carbonate (131 g, 402.06 mmol) in dioxane (800 mL) was degassed by bubbling nitrogen through for 30 minutes. Pd(OAc)2 (3.52 g, 15.679 mmol) was added, and the system was purged with nitrogen three times. The reaction mixture was heated at 100 °C for 18 hours. The reaction was cooled to room temperature and filtered through a pad of Celite. The cake was washed with EtOAc, and the solvent was evaporated under reduced pressure to give methyl 3-(benzhydrylideneamino)-5-(trifluoromethyl)pyridine-2-carboxylate (90 g, 84%) as a yellow solid. ESI-MS m / z calculated 384.10855, observed 385.1 (M+1) + ; Retention time: 2.24 minutes (LC method B).

[0533] Step 2: Methyl 3-amino-5-(trifluoromethyl)pyridine-2-carboxylate [ka] To a suspension of methyl 3-(benzhydrylideneamino)-5-(trifluoromethyl)pyridine-2-carboxylate (65 g, 124.30 mmol) in methanol (200 mL) was added HCl (3 M in methanol) (146 mL of 3 M, 438.00 mmol). The mixture was stirred at room temperature for 1.5 hours, and then the solvent was removed under reduced pressure. The residue was taken up in ethyl acetate (2 L) and dichloromethane (500 mL). The organic phase was washed with 5% aqueous sodium bicarbonate solution (3 × 500 mL) and brine (2 × 500 mL), dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was triturated with heptane (2 × 50 mL), and the mother liquor was discarded. The obtained solid was triturated with a mixture of dichloromethane and heptane (1:1, 40 mL) and filtered to give methyl 3-amino-5-(trifluoromethyl)pyridine-2-carboxylate (25.25 g, 91%) as a yellow solid. 1H NMR (300MHz, CDCl3) δ8.24(s, 1H), 7.28(s, 1H), 5.98(br.s, 2H), 4.00(s, 3H) ppm. 19 F NMR (282 MHz, CDCl) δ -63.23 (s, 3F) ppm. ESI-MS m / z calculated 220.046, found 221.1 (M+1). + ; Retention time: 1.62 minutes (LC method E).

[0534] Step 3: Methyl 3-amino-6-bromo-5-(trifluoromethyl)pyridine-2-carboxylate [ka] To a solution of methyl 3-amino-5-(trifluoromethyl)pyridine-2-carboxylate (18.75 g, 80.91 mmol) in acetonitrile (300 mL) at 0° C., N-bromosuccinimide (18.7 g, 105.3 mmol) was added in portions. The mixture was stirred at 25° C. overnight. Ethyl acetate (1000 mL) was added. The organic layer was washed with 10% sodium thiosulfate solution (3×200 mL), which was back-extracted with ethyl acetate (2×200 mL). The combined organic extracts were washed with saturated sodium bicarbonate solution (3×200 mL), brine (200 mL), dried over sodium sulfate, and concentrated in vacuo to provide methyl 3-amino-6-bromo-5-(trifluoromethyl)pyridine-2-carboxylate (25.46 g, 98%). 1 H NMR (300MHz, CDCl3) δ3.93~4.03(m, 3H), 6.01(br.s., 2H), 7.37(s, 1H) ppm. 19 F NMR (282 MHz, CDCl) δ -64.2 (s, 3F) ppm. ESI-MS m / z calculated 297.9565, found 299.0 (M+1). + ; Retention time: 2.55 minutes (LC method F).

[0535] Step 4: Methyl 3-[bis(tert-butoxycarbonyl)amino]-6-bromo-5-(trifluoromethyl)pyridine-2-carboxylate [ka] A mixture of methyl 3-amino-6-bromo-5-(trifluoromethyl)pyridine-2-carboxylate (5 g, 15.549 mmol), (Boc)O (11 g, 11.579 mL, 50.402 mmol), DMAP (310 mg, 2.5375 mmol), and CHCl (150 mL) was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and purification by silica gel chromatography (0 to 15% ethyl acetate in heptane) provided methyl 3-[bis(tert-butoxycarbonyl)amino]-6-bromo-5-(trifluoromethyl)pyridine-2-carboxylate (6.73 g, 87%) as a pale yellow solid. 1 H NMR (300MHz, CDCl3) δ1.42(s, 18H), 3.96(s, 3H), 7.85(s, 1H) ppm. 19 F NMR (282MHz, CDCl3) δ-63.9(s, 3F)ppm. ESI-MS m / z calculated value 498.06134, retention time: 2.34 minutes (LC method B).

[0536] Intermediate 2: 6-(2-allylpyrrolidin-1-yl)-3-(tert-butoxycarbonylamino)-5-(trifluoromethyl)pyridine-2-carboxylic acid [ka] Step 1: tert-Butyl 2-allylpyrrolidine-1-carboxylate [ka] s-Butyllithium (20.4 mL of 1.4 M in cyclohexane, 28.56 mmol) was added dropwise to a solution of tert-butyl pyrrolidine-1-carboxylate (3.5 g, 20.44 mmol) and tetramethylethylenediamine (2.8675 g, 3.7 mL, 24.676 mmol) in diethyl ether (80 mL) at −78° C., and the mixture was stirred for 2 hours. Zinc chloride (57 mL of 0.5 M in THF, 28.5 mmol) was then added slowly at −78° C., and the mixture was stirred for 90 minutes. A solution of copper(I) cyanide (2.2 g, 24.564 mmol) in lithium chloride (82 mL of 0.5 M in THF, 41 mmol) was slowly added at -78 °C, and the mixture was stirred for 90 min. 3-Bromoprop-1-ene (7.4094 g, 5.3 mL, 61.247 mmol) was then slowly added at -78 °C, and the mixture was stirred at room temperature overnight. Aqueous ammonium hydroxide (60 mL) was added, and the mixture was stirred at room temperature for 1 h. The phases were separated, and the aqueous phase was extracted with diethyl ether (2 × 60 mL). The organic phases were combined, washed with brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification by silica gel chromatography (0% to 20% ethyl acetate in heptane gradient) provided tert-butyl 2-allylpyrrolidine-1-carboxylate (2.9 g, 67%) as a clear oil. 1 H NMR (300MHz, CDCl3) δ1.46(s, 9H), 1.66~1.95(m, 4H), 1.99~2.23(m, 1H), 2.33~2.62(m , 1H), 3.22~3.46(m, 2H), 3.67~3.94(m, 1H), 4.97~5.11(m, 2H), 5.62~5.84(m, 1H)ppm. ESI-MS m / z calculated value 211.1572, measured value 234.2 (M+Na) + ; Retention time: 2.17 minutes (LC method B).

[0537] Step 2: 2-Allylpyrrolidine (trifluoroacetate) [ka] Trifluoroacetic acid (13.468 g, 9.1 mL, 118.12 mmol) was slowly added to tert-butyl 2-allylpyrrolidine-1-carboxylate (1.6 g, 7.5721 mmol) in dichloromethane (12 mL) at 0° C. The mixture was stirred at room temperature for 3 hours and then concentrated. Toluene (10 mL) was added, and the mixture was concentrated (repeated four times) to give 2-allylpyrrolidine (trifluoroacetate) (1.9 g, 99%) as an amber oil. 1 H NMR (300MHz, CDCl3) δ1.57~1.85(m, 1H), 1.89~2.31(m, 3H), 2.35~2.71(m, 2H), 3.32(br.s., 2H) , 3.61(br.s., 1H), 4.95~5.35(m, 2H), 5.51~5.91(m, 1H), 8.27(br.s., 1H), 9.31(br.s., 1H)ppm. 19 F NMR (282 MHz, CDCl) δ -75.9 (s, 3F) ppm. ESI-MS m / z calculated 111.1048, found 112.2 (M+1). + ; Retention time: 0.36 min (LC method B).

[0538] Step 3: Methyl 6-(2-allylpyrrolidin-1-yl)-3-[bis(tert-butoxycarbonyl)amino]-5-(trifluoromethyl)pyridine-2-carboxylate [ka] In a sealed tube, 2-allylpyrrolidine (trifluoroacetate) (338 mg, 1.5008 mmol) was added to methyl 3-[bis(tert-butoxycarbonyl)amino]-6-bromo-5-(trifluoromethyl)pyridine-2-carboxylate (500 mg, 1.0015 mmol) and DIPEA (964.60 mg, 1.3 mL, 7.4635 mmol) in acetonitrile (10 mL). The tube was sealed, and the mixture was heated at 80 °C overnight. Saturated sodium bicarbonate solution (25 mL) was added, and the mixture was extracted with ethyl acetate (3 × 25 mL). The organic phases were combined, washed with brine (25 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification by silica gel chromatography (0% to 20% gradient of ethyl acetate in heptane) provided methyl 6-(2-allylpyrrolidin-1-yl)-3-[bis(tert-butoxycarbonyl)amino]-5-(trifluoromethyl)pyridine-2-carboxylate (480 mg, 91%) as a yellow oil. 1 H NMR (300MHz, CDCl3) δ1.42(s, 18H), 1.65~1.90(m, 2H), 1.94~2.18(m, 2H), 2.24~2.40(m, 1H), 2.51~2.65(m, 1H), 3.41~ 3.52(m, 1H), 3.55~3.69(m, 1H), 3.88(s, 3H), 4.46~4.60(m, 1H), 4.95~5.11(m, 2H), 5.65~5.87(m, 1H), 7.63(s, 1H)ppm. 19 F NMR (282 MHz, CDCl3) δ -56.0 (s, 3F) ppm. ESI-MS m / z calculated 529.24, found 530.3 (M+1). + ; Retention time: 2.63 minutes (LC method E).

[0539] Step 4: 6-(2-allylpyrrolidin-1-yl)-3-(tert-butoxycarbonylamino)-5-(trifluoromethyl)pyridine-2-carboxylic acid [ka] To a solution of methyl 6-(2-allylpyrrolidin-1-yl)-3-[bis(tert-butoxycarbonylamino)]-5-(trifluoromethyl)pyridine-2-carboxylate (13.1 g, 24.74 mmol) in THF (156 mL) was added methanol (125 mL) and water (100 mL). Anhydrous lithium hydroxide (2.116 g, 86.6 mmol) was added to the mixture in three portions. The mixture was stirred at 60° C. for 3.5 hours. The THF and methanol were removed under reduced pressure, and then 70 mL of 10% aqueous HCl was added. The resulting mixture was extracted with EtOAc (3×100 mL). The organic phases were combined, washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification by silica gel chromatography (gradient of 0% to 50% EtOAc in hexanes) provided methyl 6-(2-allylpyrrolidin-1-yl)-3-(tert-butoxycarbonylamino)-5-(trifluoromethyl)pyridine-2-carboxylate (7.85 g, 76%) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ1.52(s, 9H), 1.74~1.81(m, 2H), 1.98~2.01(m, 1H), 2.15~2.26(m, 2H), 2.44~2.50(m, 1H), 3.38~3.43(m, 1H), 3.63~3.69(m, 1H), 4.25~4.32(m, 1H), 5.04~5.08(m, 2H), 5.70~5.80(m, 1H), 9.13(s, 1H), 9.67(s, 1H), 11.11(br.s, 1H). ESI-MS m / z calculated value 415.1719, measured value 416.3(M+1) + ; Retention time: 2.01 minutes (LC method A).

[0540] Intermediate 3: Preparation of (2S)-2-allylpyrrolidine (trifluoroacetate) [ka] Step 1: (2S)-tert-butyl 2-(iodomethyl)pyrrolidine-1-carboxylate [ka] To a solution of imidazole (16.9 g, 248.2 mmol) and triphenylphosphane (35.8 g, 136.5 mmol) in 2-methyltetrahydrofuran (300 mL) at 0° C., iodine (34.8 g, 137.1 mmol) was added in portions over 30 minutes. The reaction temperature was kept <6° C., and the mixture became a dark orange taffy-like substance, then pale yellow and granular upon stirring. The mixture was allowed to warm to ambient temperature, and a solution of tert-butyl (2S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (25 g, 124.2 mmol) in 2-methyltetrahydrofuran (150 mL) was added in portions. The mixture was stirred at ambient temperature for 16 hours to give a pale yellow slurry. The slurry was filtered over Celite to remove salts, and the filtrate was concentrated in vacuo. The residue was dissolved in 150 mL of EtOAc. 150 mL of hexane was added to the mixture to give an oil. This oil did not dissolve upon addition of EtOAc (approximately 300 mL). The oil was removed by suction and analyzed to be triphenylphosphine oxide. The solvent phase remaining after removal of the oil was concentrated in vacuo. A precipitate formed on standing and was stirred in 100 mL of MTBE. The precipitate was removed by filtration and washed with MTBE. The filtrate was concentrated in vacuo and purified by silica gel chromatography (0% to 40% EtOAc / hexanes) to provide tert-butyl (2S)-2-(iodomethyl)pyrrolidine-1-carboxylate (36.5 g, 94%) as a pale yellow oil. 1 H NMR (499 MHz, chloroform-d): δ 3.89 (d, J = 14.0 Hz, 1H), 3.42 (d, J = 34.7 Hz, 4H), 2.06 (s, 1H), 2.00-1.86 (m, 2H), 1.82 (q, J = 6.9 Hz, 1H), 1.47 (s, 9H) ppm. ESI-MS m / z calculated: 311.0382, found: 312.0 (M+1). + ; Retention time: 1.82 minutes (LC method A).

[0541] Step 2: (2S)-tert-butyl 2-allylpyrrolidine-1-carboxylate [ka] Copper iodide (103 g, 540.8 mmol) was suspended in THF (525 mL) under nitrogen and cooled to −40° C. with stirring. Bromo(vinyl)magnesium (1 L of 1 M, 1.000 mol) was added slowly via addition funnel over 40 minutes, maintaining the internal temperature between −40° C. and −45° C. The thick suspension was stirred for 1 hour and allowed to warm to −10° C. The black suspension was cooled to −40° C. and a solution of tert-butyl (2S)-2-(iodomethyl)pyrrolidine-1-carboxylate (105 g, 337.4 mmol) in THF (260 mL) was added dropwise over 30 minutes, maintaining the internal temperature between −40° C. and −45° C. The thick suspension was stirred for an additional 3 hours with slow warming to 18° C. The black suspension was concentrated under reduced pressure and treated with saturated aqueous ammonium chloride (300 mL) and MTBE (300 mL). The solids were removed by filtration, and the phases were separated. The organic phase was washed two more times with saturated aqueous ammonium chloride (2 × 100 mL), and the aqueous phase was back-extracted once with MTBE (100 mL). The combined organic phases were dried, filtered, and evaporated. Purification by silica gel chromatography (hexane vs. 5% acetone in hexane (product absorbs at 200-210 nm)) provided tert-butyl (2S)-2-allylpyrrolidine-1-carboxylate (32 g, 45%). 1 H NMR (400MHz, DMSO-d6) δ5.74 (ddt, J=17.3, 10.3, 7.2Hz, 1H), 5.13~4.97 (m, 2H), 3. 70(s, 1H), 3.23(dq, J=19.2, 11.3, 9.4Hz, 2H), 2.46~1.52(m, 6H), 1.40(s, 9H)ppm. ESI-MS m / z calculated value 211.15723, measured value 212.0(M+1) + ; Retention time: 1.82 minutes (LC method A).

[0542] Step 3: (2S)-2-Allylpyrrolidine (trifluoroacetate) [ka] To a solution of tert-butyl (2S)-2-allylpyrrolidine-1-carboxylate (17 g, 80.45 mmol) in DCM (120 mL) was added TFA (30 mL, 389.4 mmol) dropwise. The mixture was stirred at ambient temperature for 24 h. The solvent was removed in vacuo and the product was azeotropically treated three times with toluene (200 mL). The product was dried under vacuum for 16 h to give (2S)-2-allylpyrrolidine (trifluoroacetate) (17 g, 94%) as a dark oil. ESI-MS m / z calculated 111.1048, found 112.1 (M+1). + ; Retention time: 0.4 minutes (LC method A).

[0543] Intermediate 4: Preparation of 6-[(2S)-2-allylpyrrolidin-1-yl]-3-(tert-butoxycarbonylamino)-5-(trifluoromethyl)pyridine-2-carboxylic acid [ka] Step 1: Methyl 6-[(2S)-2-allylpyrrolidin-1-yl)-3-[bis(tert-butoxycarbonyl)amino]-5-(trifluoromethyl)pyridine-2-carboxylate [ka] To a solution of methyl 3-[bis(tert-butoxycarbonyl)amino]-6-bromo-5-(trifluoromethyl)pyridine-2-carboxylate (31.6 g, 63.29 mmol) and (2S)-2-allylpyrrolidine (trifluoroacetate) (17 g, 75.49 mmol) in acetonitrile (400 mL) was added DIEA (45 mL, 258.4 mmol) and the mixture was heated at 80° C. for 2 h. Additional DIEA (10 mL, 57.41 mmol) was added and stirred at 80° C. for 18 h. The reaction mixture was cooled to ambient temperature and the solvent was removed in vacuo. The residue was diluted with EtOAc (700 mL), washed twice with 250 mL of brine, dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica gel chromatography (gradient of 0% to 30% EtOAc in hexanes) provided methyl 6-[(2S)-2-allylpyrrolidin-1-yl]-3-[bis(tert-butoxycarbonyl)amino]-5-(trifluoromethyl)pyridine-2-carboxylate (15 g, 45%). 1 H NMR (400 MHz, chloroform-d) δ 7.63 (s, 1H), 5.78 (ddt, J = 17.3, 10.2, 7.2 Hz, 1H), 5.15–4.91 (m, 2H), 4.54 (qd, J = 7.5, 3.1 Hz, 1H), 3.88 (s, t, 3H), 3.61 (t, J = 8.6 Hz) , 1H), 3.48 (d, J = 8.4 Hz, 1H), 2.69-2.53 (m, 1H), 2.32 (dt, J = 13.7, 7.5 Hz, 1H), 2.07 (d, J = 5.6 Hz, 1H), 2.02-1.94 (m, 1H), 1.86-1.69 (m, 2H), 1.43 (s, 18H) ppm. ESI-MS m / z calculated 529.24, found 530.3 (M+1). + ; Retention time: 2.06 minutes (LC method A).

[0544] Step 2: 6-[(2S)-2-Allylpyrrolidin-1-yl]-3-(tert-butoxycarbonylamino)-5-(trifluoromethyl)pyridine-2-carboxylic acid [ka] Methyl 6-[(2S)-2-allylpyrrolidin-1-yl]-3-[bis(tert-butoxycarbonyl)amino]-5-(trifluoromethyl)pyridine-2-carboxylate (20.5 g, 38.71 mmol) was dissolved in THF (150 mL) and MeOH (150 mL) (yellow solution) and then treated with water (150 mL) (yellow emulsion), followed by LiOH (3.5 g, 146.1 mmol). The mixture was heated to 60°C and stirred for 3.5 hours. The yellow mixture was concentrated under reduced pressure to remove most of the THF and MeOH, giving a yellow emulsion that was cooled in an ice bath to give a yellow sticky suspension (pH = 14). The suspension was acidified by the slow addition of HCl (160 mL of 1 M, 160 mmol), maintaining the internal temperature at approximately 10°C (foaming), and then stirred in a cold water bath for 1 hour. The solid was collected by filtration, washed with cold water, and dried overnight. The solid was purified by silica gel chromatography eluting with a linear gradient of 100% hexane to 50% ethyl acetate in hexane to give 6-[(2S)-2-allylpyrrolidin-1-yl]-3-(tert-butoxycarbonylamino)-5-(trifluoromethyl)pyridine-2-carboxylic acid (13.4 g, 83%) as a bright yellow solid. 1 H NMR (400 MHz, chloroform-d) δ 11.11 (s, 1H), 9.68 (s, 1H), 9.13 (s, 1H), 5.83–5.67 (m, 1H), 5.12–5.02 (m, 2H), 4.29 (q, J = 7.8, 3.1 Hz, 1H), 3.66 (q, J = 9.0 Hz, 1H), 3.41 (t, J = 8.5 Hz, 1H), 2.47 (ddd, J = 13.8, 7.6, 3.2 Hz, 1H), 2.29–2.17 (m, 1H), 2.21–2.12 (m, 1H), 2.06–1.93 (m, 1H), 1.87–1.69 (m, 2H), 1.53 (s, 9H) ppm. ESI-MS m / z calculated 415.1719, observed 416.0 (M+1) + ; Retention time: 1.38 minutes (LC method M).

[0545] Intermediate 5: Preparation of 2-benzyloxy-2-(trifluoromethyl)hex-5-enehydrazide (hydrochloride) [ka] Step 1: Ethyl 2-hydroxy-2-(trifluoromethyl)hex-5-enoate [ka] To a solution of ethyl 3,3,3-trifluoro-2-oxopropanoate (25.15 g, 147.87 mmol) in EtO (270 mL) at −78°C, a solution of bromo(but-3-enyl)magnesium in THF (190 mL of 0.817 M, 155.23 mmol) was added dropwise over a period of 1.5 h (internal temperature −72°C to −76°C). The mixture was stirred at −78°C for 20 min. The dry ice-acetone bath was removed. The mixture was slowly warmed to 5°C over the course of 1 h and added to a mixture of 1 N aqueous HCl (170 mL) and crushed ice (150 g) (pH = 4). The two layers were separated. The organic layer was concentrated, and the residue was combined with the aqueous phase and extracted with EtOAc (2 × 150 mL). The combined organic phase was washed with 5% aqueous NaHCO (50 mL) and brine (20 mL) and dried over NaSO. The mixture was filtered, concentrated, and co-evaporated with THF (2 × 40 mL) to give ethyl 2-hydroxy-2-(trifluoromethyl)hex-5-enoate (37.44 g, 96%) as a colorless oil. 1 H NMR (300MHz, CDCl3) δ5.77 (ddt, J=17.0, 10.4, 6.4Hz, 1H), 5.15~4.93 (m, 2H), 4.49~4.2 8(m, 2H), 3.88(s, 1H), 2.35~2.19(m, 1H), 2.17~1.89(m, 3H), 1.34(t, J=7.0Hz, 3H)ppm. 19 F NMR (282MHz, CDCl3)δ-78.74(s, 3F)ppm.

[0546] Step 2: Ethyl 2-benzyloxy-2-(trifluoromethyl)hex-5-enoate [ka] To a solution of ethyl 2-hydroxy-2-(trifluoromethyl)hex-5-enoate (24.29 g, 87.6% purity, 94.070 mmol) in DMF (120 mL) at 0 °C, NaH (60% in mineral oil, 5.64 g, 141.01 mmol) was added portionwise. The mixture was stirred at 0 °C for 10 min. Benzyl bromide (24.13 g, 141.08 mmol) and TBAI (8.68 g, 23.500 mmol) were added. The mixture was stirred at room temperature overnight. NHCl (3 g, 0.6 equiv.) was added. The mixture was stirred for 10 min. 30 mL of EtOAc was added, followed by ice water (400 g). The mixture was extracted with CHCl, and the combined organic layers were concentrated. Purification by silica gel chromatography (0% to 20% CH2Cl2 in heptane) provided ethyl 2-benzyloxy-2-(trifluoromethyl)hex-5-enoate (26.05 g, 88%) as a pink oil. 1 H NMR (300MHz, CDCl3) δ1.34(t, J=7.2Hz, 3H), 2.00~2.19(m, 3H), 2.22~2.38(m, 1H), 4.33(q, J=7.2Hz, 2H) , 4.64(d, J=10.6Hz, 1H), 4.84(d, J=10.9Hz, 1H), 4.91~5.11(m, 2H), 5.62~5.90(m, 1H), 7.36(s, 5H)ppm. 19 F NMR (282 MHz, CDCl) δ -70.5 (s, 3F) ppm. ESI-MS m / z calculated 316.12863, found 317.1 (M+1). + ; Retention time: 2.47 minutes (LC method B).

[0547] Step 3: 2-Benzyloxy-2-(trifluoromethyl)hex-5-enoic acid [ka] A solution of sodium hydroxide (7.86 g, 196.51 mmol) in water (60 mL) was added to a solution of ethyl 2-benzyloxy-2-(trifluoromethyl)hex-5-enoate (24.86 g, 78.593 mmol) in methanol (210 mL). The reaction was heated at 50° C. overnight. The reaction was concentrated to remove methanol, diluted with water (150 mL), and the carboxylic acid sodium salt was washed with heptane (1×100 mL). The aqueous solution was acidified with a 3N aqueous solution of HCl to pH=2. The carboxylic acid was extracted with dichloromethane (3×100 mL) and dried over sodium sulfate. The solution was filtered and concentrated to give 2-benzyloxy-2-(trifluoromethyl)hex-5-enoic acid (22.57 g, 97%) as a pale yellow oil. 1 H NMR (300MHz, DMSO-d6) δ14.31 (br.s., 1H), 7.55~7.20 (m, 5H), 5.93~5.70 (m, 1H) , 5.17~4.91(m, 2H), 4.85~4.68(m, 1H), 4.67~4.55(m, 1H), 2.32~1.94(m, 4H)ppm. 19 F NMR (282MHz, DMSO-d6) δ-70.29(s, 3F) ppm. ESI-MS m / z calculated value 288.09732, actual value 287.1 (M-1); retention time: 3.1 minutes (LC method C).

[0548] Step 4: tert-Butyl N-[[2-benzyloxy-2-(trifluoromethyl)hex-5-enoyl]amino]carbamate [ka] To a solution of 2-benzyloxy-2-(trifluoromethyl)hex-5-enoic acid (21.92 g, 92.4% purity, 70.263 mmol) in DMF (130 mL) was added HATU (37.2 g, 97.836 mmol) and EtN (15 g, 148.24 mmol). The mixture was stirred for 10 minutes, and then tert-butyl N-aminocarbamate (12.2 g, 92.312 mmol) was added. The mixture was stirred at 25 °C overnight and at 40 °C for 1 hour. The mixture was diluted with ice water (500 g) and extracted with CHCl. ​​The organic layer was dried over anhydrous sodium sulfate and concentrated. Purification by silica gel chromatography (0% to 30% EtOAc in heptane) provided tert-butyl N-[[2-benzyloxy-2-(trifluoromethyl)hex-5-enoyl]amino]carbamate (26.08 g, 92%) as a white solid. 1 H NMR (300MHz, CDCl3) δ1.46(s, 9H), 2.10~2.31(m, 3H), 2.34~2.51(m, 1H), 4.60~4.72(m, 1H), 4.73~4.86(m, 1H), 4.9 5~5.19(m, 2H), 5.83(ddt, J=16.7, 10.4, 6.1Hz, 1H), 6.28(br.s., 1H), 7.30~7.51(m, 5H), 8.34(d, J=2.6Hz, 1H)ppm. 19 F NMR (282MHz, CDCl3) δ-73.6(s, 3F)ppm.

[0549] Step 5: 2-Benzyloxy-2-(trifluoromethyl)hex-5-enehydrazide (hydrochloride) [ka] To a solution of tert-butyl N-[[2-benzyloxy-2-(trifluoromethyl)hex-5-enoyl]amino]carbamate (43.12 g, 107.2 mmol) in CHCl (200 mL) was added HCl (100 mL of 4 M, 400.0 mmol) and the mixture was stirred at ambient temperature for 7 h. The solvent was removed in vacuo, the residue was stripped twice from heptane and high vacuum was used for 20 h, and the resulting solid was dried in vacuo to give 2-benzyloxy-2-(trifluoromethyl)hex-5-enehydrazide (hydrochloride salt) (35 g, 96%). 1 H NMR (400MHz, chloroform-d) δ9.92(s, 2H), 7.41~7.31(m, 2H), 7.30~7.24(m, 2H), 7.24~7.16(m, 1H), 5.72~5.57 (m, 1H), 5.02~4.87(m, 2H), 4.71(d, J=10.9Hz, 1H), 4.62(d, J=11.0Hz, 1H), 3.70(s, 2H), 2.34~1.85(m, 4H). ESI-MS m / z calculated value 302.1242, measured value 303.2 (M+1) + ; Retention time: 1.5 minutes (LC method A).

[0550] Intermediate 6: Preparation of 2-benzyloxy-2-(trifluoromethyl)hex-5-enehydrazide [ka] Step 1: 2-benzyloxy-2-(trifluoromethyl)hex-5-enehydrazide [ka] 2-Benzyloxy-2-(trifluoromethyl)hex-5-enehydrazide (hydrochloride salt) was dissolved in ethyl acetate (500 mL) and carefully treated with saturated aqueous NaHCO (500 mL) and stirred for 0.5 h. The phases were separated, and the organic phase was washed once with 1:1 saturated aqueous NaHCO / water (500 mL), once with 1:4 saturated aqueous NaHCO / water (500 mL), once with water (500 mL), and once with brine (300 mL). The aqueous phase was re-extracted once with ethyl acetate (200 mL), and the combined organic phases were dried, filtered, evaporated, co-evaporated with toluene, and further dried under vacuum to give 2-benzyloxy-2-(trifluoromethyl)hex-5-enehydrazide (50 g, 99%) as a yellow oil. 1 H NMR (400MHz, DMSO-d6) δ9.33 (s, 1H), 7.53~7.27 (m, 5H), 5.81 (ddt, J=16.6, 10.2, 6. 3Hz, 1H), 5.10~4.93(m, 2H), 4.71(s, 2H), 4.57~4.28(m, 2H), 2.27~1.84(m, 4H)ppm. ESI-MS m / z calculated value 302.1242, measured value 303.0(M+1) + ; Retention time: 1.5 minutes (LC method A).

[0551] Intermediate 7: Preparation of tert-butyl N-[2-[5-[1-benzyloxy-1-(trifluoromethyl)pent-4-enyl]-1,3,4-oxadiazol-2-yl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]carbamate [ka] Step 1: tert-butyl N-[2-[[[2-benzyloxy-2-(trifluoromethyl)hex-5-enoyl]amino]carbamoyl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]carbamate [ka] To a mixture of 6-bromo-3-(tert-butoxycarbonylamino)-5-(trifluoromethyl)pyridine-2-carboxylic acid (239.2 g, 621.1 mmol) and 2-benzyloxy-2-(trifluoromethyl)hex-5-enehydrazide (hydrochloride) (230.1 g, 761.2 mmol) in EtOAc (2.2 L) at ambient temperature, pyridine (200 mL, 2.473 mol) was added to give a precipitate. 1-Propanephosphonic anhydride (500 g, 50% w / w, 785.7 mmol) was added, and the reaction mixture was stirred at ambient temperature for 12 hours. The reaction was quenched by the slow addition of a solution of NaOH (149 g, 50% w / w, 1.863 mol) in water (2 L), and the mixture was stirred for 15 minutes. The organic phase was separated, and the aqueous phase was extracted with EtOAc (1 L). The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. Half of the solvent was removed, and the organic phase was washed twice with aqueous HCl (1000 mL of 1 M, 1.000 mol). The organic phase was dried over MgSO4, filtered, and concentrated in vacuo. The crude product was slurried in warm heptane (2.5 L) and MTBE (0.25 L), and the mixture was stirred at ambient temperature for 12 hours to give a pale yellow slurry. The slurry was filtered and the resulting filter cake was washed twice with 1 L of 10% MTBE / heptane. The off-white solid was air-dried for 2 hours and then dried in vacuo at 40° C. for 20 hours to give tert-butyl N-[2-[[[2-benzyloxy-2-(trifluoromethyl)hex-5-enoyl]amino]carbamoyl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]carbamate (379.9 g, 91%). 1H NMR (400MHz, DMSO-d6) δ11.09(s, 1H), 10.92(s, 1H), 10.35(s, 1H), 9.15(s, 1H), 7.50(d, J=7.4Hz, 2H), 7.36(dt, J=24.4, 7.2Hz, 3H), 5.87( ddt, J=16.0, 10.4, 5.2Hz, 1H), 5.09(d, J=16.9Hz, 1H), 5.02(d, J=10.1Hz, 1H), 4.84(q, J=11.4Hz, 2H), 2.35~2.12(m, 4H), 1.49(s, 9H)ppm. ESI-MS m / z calculated 668.1069, observed 670.9 (M+3, Br isotope) + ; Retention time: 3.5 minutes (LC method D).

[0552] Step 2: tert-butyl N-[2-[5-[1-benzyloxy-1-(trifluoromethyl)pent-4-enyl]-1,3,4-oxadiazol-2-yl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]carbamate [ka] tert-Butyl N-[2-[[[2-benzyloxy-2-(trifluoromethyl)hex-5-enoyl]amino]carbamoyl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]carbamate (102 g, 150.8 mmol) was dissolved in anhydrous acetonitrile (1000 mL) and DIPEA (92 mL, 528.2 mmol) was added. The resulting orange solution was heated to 70 °C (internal temperature) to produce a clear yellow solution. p-Toluenesulfonyl chloride (37.4 g, 196.2 mmol) was then added in three equal portions (12.47 g) at 10 minute intervals, and the reaction was then heated for an additional 30 minutes. The reaction was cooled to room temperature, and the acetonitrile was concentrated under reduced pressure. MTBE (1000 mL) was added to the mixture, followed by 800 mL of water. The mixture was stirred and the layers were separated. The organic layer was washed with a solution of citric acid (36.3 g, 188.9 mmol) in 700 mL of water, followed by 400 mL of saturated NaHCO3, and then 300 mL of brine. The organic layer was then dried over anhydrous MgSO4 and concentrated under reduced pressure. The material was purified using silica gel chromatography using a gradient of 15% to 50% of an 8% solution of EtOAc in hexanes to pure hexanes to provide tert-butyl N-[2-[5-[1-benzyloxy-1-(trifluoromethyl)pent-4-enyl]-1,3,4-oxadiazol-2-yl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]carbamate (91.7 g, 93%). 1 H NMR (400MHz, chloroform-d) δ10.18(s, 1H), 9.35(s, 1H), 7.55~7.47(m, 2H), 7.45~7.37(m, 2H), 7.36~7.28(m, 1H), 5.83~ 5.68(m, 1H), 5.10~4.93(m, 2H), 4.82(d, J=10.5Hz, 1H), 4.69(d, J=10.5Hz, 1H), 2.59~2.13(m, 4H), 1.56(s, 9H)ppm. ESI-MS m / z calculated value 650.0963, measured value 651.0 (M+1) + ; Retention time: 3.81 minutes (LC method D).

[0553] Intermediate 8: Preparation of tert-butyl N-[2-[5-[1-benzyloxy-1-(trifluoromethyl)pent-4-enyl]-1,3,4-oxadiazol-2-yl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]-N-tert-butoxycarbonyl-carbamate [ka] Step 1: tert-butyl N-[2-[5-[1-benzyloxy-1-(trifluoromethyl)pent-4-enyl]-1,3,4-oxadiazol-2-yl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]-N-tert-butoxycarbonyl-carbamate [ka] To a solution of tert-butyl N-[2-[5-[1-benzyloxy-1-(trifluoromethyl)pent-4-enyl]-1,3,4-oxadiazol-2-yl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]carbamate (30 g, 41.910 mmol) in MTBE (300 mL) was added DIEA (6.6780 g, 9 mL, 51.670 mmol), DMAP (0.28 g, 2.2919 mmol), and Boc anhydride (20.1 g, 21.158 mL, 92.097 mmol). The resulting yellow, cloudy solution was stirred at 35° C. overnight. After cooling to room temperature, the solvent was evaporated. The yellow oily residue was then dissolved in 300 mL of DCM and washed with water (300 mL) followed by brine (300 mL). The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. Purification by silica gel chromatography (0% to 20% EtOAc in hexanes) provided tert-butyl N-[2-[5-[1-benzyloxy-1-(trifluoromethyl)pent-4-enyl]-1,3,4-oxadiazol-2-yl]-6-bromo-5-(trifluoromethyl)-3-pyridyl]-N-tert-butoxycarbonyl-carbamate (28.68 g, 87%) as a white solid. 1H NMR (500MHz, DMSO-d6) δ8.89(s, 1H), 7.51(d, J=7.4Hz, 2H), 7.43(t, J=7.5Hz, 2H), 7.35(t, J=7.3Hz, 1H), 5.96~5.76(m, 1H), 5.11(d, J=17.2Hz, ppm ESI-MS m / z calculated 750.1488, observed 751.6 (M+1) + ; Retention time: 3.9 minutes (LC method G).

[0554] Intermediate 9: Preparation of 2-benzyloxy-2-(trifluoromethyl)pent-4-enehydrazide (hydrochloride) [ka] Step 1: Ethyl 2-hydroxy-2-(trifluoromethyl)pent-4-enoate [ka] To a solution of ethyl 3,3,3-trifluoro-2-oxopropanoate (30 g, 176.38 mmol) in diethyl ether (300 mL) at −78° C., allyl(bromo)magnesium (185 mL of 1 M, 185.00 mmol) was added dropwise over a period of 3 hours (internal temperature: −74° C. to −76° C.). The mixture was stirred at −78° C. for 45 minutes. The dry ice-acetone bath was removed. The mixture was allowed to warm to approximately 10° C. over a period of 1 hour and added to a mixture of 1N aqueous HCl (210 mL) and crushed ice (400 g) (pH 4). The mixture was extracted with EtOAc, washed with 5% aqueous NaHCO3, brine, and dried over anhydrous Na2SO4. The mixture was filtered, concentrated, and co-evaporated with hexane to give ethyl 2-hydroxy-2-(trifluoromethyl)pent-4-enoate (42.2 g, 90%) as a pale yellow oil. 1H NMR (300MHz, CDCl3) δ1.33(t, J=7.1Hz, 3H), 2.60~2.79(m, 2H), 3.84(br.s., 1H), 4.24~4.48(m, 2H), 5.09~5.33(m, 2H), 5.59~5.82(m, 1H) ppm. 19 F NMR (282MHz, CDCl3)δ-78.5(s, 3F)ppm.

[0555] Step 2: Ethyl 2-benzyloxy-2-(trifluoromethyl)pent-4-enoate [ka] To a solution of ethyl 2-hydroxy-2-(trifluoromethyl)pent-4-enoate (18.56 g, 83.105 mmol) in DMF (100 mL) was added NaH (5.3 g, 60% w / w, 132.51 mmol) at 0 °C. The reaction was stirred for 15 minutes, and benzyl bromide (21.14 g, 15 mL, 121.12 mol) and tetrabutylammonium iodide (8.5 g, 23.012 mmol) were added. The mixture was stirred at room temperature overnight. The reaction was quenched with water (300 mL) and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were washed with brine (500 mL) and dried over sodium sulfate. Purification by silica gel chromatography (20% to 60% DCM / in hexanes) provided ethyl 2-benzyloxy-2-(trifluoromethyl)pent-4-enoate (22.01 g, 70%) as a colorless oil. 1 H NMR (250MHz, CDCl3) δ7.55~7.25(m, 5H), 6.00~5.80(m, 1H), 5.30~5.10(m, 2H), 4.86(d, J=10.5Hz, 1 H), 4.68(d, J=10.5Hz, 1H), 4.33(q, J=7.0Hz, 2H), 2.81(d, J=7.0Hz, 2H), 1.34(t, J=7.1Hz, 3H)ppm. ESI-MS m / z calculated value 302.113, measured value 303.5 (M+1) + ; Retention time: 4.14 minutes (LC method G).

[0556] Step 3: 2-Benzyloxy-2-(trifluoromethyl)pent-4-enoic acid [ka] To a solution of ethyl 2-benzyloxy-2-(trifluoromethyl)pent-4-enoate (28.99 g, 95.902 mmol) in methanol (150 mL) was added a solution of NaOH (7.6714 g, 191.80 mmol) in water (50 mL). The reaction mixture was stirred at 40° C. for 3 hours. The reaction mixture was concentrated in vacuo, and the residue was diluted with water (200 mL) and washed with diethyl ether (200 mL). The aqueous layer was acidified to pH 1 with concentrated HCl and extracted with diethyl ether (3×200 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to provide 2-benzyloxy-2-(trifluoromethyl)pent-4-enoic acid (28.04 g, 99%) as a pale yellow liquid. 1 H NMR (250 MHz, CDCl) δ 7.55–7.28 (m, 5H), 5.97–5.69 (m, 1H), 5.33–5.17 (m, 2H), 4.95–4.66 (m, 2H), 2.91 (d, J = 7.1 Hz, 2H) ppm. Not a single exchangeable proton was observed by NMR.

[0557] Step 4: tert-Butyl N-[[2-benzyloxy-2-(trifluoromethyl)pent-4-enoyl]amino]carbamate [ka] To a solution of 2-benzyloxy-2-(trifluoromethyl)pent-4-enoic acid (300 g, 1.094 mol) in DMF (2 L) was added HATU (530 g, 1.394 mol) and DIEA (400 mL, 2.296 mol), and the mixture was stirred at ambient temperature for 10 minutes. To the mixture was added tert-butyl N-aminocarbamate (152 g, 1.150 mol), and the mixture was stirred at ambient temperature for 36 hours. The reaction was quenched with cold water (4 L), and the mixture was extracted with EtOAc (2 × 2 L). The organic phase was washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica gel chromatography (0% to 40% EtOAc / hexanes) provided tert-butyl N-[[2-benzyloxy-2-(trifluoromethyl)pent-4-enoyl]amino]carbamate (386.49 g, 91%) as an oil, which slowly crystallized to an off-white solid. 1 H NMR (400MHz, DMSO) δ10.00(d, J=37.9Hz, 1H), 8.93(s, 1H), 7.46~7.39(m, 2H), 7.38~7.29(m, 3H), 6.01~5.64(m, 1H), 5 .32(d, J=17.1Hz, 1H), 5.17(d, J=10.1Hz, 1H), 4.77(s, 2H), 2.96(qd, J=15.4, 6.8Hz, 2H), 1.39(d, J=17.3Hz, 9H)ppm. ESI-MS m / z calculated value 388.16098, measured value 389.0(M+1) + ; Retention time: 2.51 minutes (LC method D).

[0558] Step 5: 2-Benzyloxy-2-(trifluoromethyl)pent-4-enehydrazide (hydrochloride) [ka] To a solution of tert-butyl N-[[2-benzyloxy-2-(trifluoromethyl)pent-4-enoyl]amino]carbamate (98.5 g, 240.94 mmol) in DCM (400 mL) was added HCl in dioxane (200 mL of 4 M, 800.00 mmol). The mixture was stirred at room temperature for 2 h, concentrated, and coevaporated with DCM and hexane to give 2-benzyloxy-2-(trifluoromethyl)pent-4-enehydrazide (hydrochloride salt) (81.15 g, 97%) as an off-white solid. 1 H NMR (500MHz, DMSO-d6) δ11.07(s, 1H), 7.70~7.16(m, 5H), 5.87~5.61(m, 1H), 5.45~5 .09(m, 2H), 4.79(s, 2H), 3.6~3.4(m, 2H), 3.23~3.07(m, 1H), 3.04~2.87(m, 1H)ppm. ESI-MS m / z calculated value 288.10855, measured value 289.2(M+1) + ; Retention time: 2.0 minutes (LC method H).

[0559] Intermediate 10: Preparation of methyl 3-[bis(tert-butoxycarbonyl)amino]-6-bromo-5-methylsulfonyl-pyridine-2-carboxylate [ka] Step 1: Methyl 3-amino-5-bromo-pyridine-2-carboxylate [ka] Sulfuric acid (10 mL, 187.6 mmol) was added to a solution of 3-amino-5-bromo-pyridine-2-carboxylic acid (10 g, 43.77 mmol) in methanol (250 mL). The reaction was heated at 75° C. for 3 days. The reaction mixture was cooled to room temperature and approximately two-thirds of the solvent was removed under reduced pressure. The resulting mixture was poured onto a mixture of brine (200 mL) and ice (200 mL). The aqueous layer was extracted with EtOAc (3×200 mL). The organic layers were combined, washed with water (70 mL), 5% NaHCO (70 mL), and brine (70 mL), dried over sodium sulfate, filtered, and evaporated to give methyl 3-amino-5-bromo-pyridine-2-carboxylate (4.56 g, 45%) as a yellow solid. 1 H NMR (300MHz, CDCl3) δ3.96(s, 3H), 5.82(br.s, 2H), 7.24(d, J=1.8Hz, 1H), 8.06(d, J=1.8Hz, 1H)ppm. ESI-MS m / z calculated value 229.96909, measured value 231.1(M+1) + ; Retention time: 1.51 minutes (LC method EE).

[0560] Step 2: Methyl 3-amino-5-methylsulfonyl-pyridine-2-carboxylate [ka] A mixture of methyl 3-amino-5-bromo-pyridine-2-carboxylate (9.79 g, 42.372 mmol), methylsulfinyloxy sodium (8.8 g, 86.2 mmol), copper(I) iodide (8.8 g, 46.206 mmol), L-proline (34 mg, 0.2953 mmol), and DMF (195 mL) under nitrogen was heated at 130° C. for 3 hours. The mixture was cooled to room temperature and added to EtOAc (1.2 L) with stirring. The mixture was filtered through diatomaceous earth and washed with EtOAc. The filtrate was washed with 28% aqueous NH (1×100 mL, then 1×50 mL) and brine (50 mL), dried over Na SO , filtered, and concentrated to approximately 160 mL, resulting in a precipitate. The precipitate was collected by filtration and dried to give methyl 3-amino-5-methylsulfonyl-pyridine-2-carboxylate (6.35 g, 65%) as a yellow solid. 1 1H NMR (300MHz, DMSO-d6) δ8.23(d, J=2.1Hz, 1H), 7.73(d, J=2.1Hz, 1H), 7.09(s, 2H), 3.83(s, 3H), 3.29(s, 3H)ppm. ESI-MS m / z calculated value 230.03613, measured value 231.1(M+1) + ; Retention time: 1.22 minutes (LC method E).

[0561] Step 3: Methyl 3-amino-6-bromo-5-methylsulfonyl-pyridine-2-carboxylate [ka] To a solution of methyl 3-amino-5-methylsulfonyl-pyridine-2-carboxylate (8 g, 34.746 mmol) in acetonitrile (515 mL) was added NBS (12.7 g, 71.355 mmol). The mixture was stirred at 35° C. for 64 hours. The mixture was concentrated to remove most of the acetonitrile. The residue was diluted with ethyl acetate (200 mL) and treated with a solution of 10% aqueous sodium thiosulfate (100 mL). After stirring at room temperature for 10 minutes, saturated aqueous sodium bicarbonate (100 mL) was added. After stirring for 5 minutes, the resulting precipitate was collected by filtration, washed with water and ethyl acetate, and then dried to give methyl 3-amino-6-bromo-5-methylsulfonyl-pyridine-2-carboxylate (6.2 g, 55%) as a yellow solid. 1 H NMR (300MHz, DMSO-d6) δ7.99(s, 1H), 7.25(br.s., 2H), 3.83(s, 3H), 3.42(s, 3H)ppm. ESI-MS m / z calculated value 307.94666, measured value 308.8 (M+1) + ; Retention time: 1.57 minutes (LC method E).

[0562] Step 4: Preparation of methyl 3-[bis(tert-butoxycarbonyl)amino]-6-bromo-5-methylsulfonyl-pyridine-2-carboxylate [ka] A mixture of methyl 3-amino-6-bromo-5-methylsulfonyl-pyridine-2-carboxylate (6.2 g, 19.153 mmol), tert-butoxycarbonyl tert-butylcarboxylate (12.825 g, 13.5 mL, 58.764 mmol), DMAP (373 mg, 3.0532 mmol), and DCM (185 mL) was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. Purification by silica gel chromatography (0% to 30% ethyl acetate in heptane gradient) provided methyl 3-[bis(tert-butoxycarbonyl)amino]-6-bromo-5-methylsulfonyl-pyridine-2-carboxylate (8.72 g, 89%) as a yellow oil. 1H NMR (300 MHz, CDCl) δ 8.33 (s, 1H), 3.97 (s, 3H), 3.38 (s, 3H), 1.43 (s, 18H) ppm. ESI-MS m / z calculated 508.0515, found 352.8 (M-155). + ; Retention time: 2.08 minutes (LC method E).

[0563] Preparation of Intermediate 11: Methyl 6-chloro-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylate [ka] Step 1: Methyl 1-oxido-5-(trifluoromethyl)pyridin-1-ium-2-carboxylate [ka] Urea hydrogen peroxide (62.7 g, 646.53 mmol) was added to a solution of methyl 5-(trifluoromethyl)pyridine-2-carboxylate (40 g, 191.09 mmol) in 1,2-dichloromethane (300 mL) at 0° C. Trifluoroacetic anhydride (107.70 g, 72 mL, 507.65 mmol) was then added over 30 minutes at a temperature of −10° C. using a cooling bath (CO2 / acetone bath). The reaction mixture was then stirred for another 30 minutes at a temperature of 0° C. and then at ambient temperature for 1 hour. The reaction mixture was then poured into cooled ice water (600 mL). The mixture was diluted with dichloromethane (300 mL), and the layers were then separated. The aqueous phase was extracted with dichloromethane (2×200 mL). The combined organic phases were washed with water (2×300 mL) and brine (1×200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give methyl 1-oxido-5-(trifluoromethyl)pyridin-1-ium-2-carboxylate (47.6 g, 90%) as a pale yellow solid. 1 H NMR (300MHz, DMSO-d6) δ8.89(s, 1H), 8.02~7.90(m, 1H), 7.86~7.72(m, 1H), 3.89(s, 3H) ppm. 19F NMR (282MHz, DMSO-d6) δ-62.00(s, 3F)ppm. ESI-MS m / z calculated value 221.02998, measured value 222.1(M+1) + ; Retention time: 1.24 minutes (LC method E).

[0564] Step 2: Methyl 6-hydroxy-5-(trifluoromethyl)pyridine-2-carboxylate [ka] Trifluoroacetic anhydride (291.62 g, 193 mL, 1.3885 mol) was added dropwise to a mixture of methyl 1-oxide-5-(trifluoromethyl)pyridin-1-ium-2-carboxylate (51.058 g, 230.66 mmol) in DMF (305 mL) at 0° C. The mixture was then stirred at room temperature overnight. The mixture was concentrated under reduced pressure to remove excess trifluoroacetic acid. The remaining DMF solution was poured dropwise into a stirred water bath (1000 mL) cooled to 0° C. The precipitated solid was collected by filtration and then washed with water (300 mL). The solid was dried under vacuum to give methyl 6-hydroxy-5-(trifluoromethyl)pyridine-2-carboxylate (45.24 g, 86%) as a white solid. 1 H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 7.2 Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 4.02 (s, 3H) ppm. Not a single exchangeable proton was observed by NMR. 19 F NMR (282 MHz, CDCl) δ -66.39 (s, 3F) ppm. ESI-MS m / z calculated 221.03, found 222.1 (M+1). + ; Retention time: 1.43 minutes (LC method E).

[0565] Step 3: Methyl 6-hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylate [ka] To an ice-cold solution of methyl 6-hydroxy-5-(trifluoromethyl)pyridine-2-carboxylate (33.04 g, 149.41 mmol) in sulfuric acid (200 mL of 18.4 M, 3.6800 mol), nitric acid (13 mL of 15.8 M, 205.40 mmol) was added dropwise. After 5 minutes, the ice bath was removed, and the reaction mixture was stirred at 38°C overnight. Since the reaction was not complete, nitric acid (3 mL of 15.8 M, 47.400 mmol) was added dropwise at room temperature, and the reaction was heated at 38°C for 4.5 hours. The reaction was slowly poured onto ice-cold water (900 mL), and the mixture was cooled to 0°C for 15 minutes. The resulting solid was then isolated by filtration and washed with water (600 mL). The solid was dried under vacuum overnight to give methyl 6-hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylate (39.49 g, 99%) as a white solid. 1 H NMR (300 MHz, DMSO-d6) δ 8.54 (s, 1H), 3.95 (s, 3H) ppm. Not a single exchangeable proton was observed in the NMR. 19 F NMR (282MHz, DMSO-d6) δ-64.56(s, 3F) ppm. ESI-MS m / z calculated value 266.0151, actual value 267.1(M+1) + ; Retention time: 1.64 minutes (LC method E).

[0566] Step 4: Methyl 6-chloro-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylate [ka] A mixture of methyl 6-hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylate (10 g, 37.575 mmol) and phenyl dichlorophosphate (48.008 g, 34 mL, 227.55 mmol) was heated at 170 °C for 90 min. After cooling to room temperature, the mixture was diluted with ethyl acetate (400 mL) and washed with brine (2 × 200 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification by silica gel chromatography (0% to 15% ethyl acetate in heptane) provided methyl 6-chloro-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylate (5.45 g, 50%) as a yellow solid. 1 H NMR (300MHz, CDCl3) δ8.75(s, 1H), 4.07(s, 3H)ppm. 19 F NMR (282 MHz, CDCl) δ -64.12 (s, 3F) ppm. ESI-MS m / z calculated 283.9812, found 285.0 (M+1). + ; Retention time: 1.95 minutes (LC method E).

[0567] Intermediate 12: Preparation of 6-hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylic acid [ka] Step 1: 6-Hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylic acid [ka] A mixture of methyl 6-hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylate (32 g, 120.24 mmol) in THF (180 mL) and water (180 mL) was treated with lithium hydroxide monohydrate (15.14 g, 360.79 mmol) and stirred at 27 °C overnight. The crude reaction mixture was cooled to room temperature, the pH adjusted to 2 with 0.5 M aqueous hydrochloric acid (380 mL), then transferred to a 1 L separatory funnel containing 2-methyl THF and extracted. The layers were separated, and the organic layer was washed with water (150 mL), brine (150 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give 6-hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylic acid (29.61 g, 96%) as an off-white solid. 1 H NMR (300 MHz, DMSO-d6) δ 8.45 (s, 1H) ppm. Not a single exchangeable proton was observed in the NMR. 19 F NMR (282MHz, DMSO-d6) δ-64.53(s, 3F) ppm. ESI-MS m / z calculated value 251.9994, measured value 253.0(M+1) + ; Retention time: 0.79 min (LC method E).

[0568] Intermediate 13: Preparation of [6-[5-[1-benzyloxy-1-(trifluoromethyl)pent-4-enyl]-1,3,4-oxadiazol-2-yl]-5-nitro-3-(trifluoromethyl)-2-pyridyl]trifluoromethanesulfonate [ka] Step 1: N'-[2-benzyloxy-2-(trifluoromethyl)hex-5-enoyl]-6-hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carbohydrazide [ka] To a solution of 6-hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carboxylic acid (29.92 g, 102.66 mmol) in acetonitrile (300 mL) and DMF (60 mL) was added CDI (17.48 g, 107.80 mmol). The mixture was stirred at room temperature for 0.5 hours, and then 2-benzyloxy-2-(trifluoromethyl)hex-5-enehydrazide (hydrochloride) (33.04 g, 97.534 mmol) was added in small portions. The reaction mixture was stirred at 26°C for 19 hours. The reaction mixture was transferred to an extraction funnel and rinsed with water (300 mL) and 2-MeTHF (400 mL). The mixture was extracted with 2-MeTHF (3 x 400 mL). The combined organic layers were washed with 0.5N aqueous HCl (3 × 300 mL), brine (3 × 250 mL), dried over anhydrous NaSO, filtered, and concentrated by evaporation under reduced pressure. It was then solubilized twice in dichloromethane (2 × 300 mL), and the volatiles were removed by evaporation under reduced pressure to provide N'-[2-benzyloxy-2-(trifluoromethyl)hex-5-enoyl]-6-hydroxy-3-nitro-5-(trifluoromethyl)pyridine-2-carbohydrazide (58.5 g, 94%) as a brown foam residue. ESI-MS m / z calculated 536.11304, found 537.2 (M+1). + . Retention time: 2.03 minutes (LC method E).

[0569] Step 2: [6-[5-[1-benzyloxy-1-(trifluoromethyl)pent-4-enyl]-1,3,4-oxadiazol-2-yl]-5-nitro-3-(trifluoromethyl)-2-pyridyl]trifluoromethanesulfonate [ka] To a solution of N'-[2-benzyloxy-2-(trifluor...

Claims

1. A compound selected from the compounds of formula I: [Formula 1] and deuterated derivatives and pharma- ceutically acceptable salts thereof, In the formula, X is -N(R X1 ) - and [chemical 2] is selected from Ring A is independently C 1 ~C 6 is a 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 groups selected from alkyl and oxo; R X1 But, H, C 1 ~C 6 Alkyl (independently, hydroxy, oxo, -OR X2 , and -N(R X2 ) 2 and C 3 ~C 8 cycloalkyl; Each R X2 independently H and C 1 ~C 6 alkyl groups, Each Y is independently -C(R Y ) 2 -, -O-, -CO-, -NR YN - and [C3] wherein each R YN However, independently, H, C 1 ~C 4 Alkyl, and CO 2 R YN1 Each R YN1 But independently, C 1 ~C 4 Alkyl and C 3 ~C 6 cycloalkyl; Each R Y are independently hydrogen, hydroxy, halogen, C 1 ~C 6 Alkyl (independently, hydroxy, C 1 ~C 6 Optionally substituted with 1 to 3 groups selected from alkoxy, and Q; 3 ~C 8 Cycloalkyl, C 6 ~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5 to 10 membered heteroaryl, -OR Y1 , -CO 2 R Y1 , -COR Y1 , -CON(R Y1 ) 2 , and -N(R Y1 ) 2 Selected from or Or two R on the same atom Y Together, C 3 ~C 8 Two R 1 -R 2 -R 3 -R 4 -R 5 -R 6 -R 7 -R 8 -R 9 -R 10 -R 11 -R 12 -R 13 -R 14 -R 15 -R 16 -R 17 -R 18 -R 19 -R 20 -R 21 -R 22 -R 23 -R 24 -R 25 -R 26 -R 27 -R 28 -R 29 -R 30 -R 31 -R 32 -R 33 -R 34 -R 35 -R 36 -R 37 -R 38 -R 39 -R 40 -R 41 -R 42 -R 43 -R 44 -R 45 -R 46 -R 47 -R Y together to form a π bond, Each R Y1 are independently hydrogen and C 1 ~C 6 alkyl, or two R attached to the same nitrogen Y1 together form a 3- to 6-membered heterocyclyl, Ring B is ■C 6 ~C 10 Aryl (independently selected from halogen, C 1 ~C 6 Alkyl, and C 1 ~C 6 alkoxy; ■C 3 ~C 8 Cycloalkyl, ■ 5- to 10-membered heteroaryl, and ■ 3- to 6-membered heterocyclyl (independently C 1 ~C 6optionally substituted with 1 to 3 groups selected from alkyl; Each Q is independently ■C 1 ~C 6 alkyl, independently ○Halogen, ○Oxo, ○C 6 ~C 10 Aryl (independently selected from halogen and -OCF 3 and ○C 3 ~C 8 cycloalkyl, 1 ~C 6 Alkyl, ■C 3 ~C 8 cycloalkyl, independently ○Halogen, ○ C.N., ○C 1 ~C 6 Alkyl (independently halogen, -NH 2 and -NHCOMe, ○C 1 ~C 6 Alkoxy, ○C 6 ~C 10 Aryl (independently C 1 ~C 6 alkyl), and ○C 3 ~C 8 cycloalkyl, 3 ~C 8 Cycloalkyl, ■C 6 ~C 10 aryl, independently ○Halogen, ○ C.N., ○C 1 ~C 6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen and hydroxy); ○C 1 ~C 6 Alkoxy, independently ■Halogen, ■C 3 ~C 8 Cycloalkyl (CF 3 C optionally substituted with 1 to 4 groups selected from 1 ~C 6 Alkoxy, ○C 3 ~C 8 Cycloalkyl (independently selected from halogen, CF 3 , O.C.F. 3 , and C 1 ~C 6 alkyl), and ○C 6 ~C 10 aryl, 6 ~C 10 Aryl, ■ 5- to 10-membered heteroaryl, independently ○Halogen, ○C 1 ~C 6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen); ○C 3 ~C 8 Cycloalkyl (1 to 3 CF 3 group), and ○ 3- to 10-membered heterocyclyl, ■ 3- to 10-membered heterocyclyl, independently ○C 1 ~C 6 Alkyl (independently oxo and C 3 ~C 8 cycloalkyl), and oxo; Each R 1 are independently halogen, C 1 ~C 6 Fluoroalkyl, C 1 ~C 6 Alkyl (hydroxy, C 6 ~C 10 aryl, and 5- to 6-membered heteroaryl), —OR 2 , -N(R 2 ) 2 , -CO 2 R 2 , —CO—N(R 2 ) 2 , -C.N., C. 3 ~C 8 Cycloalkyl, C 6 ~C 10 aryl, 5- to 6-membered heteroaryl (independently C 1 ~C 6 alkyl), 3- to 6-membered heterocyclyl, -B(OR 2 ) 2 , -SO 2 R 2 , -SR 2 , -SOR 2 , -PO(OR 2 ) 2 , and -PO(R 2 ) 2 is selected from Each R 2 are independently hydrogen, C 1 ~C 6 alkyl (optionally substituted with 1 to 6 groups independently selected from halogen); 1 ~C 6 Fluoroalkyl, and C 6 ~C 10 Aryl (independently C 1 ~C 6 Fluoroalkyl and C 1 ~C 6fluoroalkoxy; Z, [C4] wherein ring C is selected from 6 ~C 10 aryl and 5-10 membered heteroaryl; R Z1 is hydrogen, -CN, C 1 ~C 6 alkyl (optionally substituted with 1 to 3 hydroxy), C 1 ~C 6 Fluoroalkyl, 3-6 membered heterocyclyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 aryl, and 5- to 6-membered heteroaryl; R Z2 is hydrogen, halogen, hydroxyl, NH 2 , NH(CO)(C 1 ~C 6 alkyl), and C 1 ~C 6 Alkoxy (independently C 3 ~C 10 cycloalkyl; Or R Z1 and R Z2 taken together form a group selected from oxo and =N-OH, Each R Z3 are independently hydroxy, C 1 ~C 6 Alkoxy, C 1 ~C 6 Alkyl, and C 6 ~C 10 aryl, or two R Z3 together form a 3- to 6-membered heterocyclyl, n is selected from 4, 5, 6, 7, and 8; Compounds, and deuterated derivatives and pharma- ceutically acceptable salts thereof, wherein m is selected from 0, 1, 2, and 3.

2. X is -N(R X1 2. The compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein:

3. X, [C5] 2. The compound of claim 1, a deuterated derivative, or a pharma- ceutically acceptable salt thereof,

4. X, -NH-, -N(CH 3 ) -, -N(CH 2 CH 3 ) -, [C6] 2. The compound of claim 1 , a deuterated derivative, or a pharma- ceutically acceptable salt thereof, selected from:

5. Each R Y are independently hydrogen, hydroxy, halogen, C 1 ~C 6 Alkyl (independently, hydroxy, C 1 ~C 6 Optionally substituted with 1 to 3 groups selected from alkoxy, and Q; 3 ~C 8 Cycloalkyl, C 6 ~C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5- to 10-membered heteroaryl, —CO 2 R Y1 , and -CON(R Y1 ) 2 Selected from or Or two R on the same atom Y Together, C 3 ~C 8 forming a ring selected from cycloalkyl and 3- to 7-membered heterocyclyl; or two R YThe compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein:

6. Each R Y1 are independently hydrogen and C 1 ~C 6 alkyl, or two R attached to the same nitrogen Y1 The compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein:

7. Each Q is independently C 6 ~C 10 2. The compound of claim 1, a deuterated derivative, or a pharma- ceutically acceptable salt thereof, wherein:

8. 2. The compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein each Q is phenyl.

9. Each R Y But independently, Hydrogen, hydroxy, -CH 3 , -CD 3 , -CH 2 CH 3 , [C7] Selected from or Or two R on the same atom Y taken together form a ring selected from cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyrryl, and tetrahydrofuryl; or two R Y The compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein:

10. Ring B is C 6 ~C 10 Aryl (independently selected from halogen and C 1 ~C 62. The compound of claim 1, a deuterated derivative, or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from aryl, aryloxy, arylsulfonyl, arylsulfate ...

11. Ring B is phenyl (independently selected from halogen and C 1 ~C 6 2. The compound of claim 1, a deuterated derivative, or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from aryl, aryloxy, arylsulfonyl, arylsulfate ...

12. Ring B is [C8] 2. The compound of claim 1 , a deuterated derivative, or a pharma- ceutically acceptable salt thereof, selected from:

13. 2. The compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein n is selected from 4, 5, 6, and 7.

14. - (Y) n -but, [Case 9-1] [C9-2] [C9-3] 2. The compound of claim 1 , a deuterated derivative, or a pharma- ceutically acceptable salt thereof, selected from:

15. Each R 1 are independently halogen, C 1 ~C 6 Fluoroalkyl, C 1 ~C 6 Alkyl (C 6 ~C 10 aryl), -OR 2 , -N(R 2 ) 2 , -CO 2 R 2 , —CO—N(R 2 ) 2 , -C.N., C. 1 ~C 6 Alkoxy, C 3 ~C 8 Cycloalkyl, C 6 ~C 10 aryl, 5- to 6-membered heteroaryl (independently C 1 ~C 6 alkyl), 3- to 6-membered heterocyclyl, -B(OR 2 ) 2 , -SO 2 R 2 , -SR 2 , -SOR 2 , and -PO(R 2 ) 2 2. The compound of claim 1 , a deuterated derivative, or a pharma- ceutically acceptable salt thereof, selected from:

16. Each R 2 But independently, C 6 ~C 10 Aryl (independently C 1 ~C 6 2. The compound of claim 1, a deuterated derivative, or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from the group consisting of fluoroalkoxy, ...

17. Each R 1 are independently -Br, -CF 3 , -NH 2 , -CH 3 , -CH(CH 3 ) 2 , -CN, -OH, -OCH 3 , -NH(CH 3 ), -NH(CH 2 CH 3 ), -CONH 2 , -CO 2 CH 3 , -SO 2 CH 3 , -SO 2 Ph, PO(CH 3 ) 2 , B(OH) 2, phenyl, pyridyl, tetrahydropyranyl, tetrahydrofuranyl, cyclopropyl, cyclohexyl, imidazolyl, [C10] 2. The compound of claim 1 , a deuterated derivative, or a pharma- ceutically acceptable salt thereof, selected from:

18. Z, [C11] and ring C is selected from 6 ~C 10 2. The compound of claim 1, a deuterated derivative, or a pharma- ceutically acceptable salt thereof, wherein:

19. Base: [C12] but, [C13] 2. The compound of claim 1 , a deuterated derivative, or a pharma- ceutically acceptable salt thereof, selected from:

20. The group: [C14] 2. The compound of claim 1, a deuterated derivative, or a pharma- ceutically acceptable salt thereof,

21. R Z1 is hydrogen, C 1 ~C 6 alkyl (optionally substituted with 1 to 3 hydroxy), C 1 ~C 6 Fluoroalkyl, 3-6 membered heterocyclyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 2. The compound of claim 1, a deuterated derivative, or a pharma- ceutically acceptable salt thereof, selected from aryl, and 5-6 membered heteroaryl.

22. R Z2 is hydrogen, halogen, hydroxy, and C 1 ~C 6 Alkoxy (independently C 3 ~C 10 2. The compound of claim 1, a deuterated derivative, or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from the group consisting of aryl, aryl, arylsulfates, arylalkylsulfates, and arylsulfates.

23. R Z1 is hydrogen, C 1 ~C 6 alkyl (optionally substituted with 1 to 3 hydroxy), C 1 ~C 6 Fluoroalkyl, 3-6 membered heterocyclyl, C 3 ~C 6 Cycloalkyl, and C 6 ~C 10 aryl; R Z2 is selected from hydrogen, halogen, and hydroxy; Or R Z1 and R Z2 2. The compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein: taken together, form a group selected from oxo and =N-OH.

24. R Z1 is hydrogen, CH 3 , C.F. 3 , C.H. 2 OH, phenyl, cyclopropyl, and tetrahydropyranyl; R Z2 is selected from hydrogen, halogen, and hydroxy; Or R Z1 and R Z2 2. The compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein: taken together, form a group selected from oxo and =N-OH.

25. R Z2 The compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein is hydroxy.

26. Z, [C15] 2. The compound of claim 1 , a deuterated derivative, or a pharma- ceutically acceptable salt thereof, selected from:

27. 2. The compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 1, wherein m is selected from 1 and 2.

28. The following: [Table 20-1] [Table 20-2] [Table 20-3] [Table 20-4] [Table 20-5] [Table 20-6] [Table 20-7] [Table 20-8] [Table 20-9] [Table 20-10] [Table 20-11] [Table 20-12] [Table 20-13] [Table 20-14] [Table 20-15] [Table 20-16] [Table 20-17] [Table 20-18] [Table 20-19] [Table 20-20] [Table 20-21] [Table 20-22] [Table 20-23] [Table 20-24] [Table 20-25] [Table 20-26] [Table 20-27] [Table 20-28] [Table 20-29] [Table 20-30] [Table 20-31] [Table 20-32] [Table 20-33] [Table 20-34] [Table 20-35] [Table 20-36] [Table 20-37] [Table 20-38] [Table 20-39] [Table 20-40] [Table 20-41] [Table 20-42] [Table 20-43] [Table 20-44] [Table 20-45] [Table 20-46] [Table 20-47] 3. A compound selected from:

29. The compound is selected from the group consisting of: [Table 21-1] [Table 21-2] [Table 21-3] 29. The compound of claim 28, selected from: a pharma- ceutically acceptable salt thereof, and a deuterated derivative of any of the foregoing.

30. A pharmaceutical composition comprising a compound, salt, or deuterated derivative of any one of claims 1 to 29 and a pharma- ceutically acceptable carrier.

31. The pharmaceutical composition of claim 30, further comprising one or more additional therapeutic agents.

32. 32. The pharmaceutical composition of claim 31, wherein the one or more additional therapeutic agents comprises at least one CFTR correcting agent.

33. The at least one CFTR corrector is (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound II): [C16] , 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound IV): [C17] , N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound V): [C18] , N-(benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound VI): [C19] , (14S)-8-[3-(2-{dispiro[2.0.2.1]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6 -Thia-3,9,11,18,23-pentaazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione (Compound VII): [C20] , (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hexan-5-yl}-9-oxa-2λ 6 -Thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadeca-1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione (Compound VIII): [C21] , PTI-428, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, and PTI-801.

34. A composition comprising a compound, salt, or deuterated derivative of any one of claims 1 to 29, or a pharmaceutical composition of claim 30, for use in the treatment of cystic fibrosis in a patient in need of such treatment.

35. The composition of claim 34, wherein the composition is administered in combination with one or more additional therapeutic agents.

36. the one or more additional therapeutic agents (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound II): [C24] , 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound IV): [C25] , N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound V): [C26] , N-(benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound VI): [C27] , (14S)-8-[3-(2-{dispiro[2.0.2.1]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2λ 6 -Thia-3,9,11,18,23-pentaazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione (Compound VII): [C28] , (11R)-6-(2,6-dimethylphenyl)-11-(2-methylpropyl)-12-{spiro[2.3]hexan-5-yl}-9-oxa-2λ 6-Thia-3,5,12,19-tetraazatricyclo[12.3.1.14,8]nonadeca-1(17),4(19),5,7,14(18),15-hexaene-2,2,13-trione (Compound VIII): [C29] , PTI-428, ABBV-2222, ABBV-2851, GLPG2737, ABBV-3221, ABBV-3748, ABBV-3903, ABBV-119, FDL-169, ARN5562, ARN21586, ARN22081, ARN22652, ARN23765, ARN23766, and PTI-801.

37. Use of a compound, salt or deuterated derivative according to any one of claims 1 to 29, or a pharmaceutical composition according to claim 30, in the manufacture of a medicament for the treatment of cystic fibrosis.

38. A compound of formula 7-7: [C32] A method for preparing a compound of formula 7-6: [C33] to a compound of formula 7-7, wherein PG is selected from suitable oxygen protecting groups; each of a and b is independently an integer selected from 0, 1, 2, and 3, with the proviso that a+b is equal to or less than 4; R X1 is selected from H, C 1 -C 6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, oxo, -OR X2 , and -N(R X2 ) 2 ), and C 3 -C 8 cycloalkyl; each R X2 is independently selected from H and C 1 -C 6 alkyl; Each Y is independently -C(R Y ) 2 -, -O-, -CO-, -NR YN -, and [C3] wherein each R YN is independently selected from H, C 1 -C 4 alkyl, and CO 2 R YN1 , and each R YN1 is independently selected from C 1 -C 4 alkyl and C 3 -C 6 cycloalkyl; each R Y is independently selected from hydrogen, hydroxy, halogen, C 1 -C 6 alkyl (optionally substituted with 1 to 3 groups independently selected from hydroxy, C 1 -C 6 alkoxy, and Q), C 3 -C 8 cycloalkyl, C 6 -C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen), 5-10 membered heteroaryl, -OR Y1 , -CO 2 R Y1 , -COR Y1 , -CON(R Y1 ) 2 , and -N(R Y1 ) 2 ; or two R Y s on the same atom are joined together to form a ring selected from C 3 -C 8 cycloalkyl and 3- to 7-membered heterocyclyl, or two R Y s, one on one atom and the second on an adjacent atom, are joined to form a π bond; each R Y1 is independently selected from hydrogen and C 1 -C 6 alkyl, or two R Y1 attached to the same nitrogen are joined to form a 3- to 6-membered heterocyclyl; Ring B is ■ C 6 -C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy); ■ C3-C8 cycloalkyl, ■ 5- to 10-membered heteroaryl, and ■ 3- to 6-membered heterocyclyl (optionally substituted with 1 to 3 groups independently selected from C 1 -C 6 alkyl); Each Q is independently ■ C 1 -C 6 alkyl, independently ○Halogen, ○Oxo, C 6 -C 10 aryl (optionally substituted with 1 to 3 groups independently selected from halogen and -OCF 3 ), and C 1 -C 6 alkyl optionally substituted with 1 to 3 groups selected from C 3 -C 8 cycloalkyl, ■ C 3 -C 8 cycloalkyl, independently ○Halogen, ○ C.N., C 1 -C 6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen, —NH 2 , and —NHCOMe); C 1 -C 6 alkoxy, C 6 -C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C 1 -C 6 alkyl), and ○ C 3 -C 8 cycloalkyl optionally substituted with 1 to 3 groups selected from ■ C 6 -C 10 aryl, independently ○Halogen, ○ C.N., C 1 -C 6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen and hydroxy); C 1 -C 6 alkoxy, independently ■Halogen, ■ C 1 -C 6 alkoxy optionally substituted with 1 to 4 groups selected from C 3 -C 8 cycloalkyl (optionally substituted with CF 3 ); C 3 -C 8 cycloalkyl (optionally substituted with 1 to 3 groups independently selected from halogen, CF 3 , OCF 3 , and C 1 -C 6 alkyl), and C 6 -C 10 aryl optionally substituted with 1 to 3 groups selected from: ■ 5- to 10-membered heteroaryl, independently ○Halogen, C 1 -C 6 alkyl (optionally substituted with 1 to 3 groups independently selected from halogen); C 3 -C 8 cycloalkyl (optionally substituted with 1 to 3 CF 3 groups), and ○ 3- to 10-membered heterocyclyl, ■ 3- to 10-membered heterocyclyl, independently C 1 -C 6 alkyl (optionally substituted with 1 to 3 groups independently selected from oxo and C 3 -C 8 cycloalkyl), and oxo; each R 1 is independently selected from halogen, C 1 -C 6 fluoroalkyl, C 1 -C 6 alkyl (optionally substituted with groups selected from hydroxy, C 6 -C 10 aryl, and 5-6 membered heteroaryl), -OR 2 , -N(R 2 ) 2 , -CO 2 R 2 , -CO-N(R 2 ) 2 , -NO 2 , -CN, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 5-6 membered heteroaryl (optionally substituted with 1-3 groups independently selected from C 1 -C 6 alkyl), 3-6 membered heterocyclyl, -B(OR 2 ) 2 , -SO 2 R 2 , -SR 2 , -SOR 2 , -PO(OR 2 ) 2 , and -PO(R 2 ) 2 ; is selected from each R 2 is independently selected from hydrogen, C 1 -C 6 alkyl (optionally substituted with 1 to 6 groups independently selected from halogen), C 1 -C 6 fluoroalkyl, and C 6 -C 10 aryl (optionally substituted with 1 to 3 groups independently selected from C 1 -C 6 fluoroalkyl and C 1 -C 6 fluoroalkoxy); The method, wherein m is selected from 0, 1, 2, and 3.

39. The following: Substantially amorphous Compound 4 (native form); Substantially crystalline Compound 5 Form A (native); Substantially amorphous Compound 19 (native form), Form A of substantially crystalline Compound 41; Substantially crystalline Compound 52 Form A (native); Substantially amorphous Compound 60 (native form); Substantially amorphous Compound 70 (native form); Substantially crystalline Compound 163 Form A (native); Substantially amorphous Compound 173 (native form); Substantially crystalline Compound 173 Form A (native); Substantially crystalline Compound 175 Form A (unmodified); Substantially crystalline dichloromethane solvate form A of compound 188 A compound selected from:

40. Formula: [C34] or a deuterated derivative thereof, or a pharma- ceutically acceptable salt of any of the foregoing.

41. Formula: [C35] Compound.

42. A pharmaceutical composition comprising the compound, deuterated derivative, or pharma- ceutically acceptable salt of claim 40 and a pharma- ceutically acceptable carrier.

43. The pharmaceutical composition of claim 42, further comprising one or more additional therapeutic agents.

44. A composition comprising a compound, salt, or deuterated derivative of claim 40, or a pharmaceutical composition of claim 42 or 43, for use in the treatment of cystic fibrosis in a patient in need of such treatment.

45. The composition described in claim 44, wherein the treatment further comprises administration of one or more additional therapeutic agents.